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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is considered the etiologic
agent of Kaposi’s sarcoma and several lymphoproliferative disorders. Recently, the fulllength KSHV genome has been cloned into a bacterial artificial chromosome (BAC) and
successfully recovered in 293 cells. The herpesviral glycoproteins are structural
components of the KSHV particle and are thought to facilitate virus entry, egress and
virus-induced cell fusion. Investigations, described herein, have focused on the genetic
manipulation of the KSHV-BAC36 in order to address the role of K8.1 glycoprotein in
virus entry and the role of the carboxyl tail α-helices of glycoprotein (gB) in virusinduced cell fusion. In addition, a panel of KSHV-glycoprotein mutants was constructed
in order to address the specific role of each glycoprotein in viral entry, egress and virusinduced cell fusion. To further address the role of K8.1 in virus infectivity, a K8.1-null
recombinant virus (BAC36∆K8.1) was constructed by deletion of most of the K8.1 open
reading frame and the insertion of a kanamycin resistance gene cassette within the K8.1
gene. Transfection of the mutant genome (BAC36∆K8.1) DNAs into 293 cells produced
infectious virions in the supernatants of transfected cells. Hence, these results clearly
demonstrated that the K8.1 glycoprotein is not required for KSHV entry into 293 cells. In
addition, two recombinant BAC36-derived genomes were constructed (via a two-step
homologous recombination procedure in bacteria) specifying truncations that fully or
partially truncated a predicted α-helical structure of the gB carboxyl terminus known to
be involved in virus-induced cell fusion from studies with the herpes simplex virus type 1
(HSV-1) gB. Initial experiments suggested that disruption of the predicted α-helical
structure gBtH2 enhanced virus-induced cell fusion. Furthermore, utilization of the
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pGET-Rec bacterial recombination system for insertional/deletional mutagenesis of the
KSHV-BAC36 genome was successfully performed to produce the following KSHVBAC36 null mutants: KSHV-BAC36∆gB, KSHV-BAC36∆gH, KSHV-BAC36∆K8.1,
KSHV-BAC36∆gL and KSHV-BAC36∆gM. The investigations herein have capitalized
on the recent development of the KSHV-BAC36 clone in order to deliver targeted
mutations to the KSHV genome.

xvi

CHAPTER I
INTRODUCTION

STATEMENT OF RESEARCH PROBLEM AND HYPOTHESIS
Kaposi’s Sarcoma Associated Herpesvirus (KSHV) is the most recently
discovered human herpesvirus (HHV-8). KSHV has been unequivocally linked to three
malignant and proliferative disorders: Kaposi’s Sarcoma, Body Cavity-Based
Lymphomas, and certain variants of the Multicentric Castleman’s Disease. Due to
KSHV’s oncogenic potential, there has been intense research interest in the virus, yet
certain basic pathogenic mechanisms regarding the viral lifecycle has not been
elucidated, particularly the mechanisms of viral entry and egress.
KSHV encodes many glycoproteins, some of which have significant homology
to glycoproteins of other viruses within the Herpesviridae Family; these include the
following: gB(ORF 8), gH (ORF 22), gM (ORF 39), gL (ORF 47) (Neipel, Albrecht, and
Fleckenstein, 1997; Russo et al., 1996), and gN (ORF 53) (Koyano et al., 2003). In
addition, K1, K8.1 and vOX2 (K14) glycoproteins are unique to KSHV with no
counterparts in other herpesviruses (Chandran et al., 1998; Chung et al., 2002; Neipel,
Albrecht, and Fleckenstein, 1997). KSHV glycoproteins gB and K8.1 mediate initial
binding of virions onto glycosaminoglycans, e.g. heparan sulfate on cell surfaces (Akula
et al., 2001a; Akula et al., 2001b; Birkmann et al., 2001; Wang et al., 2001a).
Furthermore, a soluble form of K8.1A inhibited KSHV attachment onto cells (Zhu et al.,
1999). However, a later report indicated that a similar soluble form of K8.1A did not
block KSHV infectivity (Birkmann et al., 2001). In addition, gB binds to integrins, such

1

as α3β1 membrane receptors through a RGD motif, suggesting that integrins function as
cellular receptors for KSHV entry (Akula et al., 2002; Naranatt et al., 2003). However,
soluble integrins or RGD-containing peptides failed to inhibit virus entry into 293 cells
(Inoue et al., 2003). In addition to the known role of gB in cell-surface binding, KSHV
gB is thought to play important roles in membrane fusion during virus entry (fusion of
the viral envelope with cellular membranes) virus-induced cell-to-cell fusion (Baghian et
al., 1993; Foster, Melancon, and Kousoulas, 2001), functions that seem to be conserved
for all gB homologues specified by all human and animal herpesviruses.
Recently, it has been shown that infectious virions could be produced using a
bacterial artificial chromosome (BAC) containing the entire KSHV genome (Zhou et al.,
2002). To facilitate addressing the role of individual glycoproteins in viral entry or
egress, a panel of KSHV glycoprotein knockout mutant viruses was produced in bacteria
utilizing the KSHV-BAC36 as a viral genomic template. The overall experimental
approach was validated by focusing on the role of KSHV K8.1 glycoprotein in virus
entry. The specific hypothesis for these investigations was that K8.1 is dispensable for
virus entry; this work is described in chapter II. A second aspect of the work focused on
gB, which is known to mediate fusion of the viral envelope with cellular membranes
during virus entry as well as fusion among cellular plasma membranes for a number of
different herpesviruses. gB specific mutant viruses were constructed, containing specific
gB mutations which would increase virus-induced cell membrane fusion; this work is
described in chapter III. Additional glycoprotein gene deletion mutant genomes were
produced for glycoproteins gB, gH, gL and gM; however, due to time constraints these
mutants were not fully characterized (described in chapter IV).
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STATEMENT OF RESEARCH OBJECTIVES
The overall goal of this research was to gain a better understanding of the role that
major viral glycoproteins play in the KSHV lifecycle through the production and
characterization of mutant viruses that contained deletions or mutations within each
glycoprotein gene. The specific objectives were the following: 1.) To address the role of
K8.1 in virus entry and egress; 2.) to address the potential role of the gB carboxyl
terminus in virus-induced cell fusion.
LITERATURE REVIEW
Historical Perspective of Kaposi’s-Sarcoma Associated Herpesvirus
In 1872, Moritz Kaposi, a Hungarian dermatologist, was the first to clinically
diagnose an aggressive tumor in elderly male patients as idiopathic multiple pigmented
sarcomas of the skin (Kaposi 1872). The patients that were originally described in
Kaposi’s study eventually died of their condition, which is now referred to as “classic”
Kaposi’s Sarcoma (KS). Subsequent to Kaposi’s initial description of this condition,
three additional forms of Kaposi’s Sarcoma have also been described: African-endemic,
iatrogenic and AIDS-KS. In 1994, a landmark study was published utilizing
representational differential analysis to detect the presence of herpesvirus-like DNA
sequences in biopsies of AIDS-KS tissue but not in biopsies of non-KS tissue from AIDS
patients; thus marking the discovery of a new herpesvirus, which was appropriately
named the kaposi’s sarcoma-associated herpesvirus or human herpesvirus 8(Chang et al.,
1994) . Kaposi’s sarcoma-associated herpesvirus (KSHV) has also been associated with
primary effusion lymphomas (PEL), multicentric Castleman’s disease (MCD) and
primary pulmonary hypertension.
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Herpesviruses are among the oldest viruses known to afflict mankind (Knipe,
2001). KSHV has been taxonomically categorized into the herpesviridae family and the
gammaherpesvirinae subfamily. KSHV has been shown to infect a myriad of cells in
vitro: endothelial, human foreskin fibroblast, Vero, 293, HeLa cells, etc. KSHV has
generated a considerable amount of interest in the scientific community due to the
presence of many cellular homologs encoded within its viral genome which allows the
virus to persist and evade the host immune system.
Clinical Significance of Kaposi’s Sarcoma-Associated Viruses
Kaposi’s Sarcoma
Kaposi’s Sarcoma is characterized by spindle cells that are undergoing
proliferation subsequently forming irregular microvascular channels. Although KS
tumors are predominately found in the dermis, tumors have also been found in the viscera
(Hengge et al., 2002) of some patients. Visceral dissemination results in organ failure
and eventual death. Currently there are four clinical forms of KS with varying
epidemiological parameters, which are listed as followed: 1.) Classic, 2.) AIDSassociated (epidemic), 3.) African (endemic), and 4.) Iatrogenic. The underlying current
among all of the clinical variants of KS is the requisite infection of the host by
KSHV(Aluigi et al., 1996; Ambroziak et al., 1995; Foreman et al., 1997a; Gao et al.,
1996b; Kedes et al., 1996; Lennette, Blackbourn, and Levy, 1996; Miller et al., 1996;
Parravicini et al., 1997b; Qunibi et al., 1998; Regamey et al., 1998; Schalling et al., 1995;
Simpson et al., 1996). KSHV seroconversion has been shown to occur before the
manifestation of KS and could be used to predict the development of disease(Cesarman et
al., 1996; Gao et al., 1996a; Kedes et al., 1996; Martin et al., 1998; Renwick et al., 1998).
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The assortment of the clinical variants of KS along with the other lymphoproliferative
disorders associated with KSHV infection underscores a substantial role for cofactors in
KS pathogenesis (Dourmishev et al., 2003)
Classic KS appears as rare indolent tumors occurring in elderly men of
Mediterranean descent(Ablashi et al., 2002; Dourmishev et al., 2003; Moore and Chang,
2003). The classic KS tumors manifest themselves in the lower extremities for
approximately ten or more years with a very low mortality rate (Hengge et al., 2002). In
the late 1800s, Moritz Kaposi was the first individual to describe the clinical condition of
“classic” KS in various patients; he described the patients as having multifocal pigmented
sarcomas(Kaposi, 1872). Those initial patients died of KS, yet the clinical presentation
of the disease is grossly similar to what we currently see in KS patients (Knipe et al.,
2001).
Epidemic AIDS KS served as a harbinger of the AIDS complex for homosexual
men in the early 1980s(Borkovic and Schwartz, 1981; Gottlieb et al., 1981; Hymes et al.,
1981); these individuals were dually infected with HIV and KSHV. Due to the
concurrent infection and synchronized epidemics of both AIDS and KS, this particular
epidemiological form of KS was termed epidemic AIDS KS(Borkovic and Schwartz,
1981; Gottlieb et al., 1981; Hymes et al., 1981). The most prevalent neoplasm in
homosexual AIDS patients has been KS, the AIDS epidemic form(Goedert, 2000).
Serological assays indicate a marked increase of KSHV prevalence in AIDS patients
before the onset of KS(Gao et al., 1996b; Martin et al., 1998; Simpson et al., 1996).
HIV and KSHV dually infected individuals provide a milieu which allows the
augmentation of KSHV pathogenesis by HIV at various stages: immunosuppression,
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enhancement of KSHV infection and replication, and alteration of the KSHV gene
expression profile(Dourmishev et al., 2003). The most pronounced risk factor for AIDSassociated KS in individuals infected with HIV is sexual behavior(Martin et al., 1998).
HIV infected homosexuals have a more than ten thousand time risk of developing KS as
opposed to individuals in the general population(Goedert, 2000). There is mounting
evidence that orogenital sex as opposed to anogenital sex is a greater risk factor for
KSHV infection(Dukers et al., 2000). The primary mode of KSHV transmission has yet
to be determined; however, recent evidence has postulated that KSHV transmission via
the oral route may also occur among healthy immunocompetent individuals(Cook et al.,
2002a; Cook et al., 2002b; Duus et al., 2004). A retrospective study, analyzing the
prevalence of KSHV infection among homosexual men at the beginning and during the
AIDS epidemic, showed that unprotected oral sex exhibited the highest behavorial risk
factor (Osmond et al., 2002). KSHV has been readily detectable in the saliva of
seropositive individuals (Blackbourn et al., 2000; Koelle et al., 1997; Pauk et al., 2000;
Stamey et al., 2001; Vieira et al., 1997), yet the detection of KSHV in semen has been
extremely controversial with very low reproducibility. Thus, the ever increasing
evidence suggests differing routes of transmission for KSHV and HIV.
Endemic Africa KS has preceded the widespread HIV pandemic for many
decades in Africa, particularly the equatorial region (Oettle, 1962). The greatest number
of African KS patients were found in Zaire, Uganda, and Tanzania(Ablashi et al., 2002).
Before the outbreak of HIV, African KS primarily affected young children of an
approximate age of three years; African KS also affected men of an approximate age of
thirty-five years (Wabinga et al., 1993).
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Microparticles of silica dust have been mentioned as an environmental cofactor in
children with African KS (Ziegler, Simonart, and Snoeck, 2001). Intralymphatic silica,
from animal models involving the direct intralymphatic injection of fine silica particles,
incited a rapid and robust macrophage reaction with subsequent fibrosis within lymph
vessels(Fyfe and Price, 1985). Theoretically, children who walk barefoot risk the
injection of microparticles of silica at the site of their feet, thus perhaps leading to
immune suppression in a localized area, which provides the proper milieu for the
development of African KS in individuals infected with KSHV (Ablashi et al., 2002).
African KS typically exhibits a more aggressive clinical manifestation as opposed to
classic KS, yet African KS presents a less fulminant clinical course in comparison to
African AIDS-associated KS (Bayley, 1984; Wabinga et al., 1993).
Due to the widespread dissemination of AIDS on the continent of Africa, KS is
the most frequently reported neoplasm in several African countries, which constitutes a
severe public health dilemma that has yet to be addressed(Bassett et al., 1995; Beral,
Newton, and Sitas, 1999). Epidemiologic studies differentiating between endemic
African KS and AIDS-KS would be impractical in various African countries. Although
the prevalence of KS has exploded in the HIV positive communities in Africa, a marked
increase in the prevalence of KS has been noticed in the HIV negative community, which
could be referred to as the modern version of endemic African KS(Ablashi et al., 2002).
Iatrogenic (transplant) KS has become a growing concern for transplant
recipients. KSHV has been shown to be epidemiologically linked to KS in posttransplant patients, particularly patients with kidney or liver transplants(Luppi et al.,
2003). In comparison to lymphomas or various epithelial malignancies, iatrogenic KS
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presents itself as an earlier manifestation of post-transplantation malignancy in transplant
patients(Penn, 1993). Transplant patients with KS typically involve skin lesions;
however, a significant portion of patients manifest visceral dissemination of KS (Singh,
2000). Remission of KS has been reported in all variants of KS upon removal of
immunosuppression; however, iatrogenic KS patients need to be immunosuppressed in
order to prevent allograft rejection. Greater than fifty percent of iatrogenic KS patients
have experienced tissue rejection upon removal of immunosuppresion (Singh, 2000).
There has been a contention of whether or not KS in posttransplant patients is due to
reactivation of KSHV or due to KSHV primary infection via infected organ-donor tissue.
Furthermore, it has been postulated that iatrogenic KS is due to KSHV reactivation in
areas of endemic KS; however, in areas of nonendemic KS, it is believed that posttransplantation KS is due to primary infection(Rabkin, Shepherd, and Wade, 1999).
Accumulating evidence from several published papers suggests that KSHV primary
infection of the patient is significantly higher than previously expected(Andreoni et al.,
2001; Cattani et al., 2001; Emond et al., 2002; Farge et al., 1999; Kapelushnik et al.,
2001; Luppi et al., 2000a; Luppi et al., 2000b; Munoz et al., 2002; Sarid et al., 2001).
Thus, donor/recipient screening measures, which assay for KSHV positivity, could
theoretically alleviate the number of new KSHV primary infections or reactivations in
recipient patients via the assessment of high risk patients and modulation of their
immunosuppression to reduce the possibility of developing KS (Cannon, Laney, and
Pellett, 2003; Luppi et al., 2003).
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Pleural Effusion Lymphoma (PEL)
As opposed to KS, Pleural effusion lymphomas (PELs) manifest the more
common neoplastic proliferation process, in which transformed cells exhibit a
dysregulated cellular expansion(Knipe et al., 2001). PELs, formerly known as Body
Cavity Based Lymphomas, was described first in AIDS patients (Cesarman et al., 1995).
PELs are extremely rare yet could be found predominately in HIV infected patients, but
not exclusively; PELs exhibit distinct clinical, immunophenotypic, and molecular
characteristics(Aoki and Tosato, 2003; Knipe et al., 2001). The malignancy presents
itself as an aggressive effusion in the peritoneal, pericardial, pleural, or abdominal cavity,
typically without an identifiable tumor mass (Aoki and Tosato, 2003; Leao et al., 2002).
In rare cases, PELs manifest as solid tumor masses outside the body cavities (Aoki and
Tosato, 2003; Leao et al., 2002). The prognosis for AIDS patients diagnosed with PEL is
extremely poor; usually development of the PEL malignancy would lead to death within
an average of six to eleven months on standard chemotherapy (Kaplan et al., 1997;
Levine et al., 1991). PELs have been found to be useful in scientific research to derive
cell lines which provide a source of KSHV production readily used in virologic and
serologic assays; PELs harbor approximately fifty to one-hundred and fifty viral
episomes per cell(Moore and Chang, 2003). Typically, most of the KSHV genomes are
harbored in the PEL cells in a latent state; however, KSHV within a small percentage
(less than three percent) of PEL cells spontaneously undergo lytic reactivation (Renne et
al., 1996b). Induction of the viral lytic cycle could be achieved by the addition of a
phorbol ester, tetradecanoyl-13-myristate acid or TPA (Renne et al., 1996a; Renne et al.,
1996b; Sarid et al., 1998; Zhong et al., 1996).
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Investigators agree that PELs are derived from a B-cell origin, late-stage
differentiated both pre- and post-germinal center B cells, thus PELs are not restricted to
any stage of B cell maturation(Carbone et al., 1998; Matolcsy, 1999). Another study has
shown that KSHV is detected in circulating B cells(Blackbourn et al., 1997). Infection of
B cells by KSHV mirrors the infectivity of cells susceptible to the Epstein-Barr
virus(EBV); a virus that also transforms cells and causes lymphoproliferative disorders in
infected patients(Knipe et al., 2001). Most PELs are dually infected with KSHV and
EBV genomes; the precise concerted viral mechanisms employed by both viruses leading
to the lymphoproliferative effusions are not fully understood (Ablashi et al., 2002).
Multicentric Castleman’s Disease (MCD)
Multicentric Castleman’s Disease (MCD), which is also named multicentric
angiofollicular lymphoid hyperplasia, in its systemic proliferative form involves fever,
lymphadenopathy, splenomegaly (Mikala et al., 1999). MCD could be readily
characterized by vascular proliferation in the germinal centers, which in this regard is
similar to KS (Ablashi et al., 2002). This rare B-cell lymphoproliferative disorder is
found mostly in HIV infected AIDS patients(Aoki and Tosato, 2003; Leao et al., 2002).
The predominate number of cases of MCD (greater than 90%) in AIDS patients are
infected with KSHV, thus suggesting a robust role of KSHV in the pathogenesis of MCD,
particularly in AIDS patients (Grandadam et al., 1997). Furthermore, in AIDS related
MCD, KSHV viral loads are high even though there is a lack of manifest MCD foci
within the lymph nodes of the infected patient (Parravicini et al., 1997a). In HIV-negative
healthy individuals, fifty percent of all individuals with MCD are infected with KSHV;
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however, the etiologic factors of the remainder of MCD patients that are KSHV negative
are unclear (Moore and Chang, 2003).
MCD could be categorized into either a localized and systemic manifestation.
Analogous to KS, MCD patients dually infected with HIV and KSHV present a
significantly more aggressive form of MCD with a concomitant poor prognosis
(Oksenhendler et al., 2000; Parravicini et al., 1997a; Zietz et al., 1999). In regard to
KSHV infection, MCD is a polyclonal tumor wherein the majority of the cell mass of
uninfected lymphocytes are recruited by KSHV infected B cells (Dupin et al., 1999;
Katano et al., 2000; Parravicini et al., 1997a). As opposed to PELs wherein most PEL
cells are dually infected with KSHV and EBV, MCD usually lacks co-infection with
EBV (Aoki, Jones, and Tosato, 2000; Little et al., 2001). The proportion of KSHV
lytically infected to latently infected cells is significantly higher in MCD as opposed to
PEL, thus implying different KSHV pathogenetic mechanisms found in MCD as opposed
to PEL, which could be ascribed to varying cellular and viral gene expression profiles in
both of these lymphoproliferative disorders (Rivas et al., 2001; Staskus et al., 1999;
Teruya-Feldstein et al., 1998).
Structure of the KSHV Particle
Structural studies have shown that KSHV manifests similar structural features as
the other members of the Herpesviridae family. KSHV possesses the typical
morphological characteristics with an approximately 100-150nm observed size of the
virion particle (Renne et al., 1996b). All herpesviruses are comprised of four structural
elements: 1.) a cylindrical core structure wherein linear double stranded DNA is present;
2.) an icosahedral capsid consisting of 162 hexagonal capsomeres, 3.) an amorphous
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tegument which surrounds the capsid, and 4.) a lipid bilayer envelope which is derived
from the host cell (Knipe et al., 2001).
Virion DNA extracted from the phorbol ester (12-O-tetradacanoyl-13-acetate;
TPA) induced BCBL-1 cells revealed that the KSHV genome is comprised of
approximately 165kb to 170kb (Renne et al., 1996a; Zhong et al., 1996). The KSHV
genome size is a bit larger than the prototypical herpesvirus, HSV-1, which is 135 kb.
Yet, the genome size is considerably smaller in size when compared to the viral genome
of the human cytomegalovirus, (HCMV). Although numerous studies have been
published detailing KSHV infection and pathogenesis, there has been a dearth of studies
addressing virion structure and morphology. KSHV has been difficult to cultivate in
either tissue culture or animal systems. It has been shown that KSHV and HCMV
capsids are similar via negative stained images of thin sections; KSHV nucleocapsids was
shown to be approximately 120-150nm, while HMCV was shown to be 150-200nm(Said
et al., 1997). Using electron cryomicroscopy, investigators have shown that the capsid
size and structure accords well with other members of the herpesvirus family(Trus et al.,
2001; Wu et al., 2000).
The Core and Organization of the Viral Genome
The innermost core of the KSHV particle is similar to all other herpesviruses in which the
viral DNA genome is wound (Knipe et al., 2001). Herpesviruses possess a linear doublestranded DNA genome, which range in size from 120kb to 250kb. The KSHV genome is
approximately 165 to 170kb, as shown by pulse-field gel electrophoresis of DNA purified
from intact virions (Renne et al., 1996a). Nucleotide sequence data indicated that KSHV
belongs to the gammaherpesvirus subfamily, genus Rhadinovirus (gamma-2 herpesvirus);
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KSHV is the first member of this genus known to infect humans (Moore et al., 1996b).
The linear double stranded genome consists of a 140.5kb central segment of low-GC
DNA [also known as L DNA or long unique region (LUR)], which has 53.5% G+C
content(Moore et al., 1996b; Neipel, Albrecht, and Fleckenstein, 1997; Russo et al.,
1996). The LUR is flanked by 20-35kb multirepetitive high GC DNA, which has 84.5%
G+C content [also known as H DNA or terminal repeats (TR)] (Moore et al., 1996b;
Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 1996).
Approximately 90 genes have been identified within KSHV’s LUR, which
exhibits similar genetic organization to herpesvirus saimiri (HVS) (Moore et al., 1996b;
Neipel, Albrecht, and Fleckenstein, 1997). KSHV and HVS share approximately 70
conserved genes that are arranged co-linearly, with small intermittent regions of genes
unique to each virus. The nomenclature for individual viral genes corresponds to the
previous assignation of genes for HVS, thus each conserved gene has been designated the
prefix “ORF” and numbered consecutively from left to right across the viral genome,
while the KSHV idiosyncratic genes within the intermittent regions have been named K1
to K15 (Russo et al., 1996). Other nonhuman members of the genus rhadinovirus, such
as the rhesus rhadinovirus and murine gammherpesvirus 68, have shown stark
conservation regarding their genetic organization.
The conserved genes among the rhadinovirus genus are those which function in
both virion structure and viral DNA replication (in either metabolic or catalytic roles)
such as the following: glycoprotein B (ORF8), glycoprotein H (ORF22), DNA
polymerase (ORF9), polymerase processivity factor (ORF59), DNA helicase-primase
complex (ORF40, ORF41 and ORF44), thymidylate synthase (ORF70), and thymidine
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kinase (ORF21) (McGeoch and Davison, 1999; Moore et al., 1996b; Neipel, Albrecht,
and Fleckenstein, 1997; Russo et al., 1996). Interestingly, KSHV and the Epstein-Barr
virus (EBV), the only other human gammaherpesvirus, share both structural and
biological features with a lucid genetic correspondence; both KSHV and EBV are
considered oncogenic viruses yet KSHV lacks any of the EBV unique latency genes
(Knipe et al., 2001; Russo et al., 1996). EBV and KSHV both utilize B cells as a reservoir
during latency and they both cause B cell tumors (Knipe et al., 2001). EBV proteins
induce the expression of a certain set of cellular genes, and KSHV seems to have
captured and modified this set of human cDNAs and incorporated them into its genome
(Knipe et al., 2001; Neipel, Albrecht, and Fleckenstein, 1997).
The Capsid
Similar to other herpesviruses, capsids are the first structures that arise after the
initiation of KSHV replication, which accumulate in the nucleus and upon further
maturation the capsids harbor the linear viral genome. However, viral DNA packaging
only occurs in a fraction of newly synthesized capsids (Knipe et al., 2001; Renne et al.,
1996b). Encapsidated KSHV DNA is thought to be analogous to encapsidated HSV-1
DNA, which is present within the capsid as a single linear copy encoding the entire viral
genome (Booy et al., 1991). In comparison to EBV, the KSHV genome is present in
infected cells as a circular form during latency and upon reactivation the viral genome
linearizes and is amenable to subsequent incorporation into capsids (Decker et al., 1996;
Knipe et al., 2001; Renne et al., 1996a).
In cells infected with a herpesvirus, lytic replication leads to the accumulation of
viral capsids within the nuclei, thus investigations of HSV-1 and HCMV capsid
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structures have used the nuclei of infected cells as a source of viral capsids for
biochemical analyses (Homa and Brown, 1997). Unfortunately, structural capsid studies
of gammaherpesviruses have been hampered by the unsuccessful attempts of procuring a
sufficient amount of stable intranuclear capsids. For EBV and KSHV, this technical
hurdle was overcome by using released virions in the supernatants of induced infected
cells as a stable source of KSHV capsids (Dolyniuk, Pritchett, and Kieff, 1976; Nealon et
al., 2001; Trus et al., 2001; Wu et al., 2000). The establishment of a stable source of
KSHV capsids has allowed investigators to determine the protein composition of the
capsid and the molecular ratios of the proteins involved in the architecture of the capsid
(Nealon et al., 2001; Trus et al., 2001; Wu et al., 2000). KSHV infected cells produce
three major capsid types, which can be easily visualized via electron microscopy and
separated by density gradient sedimentation. The three major capsid forms are the
following: 1.) A capsids, 2.) B capsids and 3.) C capsids. A capsids, which have a total
mass of 200MDa, are empty icosahedral shells void of DNA or any detectable internal
structure. B capsids, which have a total mass of 230 MDa, are icosahedral shells filled
with an inner array of scaffolding protein originated from ORF17.5 (Nealon et al., 2001).
C capsids, which have a total mass of 300 MDa, are icosahedral shells that are filled with
one copy of the KSHV DNA yet lack the scaffolding protein, which was present in the B
capsids. The A, B, and C capsid types consist of four viral proteins the ORF25/MCP
(major capsid protein), ORF62/TRI-1 (triplex-1), ORF26/TRI-2 (triplex-2), and
ORF65/SCIP (small capsomer interacting protein) (Nealon et al., 2001; Trus et al., 2001;
Wu et al., 2000). Herpesvirus capsids consist of 150 hexameric and 12 pentameric
capsomers formed exclusively from the KSHV-ORF25 product, the major capsid protein
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(MCP). The majority of the capsid’s mass could be attributed to MCP, which is highly
conserved throughout the herpesvirus family (Homa and Brown, 1997). The capsomers
are linked together via hetero-triplexes, which protrude from the capsid floor in between
the capsomer structures (Trus et al., 2001; Wu et al., 2000). In KSHV, the heterotriplexes consist of two molecules of ORF26/TRI-2 and one molecule of ORF62/TRI-1
(Nealon et al., 2001). Type C capsids are the only type of capsid isolated by deenveloping intact virions; moreover, type C capsids are the least abundant capsid type
(about 10-15% of total capsids produced) found in the supernatants of induced BCBL-1
cells (Gibson and Roizman 1972; Shrag et al 1989; Nealon et al., 2001). The small
percentage of type C capsids produced from BCBL-1 cells may provide an explanation of
the low infectivity of KSHV in experiments using this cell line as a source of virus stock
(Nealon et al., 2001).
The Tegument
Generally, the tegument layer of herpesviruses is an amorphous proteinaceous
region between the outer surface of the capsid and the underface of the envelope; the
tegument is considered to manifest variations in both size and composition (Roizman and
Furlong, 1974). Limited information is available in about the structure and function of
the herpesvirus tegument, particularly the KSHV tegument. Certain herpesvirus
tegument proteins have been shown to possess regulatory functions essential for the viral
lifecycle; tegument proteins are functional upon penetration of the virus into cells. Thus
tegument proteins play a key role in creating a conducive milieu for viral replication
(Knipe et al., 2001). KSHV ORF45 is an immediate-early protein shown to be present in
the tegument area of virions, thus suggesting that KSHV ORF45 plays a role in primary
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infection (Zhu and Yuan, 2003). ORF45 protein has been shown to bind cellular IRF-7
and inhibits its phosporylation and transport from the cytoplasm to the nucleus in
response to viral infection (Zhu et al., 2002). The type I IFNs (Interferons) are produced
by virus infected cells and is regulated, in part, by IRF-7, (IFN-regulatory factor) a
transcription regulator that serves a critical role in virus-mediated induction of IFN-α and
IFN-β(Samuel, 2001; Stark et al., 1998). In addition to tegument proteins, mRNAs,
spanning more than one kinetic class, are also packaged within infectious virions of alpha
and betaherpesviruses(Bresnahan and Shenk, 2000; Sciortino et al., 2001; Sciortino et al.,
2002). It remains to be seen whether or not KSHV also possesses mRNAs within intact
virions.
The Envelope
A lipid bilayer envelope, obtained from the infected cell, in which viral
glyoproteins are embedded, constitutes the outermost layer of the KSHV particle.
KSHV specifies several glycoproteins designated as gB, gH, gpK8.1, gL, gM, gN and
others (Koyano et al., 2003; Russo et al., 1996). The majority of herpesviral
glycoproteins function throughout the viral lifecycle, in the following roles: attachment,
penetration, egress, and virus-induced cell fusion (Knipe et al., 2001).
Kaposi’s Sarcoma-Associated Herpesvirus Lifecycle
The principal events in the KSHV lifecycle in cell culture systems involve the
attachment of the virus to the cell surface, penetration of the virus into the susceptible
cell, host protein synthesis shut-off, movement of the de-enveloped tegument-capsid
structure toward the nuclear pores thereby releasing viral DNA into the nucleus,
coordinated cascade of viral genome transcription, replication of the viral DNA, and
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packaging of viral genomes into capsids, maturation of the virions, and transit of
infectious virions to the extracellular spaces (Knipe et al., 2001).
Attachment
Attachment of many enveloped viruses is known to be mediated by interactions
between specific viral glycoproteins with cellular receptors. Typically, herpesvirus entry
into a susceptible cell can be categorized into two steps: 1.) Attachment of virus to cell
surfaces and 2.) Fusion of the viral envelope with cellular membranes leading to entry of
viral capsids into the cellular cytoplasm. Initial virus attachment events provide loosely
associated interactions with cells and are mediated via KSHV glycoproteins with
ubiquitous heparan sulfate proteoglycan moieties on the surface of susceptible
cells(Akula et al., 2001a; Akula et al., 2001b; Birkmann et al., 2001; Wang et al., 2001a).
Proteoglycans consist of a protein core with one or more covalently attached
glycosaminoglycans such as heparan sulfate or chondrotin sulfate. Proteoglycans are
found abundantly on the surface of mammalian cell membranes, as integral membrane
proteins, glycerol phosphatidyl inositol-linked membrane proteins, and proteins of
extracellular matrices (Stringer and Gallagher, 1997). Proteoglycans serve in various
fundamental cellular processes such as the following: 1.) cell-to-cell adhesion, 2.) cell-tomatrix adhesion, 3.) cellular motility, 4.) cellular growth and 5.) cellular signaling
(Kjellen and Lindahl, 1991; Rostand and Esko, 1997).
Enveloped viruses, particularly herpesviruses, exploit the anatomical
characteristics of mammalian cell membranes in both their attachment and entry
mechanisms. Herpesviruses spanning every subfamily have been shown to bind heparan
sulfate during the initial attachment phase of viral entry. The following herpesviruses
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bind heparan sulfate: alphaherpesvirus [HSV-1, HSV-2, PRV, and BHV-1] (Flynn and
Ryan, 1995; Flynn and Ryan, 1996; Herold et al., 1994; Laquerre et al., 1998; Liang,
Babiuk, and Zamb, 1993; Mettenleiter et al., 1990; Shieh and Spear, 1994; Shukla et al.,
1999; Shukla and Spear, 2001; Spear, 2004; Spear and Longnecker, 2003; Spear et al.,
1992; WuDunn and Spear, 1989), betaherpesviruses [HCMV and HHV-7] (Navarro et
al., 1993; Neyts et al., 1992; Secchiero et al., 1997; Skrincosky et al., 2000), and
gammaherpesviruses [BHV-4 and KSHV] (Akula et al., 2001a; Akula et al., 2001b;
Birkmann et al., 2001; Vanderplasschen, 1999; Vanderplasschen et al., 1993; Wang et al.,
2001a).
Binding of herpesvirus particles to cell surfaces is inhibited by soluble heparin, a
molecule similar in structure to heparan sulfate. The significant inhibition of KSHV
binding to susceptible cells suggests that KSHV interacts with cell surface heparan
sulfate at the attachment stage; however, the inability of heparin to completely inhibit
binding and infectivity indicates that additional ligand-receptor interactions are needed to
complete the viral entry process (Akula et al., 2001b). From the cadre of glycoproteins
on the envelope of the KSHV particle, virion envelope-associated gB and soluble
chimeric K8.1 glycoproteins have been shown to exhibit strong affinity for heparin
binding, and their binding to cell surfaces could be inhibited by the addition of heparin in
a dose-dependent manner(Akula et al., 2001a; Birkmann et al., 2001; Wang et al., 2001a).
Thus, indicating an important role for glycoproteins K8.1 and gB in KSHV attachment
mediated by heparan sulfate proteoglycan moieties.
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Receptor Facilitated Entry
KSHV manifests a broad cellular tropism, which could be attributed partially to
the weak binding of KSHV to cell surfaces via the ubiquitous heparan sulfate
molecules(Akula et al., 2001a; Akula et al., 2001b; Birkmann et al., 2001; Wang et al.,
2001a). KSHV has been shown to infect a variety of human cell types such as the
following: B, T, endothelial, epithelial, fibroblast, and keratinocyte cells; the nonhuman
cell types that are susceptible to KSHV are the following: owl monkey kidney and baby
hamster fibroblast cells (Cerimele et al., 2001; Ciufo et al., 2001; Flore et al., 1998;
Foreman et al., 1997b; Gao, Deng, and Zhou, 2003; Kliche et al., 1998; Mesri et al.,
1996; Moore et al., 1996b; Panyutich, Said, and Miles, 1998; Renne et al., 1998; Vieira et
al., 2001; Zhou et al., 2002).
Herpesviruses utilize multiple receptors for binding and entry into cells. For
example, HSV-1 can utilize one of three different classes of receptors, which strongly
bind to to the viral glycoprotein ligand gD subsequent to heparan sulfate binding by
HSV-1 gB or gC (Spear, 2004; Spear, Eisenberg, and Cohen, 2000; Spear and
Longnecker, 2003). HSV-1 receptors which bind glycoprotein gD include HVEM
(herpesvirus entry mediator), a member of the TNF receptor family; nectin-1 and nectin2, members of the immunoglobulin superfamily; and specific sites in heparan sulfate
generated by glucosaminyl 3-O-sulfotransferases (Spear, 2004; Spear, Eisenberg, and
Cohen, 2000; Spear and Longnecker, 2003). HSV-1 glycoproteins gC and gD are
conserved among most of the members of the alphaherpesvirus subfamily, but exhibit no
recognizable structural homologues in members of the betaherpesvirinae and
gammaherpesvirinae of the Herpesviridae family (Knipe et al., 2001; Spear, 2004; Spear,
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Eisenberg, and Cohen, 2000; Spear and Longnecker, 2003). However, glycoproteins gB,
gH and gL are structurally conserved among all herpesviruses and perhaps possess
conserved essential fusogenic roles in viral entry (Knipe et al., 2001; Spear, 2004; Spear,
Eisenberg, and Cohen, 2000; Spear and Longnecker, 2003).
KSHV was the first herpesvirus shown to utilize integrin as a cellular receptor for
target cells (Akula et al., 2002; Nemerow and Cheresh, 2002). KSHV gB contains an
RGD motif which binds specifically to the integrin α3β1 receptor(CD49c/29) (Akula et
al., 2002; Wang et al., 2003). Binding to integrins is not a common feature of herpesvirus
gBs; there has been no other herpesvirus gB that possesses a similar conserved RGD
motif. The integrin α3β1 is broadly expressed and has been detected on all cells
susceptible to infection by HHV-8, including human foreskin fibroblasts and B,
epithelial, endothelial, and 293 cells (Akula et al., 2002). Also, a recent study has shown
that the Epstein-Barr virus, EBV, implements an integrin-mediated mechanism to infect
the basolateral surface of polarized oropharyngeal cells; in this study, the BMRF-2
glycoprotein binds via an RGD motif and facilitates entry via the interactions with either
the β1 integrin or α5β1 integrin receptors (Tugizov, Berline, and Palefsky, 2003).
The second phase of herpesviral entry subsequent to initial and secondary
attachment is penetration of attached enveloped viruses into the cytosol of the infected
cell. Viruses have been shown to penetrate susceptible cells via two routes. The first
route of viral entry involves the virion fusing its juxtaposed envelope with the apposing
cell membrane and then release of the nucleocapsid with accompanying tegument
proteins into the cytosol, typically (but not exclusively) herpesviruses utilize this
membrane fusion pathway (Knipe et al., 2001; Liu et al., 2002; Marsh and Pelchen-
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Matthews, 2000). The second entry pathway used by viruses is a receptor-mediated
endocytosis of virions into susceptible cells; nonenveloped DNA viruses, nonenveloped
RNA viruses and enveloped RNA viruses utilize the endocytotic pathway (Anderson,
Chen, and Norkin, 1996; Jin et al., 2002; Joki-Korpela et al., 2001; Marjomaki et al.,
2002; Selinka, Giroglou, and Sapp, 2002; Sieczkarski and Whittaker, 2002b).
Endocytosis is a particularly attractive entry mechanism for viruses, particularly
DNA viruses, due to the fact that endosomes present a quick and expedient manner for
virus to traverse the labrynthine cytoplasm in order to deliver the viral DNA to an area
near the nuclear pore, thus allowing DNA viruses to replicate their genomes in the
nucleus of infected cells (Marsh and Pelchen-Matthews, 2000; Sieczkarski and
Whittaker, 2002a; Whittaker and Helenius, 1998). KSHV has been shown to enter both
human B cell line, BJAB, and human foreskin fibroblast cells, HFF, via large endocytotic
vesicles (Akula et al., 2003; Akula et al., 2001b). Epstein-Barr virus (EBV) infects two
human cell types, B lymphocytes and epithelial cells. Electron microscopic studies have
shown that EBV fuses with the lymphoblastoid cell line Raji but is endocytosed into thinwalled non-clathrin-coated vesicles in normal B cells before fusion takes place (Miller
and Hutt-Fletcher, 1992; Nemerow and Cooper, 1984). Although KSHV has been shown
to enter B cells and HFF cells via an endocytic pathway, the release of capsids into the
cytoplasm is thought to involve fusion of the viral envelope with either plasma or
endosomal membranes. Furthermore, KSHV glycoprotein induced membrane fusion in a
cell-based assay with susceptible cells as targets has been shown to require only gB, gH,
and gL in order to induce cell-to-cell fusion, thus implying a role for these glycoproteins
as fusogenic molecules in both cell-to-cell fusion and perhaps virus-to-cell fusion
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mechanisms(Pertel, 2002). The actual mechanism of virus-induced membrane fusion or
the associated viral molecules involved in mediating and/or regulating virus-to-cell or
cell-to-cell fusion has yet to be fully understood; however, herpesviral fusion
mechanisms are under intense investigation (Foster, Alvarez, and Kousoulas, 2003;
Foster et al., 2004; Foster et al., 2003; Melancon, Foster, and Kousoulas, 2004). Recent
studies on the KSHV-gB molecule has demonstrated the induction of signal transduction
mechanisms upon binding of either virions or soluble gB molecules onto target cells; the
signal transduction mechanisms seems to prepare the target cell for viral entry via
morphological changes exhibited by the following: 1.) commencement of endocytic
pathways, 2.) movement of particulate materials in the cytosol, and 3.) cytoskeletal
rearrangements through the reorganization of actin (Akula et al., 2003; Akula et al., 2002;
Akula et al., 2001b; Sharma-Walia et al., 2004; Wang et al., 2003).
KSHV Latency
One of the striking features of all herpesviruses is its ability to remain in a latent
state for extended periods of time, KSHV latency could easily last decades before
reactivation. KSHV is similar to other herpesviruses in which infections could present
itself as either latent (nonproductive) or lytic (productive). A productive lytic infection
of herpesviruses leads to large amounts of virions and cell death via lysis. Intuitively,
lytic infections are not congruent with the events leading to cell transformation and
eventual cancer; KSHV readily transforms cells leading to tumorigenesis in vivo (Ablashi
et al., 2002; Boshoff and Weiss, 1998; Moore and Chang, 2003).
EBV latent infection and the concomitant expression of the latent viral genes have
been shown to be essential for the development of EBV-related lymphoproliferative
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disorders(Griffin, 2000). Analogous to EBV, KSHV establishes a latent infection in the
vast majority of tumor cells in Kaposi’s Sarcoma lesions, thus implying that KSHV latent
infection plays an essential role in the development of Kaposi’s Sarcoma lesions(Moore
and Chang, 2001). Similar to EBV, KSHV exhibits two distinct latent and lytic DNA
replication and gene expression programs in infected cells (Ballestas, Chatis, and Kaye,
1999; Ragoczy and Miller, 2001). KSHV latent and lytic DNA replication is crucial and
necessary for the long-term persistence of the virus; moreover, both latent and lytic gene
expression programs are involved in the pathogenesis of KSHV-related
lymphoproliferative disorders(Cesarman, 2002; Jenner and Boshoff, 2002).
KSHV expresses seven genes, which constitute the latent gene expression
program; this set of latent genes have been shown to manifest both growth transforming
and cell cycle-deregulating properties thus providing a conducive milieu for KS
pathogenesis(Cesarman, 2002; Cotter and Robertson, 2002; Komatsu et al., 2002). The
KSHV genes expressed in the latent program are the following: LANA-1 (ORF73), vcyclin D (ORF72), v-FLICE (K13), kaposin A (K12), v-IRF-2 (K11.5), LANA-2 (K10.5)
and LAMP (K15). LANA-1 is perhaps the most important latent gene expressed during
the latent cycle, since it has been shown by several investigators to be the most active and
serve a myriad of roles: 1.) binds transcriptional corepressors (SAP30, Sin3A, CIR), 2.)
possesses a nuclear localization motif, 3.) binds KSHV TR DNA cooperatively and
supports TR directed viral replication, 4.) binds host chromatin proteins, 5.) binds and
inhibits p53, 6.) binds RB1, 7.) transcriptional activation through E2F, 8.) transcriptional
activation of EBV latency promoters, 9.) binds HIV-1 Tat, and 10.) binds to KSHV-Rta,
the KSHV major transactivator(Dourmishev et al., 2003; Lan et al., 2004).
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LANA-1, v-cyclin D and v-FLICE (K13) are latent transcripts present and
expressed from a differentially spliced polycistronic mRNA, in which their transcription
is regulated via a common promoter (Cesarman et al., 1996; Dittmer et al., 1998;
Grundhoff and Ganem, 2001; Sarid et al., 1999; Talbot et al., 1999). LANA-1 has been
consistently shown to be the immunodominant latent antigen expressed in KS lesions
(Dupin et al., 1999; Gao et al., 1996a; Gao et al., 1996b; Kedes et al., 1997; Kedes et al.,
1996; Kellam et al., 1997; Rainbow et al., 1997). LANA-1 consists of 1,162 amino acid
and is identified as protein doublets of 222- to 234-kDa in infected cell lines by Western
blot analysis (Kedes et al., 1997; Rainbow et al., 1997). LANA-1 exhibits a punctuate
nuclear distribution pattern in immunohistochemical experiments (Gao et al., 1997; Gao
et al., 1996b; Kedes et al., 1996). LANA-1 has been shown to be a multifunctional
protein able to autoactivate its own promoter (Jeong, Papin, and Dittmer, 2001; Renne et
al., 2001). Viruses that establish latent infection must maintain their DNA in the host
nucleus through many cellular generations; thus KSHV must replicate its latent circular
genome before each cell division and then successfully segregate into progeny cells.
KSHV latently infected cells harbor several copies of an extrachromosomal circular
KSHV DNA, also known as the KSHV episomes. In uninfected B lymphoblastoid cells,
the expression of KSHV LANA-1 allows for the persistence of an episome containing the
KSHV terminal repeat (TR) sequence (Ballestas, Chatis, and Kaye, 1999; Ballestas and
Kaye, 2001); thus showing a necessary and sufficient role for LANA-1 in KSHV episome
persistence in transfected cells Ballestas, 1999 #1325; Ballestas, 2001 #794}.
Furthermore, LANA-1 has been shown to specifically bind KSHV TR DNA and allow
for its replication (Cotter and Robertson, 1999; Cotter, Subramanian, and Robertson,
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2001; Fejer et al., 2003; Garber, Hu, and Renne, 2002; Grundhoff and Ganem, 2003; Hu,
Garber, and Renne, 2002; Lim et al., 2002).
The gene expression profile of genes within a given cell determines the cell fate
and is in a large part due to effects of chromatin remodeling and structure (Litt et al.,
2001). In KSHV infected pleural effusion lymphoma cells, the majority of cells harbor
KSHV in a latent state, in which most of the viral genes are silenced; the precise
mechanisms of viral gene silencing are unknown (Renne et al., 1996b). LANA-1 has
been shown to localize at the host heterochromatin region, an area where the majority of
the genes are inactive or silenced (Szekely et al., 1999). The chromatin protein
SUV39H1 methylates the histone H-3 protein thus allowing for the Heterochromatin
protein 1 (HP-1) to bind to the methylated histone H-3 protein and expand the
heterochromatin region(Aagaard et al., 1999; Bannister et al., 2001; Lachner et al., 2001).
A recent study has shown that LANA-1 can specifically recruit SUV39H1 and HP-1 to
the KSHV genome thus leading to formation of heterochromatin, which could in part
explain the localization of the KSHV latent genome in the heterochromatin(Sakakibara et
al., 2004).
KSHV has been shown to associate with mitotic chromosomes(Ballestas, Chatis,
and Kaye, 1999; Krithivas et al., 2002; Piolot et al., 2001; Szekely et al., 1999);
immunofluorescence experiments have shown that the concentration of LANA-1 at sites
of KSHV DNA along mitotic chromosomes(Ballestas, Chatis, and Kaye, 1999; Cotter,
Subramanian, and Robertson, 2001; Jones et al., 1998; Szekely et al., 1998). During
latency, LANA-1 binds specifically to the TR region of DNA repeat sequences consisting
of 801 base-pair units and containing an origin of replication (OriP) (Ballestas, Chatis,
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and Kaye, 1999; Ballestas and Kaye, 2001; Garber et al., 2001). The tethering of the
KSHV genome by LANA-1 is also done by its interaction with host chromatin proteins
such as histone H1, MeCP, DEK, RING3(Cotter, Subramanian, and Robertson, 2001;
Krithivas et al., 2002; Mattsson et al., 2002). Unlike other KSHV promoters tested thus
far, LANA promoter is not affected by tetradecanoyl phorbol acetate or viral lytic cycle
functions. It is, however, subject to control by LANA itself and cellular regulatory
factors, such as p53.
Viral Gene Transcription and Expression
Traditionally, transcription of herpesvirus genes is tightly regulated and is
sequentially ordered in a cascade fashion (Knipe et al., 2001). The sequentially ordered
cascade of transcription occurs via a simultaneously sequentially ordered viral protein
cascade which modulates viral gene expression. Herpesviruses conscript the host RNA
polymerase and other members of the host transcriptional apparatus in order to execute
its viral transcriptional program; transcription of herpesviral DNA occurs in the nucleus
and the viral proteins are synthesized in the cytoplasm (Knipe et al., 2001). Herpesviral
genes are categorized into mutually exclusive latent and lytic profiles. This dichotomy of
herpesviral gene transcription involves the latent phase which occurs while the viral
genome is maintained as an episome and a lytic phase which takes place in a cascade
fashion during productive (lytic) infection. Upon establishment of a latent infection
(nonproductive) only a handful of genes are expressed. During the course of a productive
(lytic) herpesviral infection, approximately eighty genes are expressed. Lytic infection of
KSHV leads to cell lysis and therefore cell death, which is counterintuitive and
inconsistent with the establishment of KSHV transformation of the infected cell. A
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strikingly low level of KSHV infected PEL cultures undergo spontaneous lytic gene
expression which could be readily detected in a stable milieu of PEL cultures that exhibit
latent expression; the infrequent spontaneous KSHV-reactivation correlates well with the
infrequent reactivation detected in KS clinical samples (Fakhari and Dittmer, 2002;
Jenner et al., 2001; Paulose-Murphy et al., 2001; Sarid et al., 1998). The majority of
infected cells in KS specimens exhibit latent KSHV gene expression, with a scant number
of cells expressing lytic transcripts (Chan, Bloomer, and Chandran, 1998; Dupin et al.,
1999; Katano et al., 2000; Lin, Dai, and Ricciardi, 1998; Orenstein et al., 1997;
Parravicini et al., 2000; Staskus et al., 1997; Sun et al., 1999), thus implying that the low
level of spontaneous lytic gene expression is not an artifact of tissue culture models.
Recently, models of de novo infection of cultured endothelial cells have also manifested a
similar “hodge-podge” pattern of latent and lytic gene expression (Ciufo et al., 2001;
Lagunoff et al., 2002; Moses et al., 1999). Both latent and lytic cycle replication are
crucial for the long-term persistence of the virus, and gene products from both latent and
lytic gene expression programs have been implicated in the pathogenesis of KSHVassociated disorders (Cesarman, 2002; Jenner and Boshoff, 2002).
Classification of the latent or lytic gene expression of individual KSHV ORFs
would serve an immense role in the prediction of their potential contribution to the
pathogenesis of the KSHV infection. The facilitation of cultured PEL cells latently
infected with KSHV and inducing lytic reactivation with common laboratory chemicals
(such as phorbol esters or sodium butyrate) have led to clear assignation of individual
KSHV genes to either the latent or lytic gene expression. Typically, PEL cell lines (in
which every cell in the PEL culture is infected with KSHV) carry an approximately 40 to
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150 copies of KSHV DNA per cell genome (Drexler et al., 1998). Upon routine passage
of the PELs, the virus is consistently maintained as a latent episome, with concomitant
restriction of lytic viral gene expression and a paucity of virus production. Upon chemical
induction of PELs, viral gene expression switches from the latent program to an ordered
cascade of lytic gene expression, leading to viral replication, virion production, cell lysis,
and viral release (Renne et al., 1996a; Renne et al., 1996b; Sarid et al., 1998; Zhong et
al., 1996).
The expression pattern of each KSHV ORF was categorized into three classes of
gene transcription: I, II, and III; the assignation of each ORF to its respective classs was
determined by the individual gene response to the addition of TPA to PEL cultures (Sarid
et al., 1998). Class I transcripts are constitutively expressed and are not induced by
phorbol esters. Class I gene transcripts correspond directly with the latent gene
expression profile, which includes ORF73 (LANA-1), ORF72 (viral cyclin D [vCyc])
and K13 (fas-ligand IL-1 β-converting enzyme inhibitory protein [vFLIP]); these proteins
are readily detected in KS samples further establishing the categorization within the latent
phase of the KSHV transcriptional program (Davis et al., 1997; Dittmer et al., 1998). The
three mentioned class I KSHV-ORFs have corresponding sequence homologs in HVS
(Nicholas, Cameron, and Honess, 1992; Thome et al., 1997), and their respective
expressed protein serve crucial roles in latency and cellular transformation (Dourmishev
et al., 2003). ORF K13 (vFLIP) encodes a viral inhibitor of a cellular homologue of the
Fas-mediated apoptosis (Thome et al., 1997). ORF 72 (vCyc) encodes a functional cyclin
D homolog which could substitute for human cyclin D by phosphorylating the
retinoblastoma tumor suppressor protein (Chang et al., 1996). ORF73 (LANA-1)
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encodes LANA (Rainbow et al., 1997), a highly immunogenic protein that is highly
expressed and is the basis for both immunofluorescence and Western assay-based
serological tests (Gao et al., 1996a).
The second class of gene transcription, class II, includes mRNAs which are
detected in variable abundance of high, moderate, or low in unstimulated cultures grown
under standard growth conditions without phorbol esters, yet class II transcripts could be
readily induced to higher levels of transcription by TPA(Sarid et al., 1998). Examples of
class II mRNAs that are transcribed at moderate levels without TPA treatment include the
following: cytokines v-IL-6 (ORF K2), v-MIP-II (ORF K4), and v-IRF (ORF K9). A
true latent transcription is restricted in both PEL and KS lesions. However, a number of
genes are expressed, generally at low transcription levels, in PEL without TPA treatment
and are inducible with TPA (class II). The majority of class II genes includes typical
herpesviral regulatory and viral DNA replicative genes, along with a majority of the viral
homologs of cellular genes(Sarid et al., 1998). Interestingly, the class II category of
transcription includes many unique KSHV genes (e.g., the viral cytokines and v-IRF),
which lead many to believe that these transcripts serve essential roles in the manipulation
of cellular pathways, regulation of viral infection and transformation of the host cell(Gao
et al., 1997; Moore and Chang, 1998). Both class I and II genes are the least conserved
among all herpesviruses, and these genes tend to cluster within the same region of the
KSHV genome; this region containing regulatory genes are also referred to as “latency
islands’ (Knipe et al., 2001; Moore et al., 1996a; Moore and Chang, 2001).
The final class of gene transcription, class III, involves transcripts that could only
be detected after induction with the phorbol esters (Sarid et al., 1998). Class III
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transcripts include lytic genes which are transcribed during active infection and are
necessary for efficient lytic-viral replication and virion particle production; examples of
class III include the following transcripts: ORF 25 (major capsid protein), ORF 6 (DNA
polymerase), and ORF 22 (glycoprotein H) (Sarid et al., 1998). The class III category
consists of many genes which are highly conserved among all herpesviruses and possess
functional roles in DNA replication and virion morphogenesis (Knipe et al., 2001; Sarid
et al., 1998).
Reactivation
Typically in traditional herpes simplex infections (the prototype herpesvirus), a
tegument protein localizes to the nucleus and activates the immediate early gene
expression, which in turn commences the sequentially ordered cascade of viral gene
expression characteristic of herpesviruses (Knipe et al., 2001). The two human gamma
herpesviruses, EBV and KSHV, manifest similar patterns of the latent and lytic phases of
infection, and both of these gammaherpesviruses require a reactivation mechanism in
order to switch from the latency phase to the lytic phase. KSHV latency is critical in the
establishment of a permanent infection both in vitro and in vivo, the latency phase
permits the virus evasion of the host immune surveillance and to establish persistent
infection (Moore and Chang, 2003). In addition, latent infection by either KSHV or EBV
plays a major role in tumorigenesis (Cesarman, 2002; Chang and Moore, 1996). Due to
KSHV’s characteristic establishment of latent infection in susceptible cells, viral
reactivation must overcome a stringent regulation of viral gene expression, wherein viral
gene expression is highly limited and tightly controlled. KSHV spontaneously reactivates
in infected cells allowing for viral lytic replication. Both tetradecanoyl phorbol acetate
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(TPA) and sodium butyrate (NaB), have been shown to disrupt the latency of KSHV in
BCBL-1 cells and induce lytic viral replication (Arvanitakis et al., 1996; Renne et al.,
1996b; Yu et al., 1999). As mentioned in the previous section, five latent genes are
expressed during latency: 1.) LANA-1, 2.) v-cyclin, 3.) v-FLIP, 4.) kaposin, and 5.)
vIRF-2 (Burysek and Pitha, 2001; Dittmer et al., 1998; Muralidhar et al., 1998; Rainbow
et al., 1997; Sadler et al., 1999; Saveliev, Zhu, and Yuan, 2002). The expression profile
of these latent genes serve a crucial role in the maintenance of latency and cellular
transformation, which at this point has not yet been fully understood. The current school
of thought suggests that lytic reactivation of a low percentage of infected cells is
necessary for KS development (Lukac, Kirshner, and Ganem, 1999; Martin and Osmond,
1999; Whitby et al., 1995). Accumulation of evidence over the years clearly suggests a
role for reactivation and/or lytic replication in the pathogenesis and induction of KS
tumors: 1.) linkage between the humoral immune response to KSHV infection and KS
tumor progression (Whitby et al., 1995); 2.) augmentation of KSHV viral load in patients
correlates with progression from asymptomatic phase to KS (Ambroziak et al., 1995); 3.)
patients dually infected with both KSHV and HIV when treated with ganciclovir, a drug
that effectively targets KSHV lytic replication, leads to a decreased incidence of KS
development (Martin and Osmond, 1999), and 4.) both KS tumor cells (typically manifest
a latent KSHV infection) and KSHV infected spindle cells (also typically manifest a
latent KSHV infection); yet, KS tumor cells and KSHV infected spindle cells consistently
exhibits a certain, albeit low, percentage of latent cells undergoing spontaneous
reactivation with concomitant lytic replication (Reed et al., 1998; Staskus et al., 1999;
Staskus et al., 1997; Zhong et al., 1996). Viral lytic reactivation and DNA replication is
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considered crucial in KSHV spread from the lymphoid reservoir, B-cells, to endothelial
cells thus leading to the KS spindle cell formation (Offermann, 1999). Hence the
reactivation mechanisms regulating the latent to lytic replication switch in KSHV
infected cells serves as an essential cog in the development of KS and the KSHV-related
lymphoproliferative disorders.
Regulation of Transcriptional Activation
Upon phorbol ester induction of KSHV latently infected cells, the sequentially
ordered cascade of the KSHV lytic lifecycle commences with rapidity due to the
functional role of the KSHV-regulator of transcription activator (Rta). Although the
majority of KSHV genes have been screened, the KSHV-Rta has been the only protein
when overexpressed sufficient for viral reactivation (Gradoville et al., 2000; Lukac,
Kirshner, and Ganem, 1999; Lukac et al., 1998; Sun et al., 1998). KSHV-Rta was
initially identified based on positional analogies and sequence homology with EBV and
HVS (Sun et al., 1998). The KSHV-Rta is one of the earliest immediate-early transcripts
induced upon viral reactivation (Sarid et al., 1998; Sun et al., 1999; Zhu, Cusano, and
Yuan, 1999). The major ORF50 transcript is a tricistronic mRNA, which also encodes
the genes ORF-K8 (K-bZIP/RAP) and ORF-K8.1 (K8.1 glycoprotein) (Gruffat et al.,
1999; Lin et al., 1999; Lukac et al., 1998; Seaman et al., 1999; Sun et al., 1998; Zhu,
Cusano, and Yuan, 1999); alternative splicing mechanisms of the neighboring exons of
this tricistron also leads to the expression of two minor tricistronic transcripts (Zhu,
Cusano, and Yuan, 1999). The K-bZIP or RAP (ORF-K8) transcript is also produced
with immediate-early kinetics independently of the upstream ORF50 gene but its role in
reactivation has not been fully determined (Saveliev, Zhu, and Yuan, 2002). In clinical
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samples, the Rta is detected corresponding with the lytic pattern in KS lesions (Katano et
al., 2001; Sun et al., 1999). Rta, a 691 amino acid protein, has been shown to be highly
posttranslationally modified and extensively phosphorylated (Lukac, Kirshner, and
Ganem, 1999; Lukac et al., 1998). Numerous studies have shown via transfections
experiments that Rta is capable of transactivating KSHV promoters of genes that are
typically expressed upon a productive lytic infection (Chang et al., 2002; Chen et al.,
2000; Jeong, Papin, and Dittmer, 2001; Lukac et al., 2001; Lukac, Kirshner, and Ganem,
1999; Lukac et al., 1998; Song et al., 2001; Wang et al., 2001b; Zhang, Chiu, and Lin,
1998). Rta possesses a transcriptional activation domain located at its carboxyl terminus
domain which exhibits a similar structure conserved among several eukaryotic
transcriptional activation domains (Lukac et al., 1998); deletion of this transcriptional
activation domain generates an Rta-specific dominant negative inhibitor of
transactivation Rta which upon transfection into BCBL-1 effectively suppresses
spontaneous lytic reactivation from latency along with suppression of viral replication
induced by the following chemical agents: TPA, sodium butyrate, and ionomycin (Lukac,
Kirshner, and Ganem, 1999). Rta binds directly to various viral promoters with specific
sequences (Chang et al., 2002; Deng et al., 2002b; Liang et al., 2002; Lukac et al., 2001;
Song et al., 2002; Song et al., 2001). The majority of the targets of Rta transactivation
are considered essential for lytic replication, Rta has been shown to transactivate the
following genes which are considered essential for the virus to subvert normal regulatory
cell growth mechanism: kaposin, vIL-6, vMIP-I, vIRF-1, vGPCR, and K1 (Bowser,
DeWire, and Damania, 2002; Chen et al., 2000; Curreli et al., 2002; Deng et al., 2002b;
Ueda et al., 2002; Wang et al., 2001b). The significance of Rta in the dysregulation of
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cellular growth pathways is shown by Rta-mediated activation of cellular IL-6 (Deng et
al., 2002a), the ability of Rta to block p53-mediated apoptosis via competitive binding to
CBP(Gwack et al., 2001). Concordant with the orchestration of the KSHV lytic cycle by
Rta with concomitant manifestation of pathogenic progression, a clinical study has shown
the Rta promoter is repressed by methylation and upon demethylation of the promoter
latent KSHV genome is induced and begin lytic replication (Chen et al., 2001).
Viral DNA Replication
As a gamma-herpesvirus, KSHV possesses both latent and lytic replication
cycles(Miller et al., 1997; Renne et al., 1996a). However, latency expresses only a
minimal number of viral genes, and no infectious virus is produced during this phase. In
KSHV latently infected cells, multiple copies of the viral genome are harbored and
maintained as extrachromosomal episomes and latent KSHV DNA replication is
synchronized with host cell division (Ballestas, Chatis, and Kaye, 1999). The terminal
repeat (TR) sequence in the KSHV genome is necessary and sufficient for persistence of
the viral episome and potentially serves as the origin of latent plasmid replication (ori-P)
(Ballestas and Kaye, 2001). LANA-1 binds to cis-acting region within the KSHV TR
DNA and acts in trans on the ori-P to mediate episome persistence (Ballestas and Kaye,
2001). Upon KSHV reactivation with the concomitant disruption of latency, the virus
switches to a lytic life cycle which entails the facilitation of its lytic encoded replication
proteins (Miller et al., 1997; Renne et al., 1996a). During the viral lytic component of the
lifecycle, KSHV expresses the majority of its genes, and viral DNA is amplified by a
viral encoded replication apparatus different from the latent viral DNA replication
(Gradoville et al., 2000; Wu et al., 2001).
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In herpesviruses, lytic DNA replication is different in two regards from the latent
DNA replication. Firstly, upon lytic DNA replication viral DNA is amplified from a
range of 100 to a 1,000-fold via a rolling circle mechanism, which produces viral progeny
in concatemeric molecules also referred to as “head-to-tail” concatemers (Knipe et al.,
2001). This rolling circle replication which occurs during the lytic phase of the viral
lifecycle is in stark contrast to latent DNA replication which occurs simultaneous with
the host cell division with the subsequent effect of maintaining a stable and low number
of viral episomes. Secondly, lytic herpesviral DNA replication employs its own DNA
replication machinery replete with its own DNA polymerase and associated viral
components of the replication apparatus (Knipe et al., 2001). The herpesviral-encoded
lytic replication apparatus is another distinction from the herpesviral latent DNA
replication which requires the host cellular DNA polymerase along with its accessory
proteins.
The herpesviral lytic DNA replication is initiated from an origin (ori-Lyt) and
requires many viral gene products. The origin region or ori-Lyt is bound by a virusencoded origin-binding protein (OBP) that recruits the core replication machinery. A
number of herpesvirus lytic origins have been identified and characterized (Anders et al.,
1992; Anders and Punturieri, 1991; AuCoin et al., 2002; Hammerschmidt and Sugden,
1988; Pari et al., 2001; Stow, 1982; Stow and Davison, 1986). These studies indicate
several common features that have been identified within the herpesviral lytic origins,
such as, AT-rich regions that are presumably sites where DNA is melted or unwound,
numerous transcription factor-binding sites, and promoter enhancer elements, that are
associated with active transcription or assembly of the transcription machinery. In the
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KSHV genome, two copies of the lytic DNA replication origin [ori-Lyt (L) and ori-Lyt
(R)] have been identified (AuCoin et al., 2002; Lin et al., 2003). The first ori-Lyt is
located in the KSHV genome between K4.2 and K5 and the second ori-Lyt is located
between K12 and open reading frame 71 (ORF71). KSHV lytic origins closely resemble
the lytic origin of a related herpesvirus, rhesus macaque rhadinovirus (RRV) (Pari et al.,
2001). Both RRV and KSHV lytic origins have GC-rich regions proximal to an AT-rich
region. Initial mapping studies indicated that replication was dependent on the presence
of the AT-rich region and a portion of GC-rich region (AuCoin et al., 2002; Pari et al.,
2001).
The lytic herpesviral replication apparatus involving all of its necessary viral
trans-acting factors required for origin dependent DNA replication has been described
for the Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), and herpes simplex
virus type 1 (HSV-1) using a transient co-transfection replication assay (AuCoin et al.,
2004; Fixman, Hayward, and Hayward, 1995; Pari et al., 2001; Sarisky and Hayward,
1996; Wang, Zhang, and Montalvo, 1998; Wu et al., 1988). A common theme to the
herpesviral replication apparatus, which spans the three herpesviral subfamilies, is the
requirement of six core replication proteins for ori-Lyt -dependent DNA replication:
DNA polymerase, processivity factor, helicase, primase, primase-associated factor, and a
ssDNA binding protein (Knipe et al., 2001). The KSHV genome encodes a set of six
genes which have varying levels of homology to their respective core replication gene
counterparts in EBV, HSV, and HCMV; the six KSHV core replication proteins are listed
as followed: ORF9 (POL; DNA Polymerase), ORF59 (PPF; polymerase processivity
factor or DNA replication protein), ORF6 (SSB; single-stranded DNA binding protein),
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ORF56 (PRI; component of DNA helicase-primase complex), ORF40/41 (PAF;
polymerase accessory factor), and ORF44 (HEL; component helicase-primase complex).
Importantly, each herpesvirus encodes an initiator protein or an origin binding
protein, which allows the viral replication proteins to assemble and dock onto the ori-Lyt.
The Zta protein has been shown to be essential for EBV origin-dependent DNA
replication and serves to activate transcription as well as play a direct role in DNA
replication (Chang et al., 1990; Sarisky and Hayward, 1996). In terms of KSHV, Rta
serves as the major transactivator of gene expression and its presence has been shown to
be sufficient for KSHV viral reactivation. However, another protein displaying delayed
early kinetics, K-bZIP (K8, RAP), is postulated to be the initiator protein and may have a
direct role in the initiation of DNA replication (Lin et al., 2003).
KSHV Glycoproteins and Their Putative Functions
The Kaposi’s sarcoma-associated herpesvirus genome encodes several
glycoproteins, some of which possess significant homology to glycoproteins of other
herpesviruses. These include glycoprotein B (gB)[ORF8]), gH (ORF22), gM (ORF39),
gL (ORF47) (Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 1996), and gN
(ORF53) (Koyano et al., 2003). In addition, the K8.1 and vOX2 (K14) glycoproteins are
unique to KSHV, with no counterparts in other herpesviruses (Chandran et al., 1998;
Chung et al., 2002; Neipel, Albrecht, and Fleckenstein, 1997; Schulz, 1998).
Glycoproteins serve various functions at key points along the virus replicative cycle
which include the following: virus attachment, penetration, cell-to-cell spread, egress,
and virus-induced cell fusion. This section will review the features of these glycoproteins
and describe the putative functions associated with each glycoprotein. Description of the
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K8.1 glycoprotein is not included in this section, since an extensive discussion of K8.1 is
located in the next chapter.
Glycoprotein B (gB)
Glycoprotein B (gB) is conserved across all subfamilies of herpesviruses. gB
exists on the surface of infected cells or on virion envelopes as a homodimeric membrane
protein that is N-glycosylated at multiple sites (Claesson-Welsh and Spear, 1986;
Claesson-Welsh and Spear, 1987; Horsburgh et al., 1999; Ligas and Johnson, 1988;
Roop, Hutchinson, and Johnson, 1993; Spear et al., 2003). Herpesviral gB displays the
highest degree of conserved homology among the glycoproteins in the Herpesviridae
family; moreover, the carboxy-tail domain of gB exhibits the highest degree of conserved
homology within the gB molecule (Goltz et al., 1994; Pereira, 1994; Ross et al., 1989).
A wealth of evidence indicates that gB plays important roles in membrane fusion
phenomena during virus entry and virus-induced cell fusion: HSV-1 mutant viruses
lacking gB are not able to enter into cells (Cai et al., 1987) due to a post-attachment
defect that can be resolved by polyethylene glycol mediated fusion of viral envelopes
with cellular membranes (Cai, Gu, and Person, 1988). Point mutagenesis in which single
amino acid substitutions and/or truncations of the carboxyl terminus of gB cause
extensive virus-induced cell fusion (Baghian et al., 1993; Bzik et al., 1984; Cai et al.,
1988; Haan, Lee, and Longnecker, 2001). Transient transfection experiments showed
that the transient co-expression of HSV-1 gB along with gD, gH and gL causes cell-tocell fusion, which is substantially increased by carboxyl terminal truncations of gB
(Highlander et al., 1991; Kousoulas, Person, and Holland, 1978; Pogue-Geile et al.,
1984). Similarly, transient transfection experiments using KSHV-gB along with gH and
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gL were sufficient to cause cell-to-cell fusion; however, upon deletion of the final 59 a.a.
of the KSHV-gB carboxyl tail (termed gB-Mut) cell-to-cell fusion was significantly
enhanced. These results suggest a direct role for gB in membrane fusion and suggest that
perturbations of the carboxyl terminal domains of gB facilitate gB-mediated cell-to-cell
fusion.
The KSHV-gB molecule, similar to other herpesviral glycoproteins categorized as
type I integral membrane proteins, consists of four domains: 1.) signal peptide domain,
2.) ectodomain (the domain of the molecule which is exposed towards the outside of the
cell), 3.) transmembrane domain, and 4.) carboxyl-tail domain (domain which is
hydrophilic and located within the cytosol). The first 23 amino acids (a.a.) of KSHV-gB
constitute the putative signal peptide and amino acids 733 through 752 constitute the
transmembrane domain of gB, thus the KSHV-gB molecule can be categorized into the
ectodomain (703 a.a.) and the carboxyl terminal tail (93a.a.) (Pertel, 2002; Pertel, Spear,
and Longnecker, 1998; Wang et al., 2003). The carboxyl tail of KSHV-gB manifests
characteristics similar to the cytoplasmic terminal domain of HSV1-gB, in which the
amino acid residues in this region are hydrophilic and positively charged (Pellett et al.,
1985; Pertel, Spear, and Longnecker, 1998). The KSHV-ORF8 encodes the gB gene
(Russo et al., 1996). Based on its primary structure the predicted molecular weight of
KSHV-gB would be expected to be 91.3 kDa; however, studies have shown that a fully
processed gB could be detected well over 100 kDa (Akula et al., 2001a; Baghian et al.,
2000; Pertel, Spear, and Longnecker, 1998). KSHV-gB possesses thirteen possible Nlinked glycosylation sites (Asn-X-Thr/Ser motif whereby the X is any amino acid except
proline (Bause, 1983; Gavel and von Heijne, 1990; Marshall, 1972). Glycosylation
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inhibition experiments using both N-glycosidase F (Endo F), endoglycosidase H (Endo
H) (Baghian et al., 2000; Pertel, Spear, and Longnecker, 1998) and tunicamycin (an
antibiotic which is an inhibitor of N-linked glycosylation) (Baghian et al., 2000) have
clearly shown that the KSHV-gB contains predominantly N-linked carbohydrates.
In virion preparations produced from BCBL-1 cells, it has been shown that the
virion envelope-associated gB is present on the surface of both infected cells and the
virion envelope (Akula et al., 2001a; Baghian et al., 2000). Among the several
glycoproteins on the envelope of the KSHV particle, virion envelope-associated gB has
been shown to exhibit strong affinity for heparin as demonstrated by experiments in
which virion envelope-associated gB binds to heparan-agarose beads, and binding of a
biotinylated peptide of a gB-heparan binding domain (gB-HBD peptide consisted of the
following 108-117 gB-a.a. sequence: HIFKVRRYRK binds in a dose-dependent manner
to BSA-Heparan coated 96 well plates(Akula et al., 2001a).
The role of gB in viral attachment and penetration is clearly shown as rabbit
polyclonal anti-gB antibodies block KSHV infectivity in human foreskin fibroblast cells
(HFF) in a dose-dependent manner; the rabbit polyclonal anti-gB antibodies were raised
in New Zealand white male rabbits which were immunized with purified GST-gB fusion
protein (Akula et al., 2001a). The role of KSHV-gB in viral entry was further established
in a study which demonstrated that the integrin α3β1 molecule is one of the cellular
receptors utilized by KSHV for viral entry into susceptible cells; KSHV was the first
herpesvirus shown to utilize integrin as a cellular receptor for target cells (Akula et al.,
2002; Nemerow and Cheresh, 2002). The RGD (Arg-Gly-Asp) amino acids constitute a
motif which is necessary for a myriad of cellular ligands that bind to host cell surface
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integrin molecules (Plow et al., 2000). Immediately behind the KSHV-gB signal peptide,
the gB molecule contains an RGD motif (a.a. 27-29) which binds specifically to the
integrin α3β1 receptor(CD49c/29) (Akula et al., 2002; Wang et al., 2003). Interestingly,
the gB/integrin interaction is not a common feature of herpesvirus gBs; there has been no
other gB in the entire Herpesviridae family that possesses a similar conserved RGD
motif. In a dose-dependent manner, peptides with the RGD motif efficiently blocked
KSHV infection in a range from 40-80% and antibodies raised against a peptide with the
gB-RGD sequence also blocked KSHV infection up to 60% in a dose-dependent manner
(Akula et al., 2002). Integrin α3β1 is broadly expressed and has been detected on all cells
susceptible to infection by HHV-8, including human foreskin fibroblasts and B,
epithelial, endothelial, and 293 cells(Akula et al., 2002; Plow et al., 2000; Wu and
Dedhar, 2001). Both soluble integrin α3β1 protein and anti-integrin antibodies against
efficiently blocked KSHV infectivity up to 80% and 50%, respectively (Akula et al.,
2002). Furthermore, the inability of these molecules to completely neutralize viral
infectivity leads to implications of potentially other cellular receptors utilized by KSHV
for entry. Interestingly at similar concentrations used for the above mentioned virus
neutralization experiments, RGD peptides, RGD-gB antibodies, anti-integrin antibodies
and soluble integrin α3β1 proteins could not inhibit KSHV binding to HFF cells yet
soluble heparin almost completely blocks viral attachment, thus suggesting a postattachment role for the gB/integrin interaction, in which gB binding to the integrin
receptor is able to facilitate viral entry into susceptible cells (Akula et al., 2002).
Envelope-associated KSHV-gB clearly binds to both heparan sulfate receptors
(HS) and integrin α3β1 which are located on the surface of target cells, thus two different
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motifs (HBD and RGD) of KSHV-gB mediates KSHV binding via HS and viral entry via
integrin α3β1 cellular receptor, respectively (Akula et al., 2001a; Akula et al., 2002;
Akula et al., 2001b). Interestingly, soluble gB proteins upon binding to target HFF cells
induce morphological changes, e.g., cell rounding and detachment, yet these cells
remained viable with no noticeable cellular death (Akula et al., 2003). These results are
consistent with the morphological changes noticed by integrin-mediated clumping of
integrin molecules with concomitant rearrangement of the actin cytoskeleton (van der
Flier and Sonnenberg, 2001).
Glycoprotein H (gH) and Glycoprotein L (gL)
The products of the KSHV-ORF22 and KSHV-ORF47, gH and gL respectively
form heterodimers which are components of the virion envelope (Naranatt, Akula, and
Chandran, 2002). The virion envelope embedded glycoprotein H (gH) has been highly
conserved among all members of the herpesvirus family, gH has been shown to be
essential for virus penetration and cell-to-cell spread (Babic et al., 1996; Duus, Hatfield,
and Grose, 1995; Forghani, Ni, and Grose, 1994; Fuller, Santos, and Spear, 1989; Haddad
and Hutt-Fletcher, 1989; Hutchinson et al., 1992; Khattar et al., 1996; Klupp et al., 1997;
Li, Turk, and Hutt-Fletcher, 1995; Lomonte et al., 1997; Mukai et al., 1997; Strnad et al.,
1982; Wu, Reed, and Lee, 2001; Wu et al., 1999). Expression of gH in the absence of gL
leads to a protein that is incorrectly folded and processed. Heterodimeric complex
formation between gH and gL is a common theme among herpesviruses: Herpes simplex
virus-type1 (HSV-1) (Hutchinson et al., 1992), varicella zoster virus (VZV) (Forghani,
Ni, and Grose, 1994), human cytomegalovirus(HCMV) (Kaye, Gompels, and Minson,
1992), human herpesvirus 6 (HHV-6) (Liu et al., 1993), HHV-7 (Mukai et al., 1997),
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Epstein-Barr virus (EBV) (Yaswen et al., 1993). However, a heterocomplex is formed in
EBV, the gH, gL, and gp42 complex is required for the infectivity of B cells, yet gp42 is
not required for the infectivity of epithelial cells (Li, Turk, and Hutt-Fletcher, 1995).
KSHV gL is required for the proper processing and transport of KSHV gH to the infected
cell membranes. Anti-gH and anti-gL rabbit antibodies neutralized KSHV infectivity
without inhibiting the binding of virus to the target cells, suggesting that gH and gL play
an important role in the post-binding step of KSHV infection. KSHV gH and gL
expression can be readily detected during lytic replication upon the addition of TPA to
BCBL-1 cells(Naranatt, Akula, and Chandran, 2002). KSHV-gL has been shown to be
independently expressed on cell surfaces. Independent expression of gH without gL
causes gH misfolding and aggregation of gH in the ER; however, coexpression of KSHVgH with KSHV-gL facilitates the correct processing of gH and mediates transport
through the golgi apparatus with subsequent cell surface expression (Naranatt, Akula, and
Chandran, 2002). Antibodies to either gH and gL do not inhibit KSHV binding, yet antigH and anti-gL antibodies do neutralize KSHV infectivity at a post-attachment step of
HHV-8 infection (Naranatt, Akula, and Chandran, 2002).
Glycoprotein M (gM) and Glycoprotein N (gN)
The glycoproteins M and N, (gM and gN), have been conserved throughout the
entire family, Herpesviridae. The products of the KSHV-ORF39 and KSHV-ORF53 are
gM and gN, respectively. Both KSHV-gM and gN are N-glycosylated and form
heterodimers as shown by immunoprecipitation experiments. The heterodimer formation
between gM and gN is consistent with heteroduplex formation in other herpesviruses as
well (Jons, Dijkstra, and Mettenleiter, 1998; Lake, Molesworth, and Hutt-Fletcher, 1998;

44

Mach et al., 2000; Rudolph et al., 2002; Tischer et al., 2002; Wu, Zhu, and Letchworth,
1998). The glycosylated forms of gM are observed at 46 and 80 kDa and upon the
addition of tunicamycin, an inhibitor of N-glycosylation, the molecular sizes are reduced
to 39 and 71 kDA. The glycosylated form of gN is approximately 26 kDa and upon
tunicamycin treatment the unglycosylated form is approximately 18 kDa. gN was shown
to be required for proper post-translational modification and transport of gM to both the
cell surface(Koyano et al., 2003). In addition, gM was shown to be present on the surface
of the virion envelope, since an anti-peptide antibody directed against gM reacted with
double-purified sucrose gradient centrifugations (Koyano et al., 2003). The KSHV-gM
and -gN heterocomplex was shown to inhibit cell fusion in an in vitro HSV-1 and MoMuLV (Molony murine leukemia virus) cell fusion assay (Koyano et al., 2003).
Glycoprotein OX2 (vOX2)
Viral genomic analysis of KSHV suggests that ORFK14 possesses a significant
level of homology with cellular OX2, currently designated as viral OX2 (vOX2).
Cellular OX2 belongs to a group of leukocyte glycoproteins which are expressed on the
surface of a myriad of cells: activated T cells, B cells, follicular dendritic cells, neurons,
and vascular endothelial cells (Wright et al., 2003; Wright et al., 2000). The respective
receptor for CD200 is CD200R which has been primarily found mainly on cells of
myeloid origin (Wright et al., 2003; Wright et al., 2000). Recently, a study indicated that
the CD200/CD200R interaction could enact its immunosuppressive effect via T-cell
involvement, since the receptor, CD200R, is also present on the surface of certain T-cells
(Wright et al., 2003). CD200 possesses a small carboxy-tail without noticeable signal
transduction motifs; however, the CD200R possesses a large cytoplasmic tail with
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tyrosine-based signaling motifs, which potentially could be used to deliver its restrictive
immunological effect on myeloid cells (Wright et al., 2003). The KSHV ORFK14
encodes the vOX2 specifying 271 amino acids, which is analogous to both the cellular
OX2 (278 amino acids) and rhesus rhadinovirus RRV ORF-R14 (253 amino acids),
which is a homologue of KSHV vOX2 (Alexander et al., 2000; Searles et al., 1999).
Similar to both cellular OX2 and RRV R14 homologues, the predicted KSHV vOX2
contains a typical signal peptide sequence at its amino-terminal region and contains five
potential N-glycosylation sites in its extracellular domain. ORFK14 (vOX-2) exhibits a
low 40% DNA sequence identity to cellular OX-2. vOX-2 binds to the receptor CD200R
with almost identical affinity and kinetics as the cellular OX-2(Chung et al., 2002). The
c-OX2-OX2R interaction delivers a restrictive signal to macrophages and thus limits
macrophage activation. Subsequently, blocking of this interaction with anti-OX2R
antibody exacerbates tissue damage in inflammatory sites (Wright et al., 2000). A recent
study has shown that the KSHV ORF-K14, vOX-2, can inhibit TNF-α secretion from
activated macrophages which is mediated by cell surface interaction of CD200R on the
surface of macrophages with vOX-2 expressed on the surface of KSHV-infected cells
undergoing viral lytic replication (Foster-Cuevas et al., 2004). vOX2 encodes a
glycosylated protein with an apparent molecular mass of 55 kDa, is expressed on the
surface of KSHV-infected cells during viral lytic replication, and specifically recognizes
myeloid-lineage cells(Chung et al., 2002). The fact that viral homologs to CD200
[Betaherpesvirinae (HHV-6 (Gompels et al., 1995) and HHV-7 (Muralidhar et al., 2000);
Gammaherpesvirinae (rhesus macaque rhadinovirus (Desrosiers et al., 1997; Searles et
al., 1999) and KSHV(Chang et al., 1994); along with numerous viruses within the Pox
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family(Cameron et al., 1999; Lee, Essani, and Smith, 2001; Willer, McFadden, and
Evans, 1999)] span large taxonomical gaps, suggests a common viral immunoevasion
strategy which negatively restricts activated macrophages, thus potentially allowing a
milieu conducive for KS sarcomagenesis (Chung et al., 2002; Foster-Cuevas et al., 2004).
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CHAPTER II
KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS GLYCOPROTEIN
K8.1 IS DISPENSABLE FOR VIRUS ENTRY∗

INTRODUCTION
Kaposi’s sarcoma-associated herpesvirus (KSHV), also referred to as human
herpesvirus 8 (HHV-8) is a member of the γ2 herpesvirus family (genus Rhadinovirus)
(Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 1996). KSHV is etiologically
associated with Kaposi’s sarcoma (KS), primary effusion/body cavity-based lymphoma
(PEL/BCBL) and multicentric Castleman’s disease (Antman and Chang, 2000; Ganem,
1998; Schulz, Chang, and Moore, 1998; Schulz, Sheldon, and Greensill, 2002). Recently,
it was suggested that KSHV may have a role in the development of primary pulmonary
hypertension (Cool et al., 2003). KSHV can infect a variety of human cell types,
including B, T, endothelial, epithelial, fibroblast and keratinocyte cells, and nonhuman
cell types, including owl monkey kidney and baby hamster kidney fibroblast cells
(Cerimele et al., 2001; Ciufo et al., 2001; Flore et al., 1998; Foreman et al., 1997; Gao,
Deng, and Zhou, 2003; Kliche et al., 1998; Mesri et al., 1996; Moore et al., 1996; Moses
et al., 1999; Panyutich, Said, and Miles, 1998; Renne et al., 1998; Vieira et al., 2001;
Zhou et al., 2002).
Generally, all herpesviruses initiate infection via direct binding onto various
receptors on cell surfaces mediated by several viral glycoproteins embedded into viral
envelopes. Viral glycoproteins play important roles in virus attachment onto susceptible
∗
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cells, fusion of the viral envelope with either cellular or endosomal membranes, and
virion morphogenesis and egress [reviewed in: (Kieff and Rickinson, 2001; Mocarski and
Courcelle, 2001; Roizman and Knipe, 2001)]. Herpes simplex virus (HSV), human
cytomegalovirus (HCMV), and Epstein Barr Virus (EBV) have been shown to enter into
cells via either pH-independent or pH-dependent pathways depending on the cell type
(Bodaghi et al., 1999; Compton, Nepomuceno, and Nowlin, 1992; Miller and HuttFletcher, 1992; Nemerow and Cooper, 1984; Nicola, McEvoy, and Straus, 2003;
Roizman and Knipe, 2001; Spear, 1993). KSHV has been shown to enter into certain
cells (Human foreskin fibroblast cells and B cells) via endocytosis (Akula et al., 2003;
Akula et al., 2001b). Regardless of the mode of virus entry, release of capsids into the
cytoplasm is thought to involve fusion of the viral envelope with either plasma or
endosomal membranes.
KSHV codes for a number of glycoproteins, some of which have significant
homology to glycoproteins of other herpesviruses. These include gB(ORF 8), gH (ORF
22), gM (ORF 39), gL (ORF 47) (Neipel, Albrecht, and Fleckenstein, 1997; Russo et al.,
1996), and gN (ORF 53) (Koyano et al., 2003). In addition, K1, K8.1 and vOX2 (K14)
glycoproteins are unique to KSHV with no counterparts in other herpesviruses (Chandran
et al., 1998; Chung et al., 2002; Neipel, Albrecht, and Fleckenstein, 1997; Schulz, Chang,
and Moore, 1998). KSHV glycoproteins gB and K8.1A mediate initial binding of virions
onto glycosaminoglycans, e.g. heparan sulfate on cell surfaces (Akula et al., 2001a;
Akula et al., 2001b; Birkmann et al., 2001; Wang et al., 2001). In agreement with the
strong binding of purified K8.1A to heparan sulfate moieties on cell surfaces, initial
studies showed that a soluble form of K8.1A inhibited KSHV attachment onto cells
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(Wang et al., 2001). However, a later report indicated that a similar soluble form of
K8.1A did not block KSHV infectivity (Birkmann et al., 2001). In addition, gB binds to
integrins, such as α3β1 membrane receptors through a RGD motif, suggesting that
integrins function as cellular receptors for KSHV entry (Akula et al., 2002; Naranatt et
al., 2003). However, soluble integrins or RGD-containing peptides failed to inhibit virus
entry into 293 cells (Inoue et al., 2003).
There are two ORFs originating from the K8.1 gene via spliced transcripts, K8.1A
and K8.1B. The K8.1A cDNA encodes a 228 amino-acid (aa) protein containing a signal
sequence, transmembrane domain and four N-glycosylation sites. The K8.1B cDNA
encodes a 167 aa glycoprotein sharing similar amino and carboxy termini with K8.1A but
contains an in-frame deletion (Chandran et al., 1998; Raab et al., 1998). K8.1A is the
predominant form detected within infected cells and the virion envelopes (Zhu, Puri, and
Chandran, 1999). The K8.1 gene has attracted significant interest due to the fact that it is
positionally co-linear to the EBV major glycoprotein gp350/220 (Gong and Kieff, 1990),
gp150 of murine gammaherpesvirus 68 (MHV 68) (Stewart et al., 1996), herpes virus
saimiri (HVS) ORF 51 gene (Albrecht et al., 1992) and the BOEFD1 gene of bovine
herpesvirus-4 (BHV-4) (Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 1996).
EBV gp350/220 has been shown to be involved in the binding of the virus to the target
cells via the CD21 receptor on B cells (Fingeroth et al., 1984; Nemerow et al., 1989;
Nemerow et al., 1987; Nemerow et al., 1985; Tanner et al., 1987); however, gp350/220 is
not required for virus entry into fibroblasts (Janz et al., 2000).
Recently, the KSHV genome was cloned into a bacterial artificial chromosome
(BAC) and was shown to produce infectious virus (Zhou et al., 2002). To resolve whether
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K8.1A functions in virus infectivity, we utilized the recombinant KSHV BAC36 as the
initial template to construct a KSHV K8.1-null virus to address the role of K8.1
glycoproteins in the KSHV lifecycle. Our data indicate that both K8.1 glycoproteins are
dispensable for virus entry.
MATERIALS AND METHODS
Cells and Viruses
293 cells were grown in Dulbecco’s modified Eagle medium (GIBCO-BRL; Grand
Island, N.Y.) supplemented with 2 mM glutamine, 10% fetal calf serum (FBS) and
antibiotics. The KSHV BAC36 virus contains the green fluorescent protein (GFP) gene
cassette under the human cytomegalovirus immediate early promoter (HCMV-IE),
constitutively expressing the GFP gene, inserted between KSHV ORF18 and ORF 19
(Zhou et al., 2002).
Immunofluorescence Assay
Detection of K8.1A was monitored by indirect immunofluorescence using FITCconjugated goat anti-mouse IgG, which detected expression of the K8.1A plasmid in
transiently transfected 293 cells. Transfected cells were incubated for 48 hours at 37°C,
and then subsequently fixed with cold methanol for 20 minutes. Monolayers were
blocked for 1 hour with 10% normal goat serum in PBS followed by 1 hour incubation
with the primary monoclonal antibody (65), (19B4) directed against the K8.1 proteins, at
a dilution of 1:500. Cells were then rinsed three times with PBS and incubated for 1 hour
with the secondary antibody, a fluorescein-conjugated goat anti-mouse antibody (ICN
Pharmaceuticals, Inc., Aurora, OH), diluted at 1:50. Cells were then washed 5 times with
PBS and viewed via a fluorescence microscope.
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Immunoblot Analysis
Cell lysates of K8.1A transfected 293 cells or induced BCBL-1 cells were boiled in
loading buffer for 5 min and the proteins were separated by SDS-PAGE. Proteins were
electrotransferred onto nitrocellulose membranes, blocked with BLOTTO (5% nonfat
milk in 0.01 M PBS/0.05% Tween 20), and then reacted for 1 hour with a primary
antibody (K8.1A monoclonal; 19B4) at a dilution of 1:1000. A horse-radish peroxidase
(HRP)-conjugated secondary antiserum at a dilution of 1:10,000 in PBS containing 10%
goat serum was used. The reaction was visualized using the Western-blotting
chemiluminescence detection reagents (Pierce Inc.; Rockford, IL).
Construction of a KSHV-Mutant with Deletion of the K8.1 Gene (BAC36∆K8.1)
Mutagenesis of BAC36 DNA was accomplished in Escherichia coli using the λ gam,
recE recT (GET) recombination system (Narayanan et al., 1999; Orford et al., 2000).
Electrocompetent DH10B E. coli cells harboring BAC36 were transformed with the
plasmid pGETrec, which contains the genes encoding recE, recT and bacteriophage λ
gam, grown on plates containing chloramphenicol (12.5µg/ml) and ampicillin
(100µg/ml). Individual colonies were picked and grown overnight in Luria-Bertani (LB)
medium containing chloramphenicol and ampicillin. The next day, the culture was
inoculated into 250ml of LB containing chloramphenicol and ampicillin until a 0.4
optical density was reached at 600nm. Addition of L-arabinose to a final concentration
of 0.2% (w/v) and further incubation of 40 minutes induced the expression of the recE,
recT and λ gam genes from the plasmid pGETrec. The cells were then harvested and
made electrocompetent. A PCR fragment containing the kanamycin gene flanked by
60bp of viral sequences on both sides was used for recombination to construct
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BAC36∆K8.1, containing the kanamycin cassette within the targeted K8.1 genomic
region. Briefly, 40µl of electrocompetent DH10B cells, harboring both BAC36 and
pGETrec, were electroporated with 200ng of purified PCR product to delete the target
gene (K8.1 glycoprotein) using standard electroporation parameters (1.8kV/cm, 200Ω
and 25µF). Following electroporation, cells were grown in 1ml of LB for 60min and
subsequently streaked onto LB agar plates containing both chloramphenicol (12.5 µg/ml)
and kanamycin (50µg/ml). Episomal mutant BAC36 DNA containing the deletion in
either the K8.1 gene via insertion of the kanamycin cassette was isolated from bacteria
colonies and a second round of electroporation was performed to remove the plasmid
pGETrec and grown on agar plates with chloramphenicol and kanamycin.
Confirmation of the K8.1 Deletion in BAC36∆K8.1 DNA
KSHV BAC DNAs (BAC36 and BAC36∆K8.1) were purified from 1 liter of BAC
cultures using the Qiagen Large-Construct Kit (Qiagen; Valencia, CA). BAC DNA was
digested with KpnI and run on 0.8% agarose gels, and the restricted DNA was transferred
to charged nylon membranes (BioRAD; Richmond, CA). Southern-blot hybridization
was performed using a biotin-labeled kanamycin resistance gene probe by labeling a
1.1kb kanamycin PCR fragment with biotin (New England Biolabs; Boston, MA).
Chemiluminescence detection of the DNA was performed using the North2South
Chemiluminescent Hybridization and Detection Kit as described by the manufacturer
(Pierce Inc.; Rockford, IL).
Transient Transfection of KSHV BAC DNAs
Transient transfection of 293 cells with BAC DNAs was performed using Superfect
(Qiagen; Valencia, CA). 293 cells were grown to 80% confluency in 6 well plates. Cells
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were transfected with BAC DNA mixed with Superfect in DMEM media as
recommended by the manufacturer (Qiagen). After 4 hours of incubation at 37°C, the
media was removed from the transfected cells and washed with PBS and subsequent
fresh DMEM media with 10% fetal calf serum was added.
Immunohistochemical Staining
293 cells in 6 well plates were transfected with BAC36 or BAC36∆K8.1 DNA either
alone or cotransfected with the Rta plasmid for induction of the lytic cycle. Forty-eight
hours after transfection, cells were washed with PBS and fixed with electron microscopygrade 2% paraformaldehyde (Electron Microscopy Sciences; Fort Washington, PA) for
10min, and then washed twice with phosphate-buffered saline-50mM glycine. Blocking
of cell monolayer for 1 hour was performed using 5% normal goat serum and 5% bovine
serum albumin in PBS. Cells were then incubated for 1 hour with a primary antibody,
washed three times with PBS, and then incubated for 1 hour with a secondary antibody
conjugated with biotin. Cells were washed three times with PBS, and the cells were then
reacted with a 1:3000 dilution of hrp-streptavidin in 10% goat PBS for 1 hour. Cells
were washed five times and substrate from Vector VIP was added (Vector Laboratories
Inc.; Burlingame, CA). Cells were examined using a light microscope (Nikon Inc;
Garden City, NY). Primary antibodies used in these studies were: anti-K8.1 {19b4;(Wu et
al., 2000)}, anti-ORF59, and anti-LANA antibody (Advanced Biotechnologies, Inc,
Columbia, MD).
Production of Infectious KSHV Particles
293 cells were transfected with either BAC36, BAC36∆K8.1 or EGFP-C1 DNA each
mixed with the ORF50 (RTA) and either pCDNA3.1 (negative control) or pCDNAK8.1
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(complementing plasmid) in 6 well plates. Transfected cells were induced with a final
concentration of 25ng/ml of tetradecanoyl phorbol acetate (TPA) (Sigma; St. Louis, MO)
and 1,000 units/ml of Interferon-α (Sigma) for 5 days. Supernatant was collected from
induced cell lines and centrifuged three times at 5,000g for 15min. Supernatants were
freeze-thawed three times to eliminate any surviving cells. The viral supernatant was then
used for infection or quantitative PCR analysis.
Infection of Cells with Harvested Supernatants
Supernatants from transiently transfected cells were used as viral inoculum to infect
cells in a 96 well plate at 80% confluency. Infection was performed in triplicate; 50µl of
the infectious viral inoculum with Polybrene added to a final concentration of 5 µg/ml
(Sigma; St. Louis, MO) was placed on 293 cells for five hours and then 50µl of fresh
media was added and the plate was incubated overnight at 37˚C. The next day, the viral
inoculum was removed and fresh media was added. Infectivity was determined two days
postinfection by counting the number of green fluorescent protein (GFP)-expressing cells
via fluorescence microscopy as described previously (Gao, Deng, and Zhou, 2003).
Sample Preparation for KSHV Quantitative TaqMan PCR
293 cells were co-transfected with various combinations of KSHV BAC genomes and
plasmids pRTA, pCDNA3.1 and pCDNAK8.1. All transfections contained the same
amount of total DNA transfected. The amount of BAC36 or BAC∆K8.1 remained
constant, while varying amounts of pCDNA3.1 (control), the RTA expressing plasmid
and the pCDNAK8.1 complementing plasmid were used. TPA (25ng/ml) and interferonα (1000 units/ml) were added 24 hours post-transfection to enhance viral induction. The
supernatants were centrifuged three times at 5,000g for 15 minutes to remove floating
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cells. The supernatants collected after centrifugation were subsequently treated with
TurboDNAse (Ambion Inc; Austin,TX), for three hours at 37°C to ensure that
unencapsidated genomes were not present during the real-time PCR assay. In these
experiments, one unit of TurboDNAse was used per 100 µl of sample. In control
experiments, one unit of TurboDNAse reduced BAC36 DNA by more than one thousand
fold as determined by TaQman PCR. Viral DNA from supernatants was extracted in
triplicate using a standard Proteinase K, phenol/chloroform protocol.
KSHV TaqMan PCR Quantitation
Reagents and enzymes used for TaqMan PCR were obtained from PE Applied
Biosystems (Foster City, CA). The sequence for the TaqMan FAM-probe and primers to
ORF37 used for the quantitative detection of KSHV molecules were published previously
(Stamey et al., 2001) and listed in Table 1. Each 25µl PCR contained a 1X TaqMan
universal PCR master mix, 0.25 µl of 20 µM Primer stock for both forward and reverse
primers. The 100 µM ORF37-FAM labeled probe was diluted 1:50 and 0.25µl of probe
was used per reaction. The reaction conditions were as followed: 2 minutes at 50°C, 10
min at 95°C with a subsequent 40 cycles two-step PCR (95°C for 15 sec, 60°C for 1
min). During amplification, an ABI-prism 7700 sequence detector monitored real-time
PCR amplification by quantitatively analyzing fluorescence emissions. Samples were
analyzed in triplicate on three independent runs. The Ct value is defined as the cycle
number in which the fluorescence detected exceeded an established threshold level that
was kept constant in all experiments (Heid et al., 1996). The concentration of the BAC36
DNA after purification using the Large Construct Kit (Qiagen; Valencia, CA) was
determined by optical density at 260nm and comparative gel electrophoresis to known
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amounts of molecular markers. Serial ten-fold dilutions of BAC36 DNA were used as
controls to construct a standard curve based on the Ct value and logarithmic amounts of
diluted BAC36. The number of KSHV genomes in each specific supernatant sample was
determined by comparison of the obtained Ct value to corresponding values of the
standard curve reflecting a specific amount of KSHV viral DNA. The number of
genomes within this specific amount of viral DNA was obtained using the following
relationship: one KSHV genome was approximately equal to 0.197 femtograms.
RESULTS
Construction of the KSHV BAC36∆K8.1
The complete KSHV genome was recently cloned into a bacterial artificial
chromosome (BAC36) enabling the genetic manipulation of the KSHV genome in E.
coli. BAC36 constitutively expresses the GFP gene allowing detection of eukaryotic
cells containing KSHV genomes (Zhou et al., 2002). The BAC-based GET homologous
recombination system was utilized to construct a large deletion within the K8.1 gene in E.
coli. Deletion of most of the K8.1 gene was accomplished by targeting the K8.1 ORF
using specific primers as detailed in the Materials and Methods section. The genomic
region encompassing the K8.1 gene codes for the K8.1A and K8.1B via spliced
transcripts. The 5’ most primer (primer A; Table 2.1, Figure 2.1A) used for homologous
recombination overlaps the K8.1 ATG and extends into the K8.1 ORF by 6 nucleotides.
Insertion of the kanamycin cassette inserted multiple stop codons in different frames
immediately down stream of the ATG codon preventing the expression of any aberrant
proteins. The 3’ primer (primer B; Table 2.1, Figure 2.1A) is approximately 90
nucleotides upstream of the TAA stop codon of K8.1 (Figure 2.1B).
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TABLE 2.1. Synthetic Oligonucleotide Primers and TaqMan Probe.
Primer
A: 5’K8.1/KanF
recombination

Primer Sequence

Purpose & Prod. Size

5’--CAATATTAAAGGGACCCAAGTTAATCCCTTAAT

GET-

CCTCTGGGATTAATAACCATGAGTTAGCCACGTTG
TGTCTCAAAATCTCTGATGTTA--3’

(1.2kb)

B: 3’K8.1/KanR

5’--CTAGCACAGGTAAAGTATAAGGACAAGTCCCAGC
AATAAACCCACAGCCCATAGTATGTACGGTTGATGA
GAGCTTTGTTGTAGGTGGAC--3’

C: 5’K8.1/up

5’--CATGCTGATGCGAATGTGCCA--3’

Diagnostic PCR
(wt) BAC36,

(964bp);
D: 3’K8.1/nostop
5’--CACTATGTAGGGTTTCTTACG--3’
BAC36∆K8.1;(1.4kb)
E: 5’KanFwd
Probe (1.1kb)
F: 3’KanRev

5’--ATGAGCCATATTCAACGG--3’

Kanamycin

5--CTCATCGAGCATCAAATG--3’

G: 5’ORF37-Fwd
(99bp)
H: 3’ORF37-Rev

5’--TCGGTGGCGATGCTTTAGAC--3’

Taqman product

I: RF37-Fam-probe
Probe

5’--TCGTAACCCCCGTCTACTTTCCCCG--3’

Taqman FAM-

J: K8.1F
product(0.8kb)
K: K8.1R

5’--TAACCATGAGTTCCACACAGATTC--3’

K8.1A

5’--TGAAGCAGACGATGCTTTGC--3’

5’--GGTTTTGTGTTACACTATGTAGG--3’
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Figure 2.1: Schematic representation. (A) Schematic illustration of the GET
homologous recombination BAC36∆K8.1 DNA. A PCR fragment containing the
kanamycin resistance gene flanked by 60bp of the K8.1 upstream and 3’end sequences
was used to construct BAC36∆K8.1 DNA recombinants containing the kanamycin
resistance gene cassette within the targeted genomic site. The primer binding sites of the
majority of the primers (Table 2.1) used to create the BAC36∆K8.1 DNA are as shown.
(B) Schematic representation of the ORF 50 gene locus and the relevant transcript coding
for ORF 50 as presented in detail previously (West and Wood, 2003). Vertical dashed
lines indicate the deleted genomic region encompassing most of the K8.1 ORF. The
relative location of each gene is indicated as well as the location of splice donor (SD) and
splice acceptor (SA) sites are indicated.
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The BAC36∆K8.1 construct was tested for the presence of the engineered insertion
via diagnostic PCR and Southern-blotting (Figure 2.2). Primers C and D (Table 2.1, Fig.
2.1A) located immediately upstream of the K8.1 gene and within the 3’ undeleted portion
of the K8.1 ORF, respectively, were used to amplify a diagnostic DNA fragment from
KSHV DNA purified from BCBL-1 cells, BAC36 DNA and BAC36∆K8.1 DNA (Figure
2.2A). DNA from BCBL-1 cells and BAC36 produced a predicted DNA fragment of 964
bp. In contrast, amplification of the targeted region of the BAC36∆K8.1 DNA produced a
DNA fragment of approximately 1.4 kbp as predicted after insertion of the kanamycin
gene cassette. Further confirmation of the genetic content of the BAC36∆K8.1 was
obtained via restriction endonuclease fragment analysis and Southern-blotting (Figure
2.2B). Restriction enzyme analysis of BAC36 and BAC36∆K8.1 DNA with KpnI
revealed a similar DNA fragmentation pattern with the exception that a DNA fragment of
approximately 4.6 kbp was absent in the BAC36∆K8.1 profile in comparison to the
BAC36 restriction pattern. In addition, the BAC36∆K8.1 pattern included a new DNA
fragment migrating with an apparent molecular mass of approximately 5 kbp in
agreement with the theoretical size of a new DNA fragment produced after insertion of
the kanamycin gene cassette within the K8.1 gene (Figure 2.2B: panel 1). Southernblotting using a biotinylated kanamycin gene probe of KpnI digested BAC36 and
BAC36∆K8.1 DNA revealed the presence of a unique kanamycin insertion within a DNA
KpnI fragment of approximately 5 kbp, while there was no reaction of the probe with the
BAC36 DNA. A pre-biotinylated molecular weight ladder was used for DNA fragment
size determination (Figure 2.2B: panel 2). These results are consistent with the insertion
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Figure 2.2: Genomic analysis of BAC36∆K8.1 DNA. (A) PCR assay to confirm the
deletion of the K8.1A gene in BAC36. Amplification of the K8.1 region produced a 964bp band
from both BCBL-1 and BAC36 DNAs; the mutant BAC36∆K8.1 DNA showed a band of 1405
bp due to the size difference in the deletion/insertion mutagenesis. Lane M, molecular size
markers. (B: Panel 1) Restriction fragment analysis of BAC36∆K8.1 DNA and wild-type
BAC36 DNA. The KpnI restriction pattern of BAC36∆K8.1 DNA was compared to that of
wild-type BAC36 DNA. As predicted from the KpnI restriction pattern, the introduction of the
kanamycin resistance gene into BAC36 led to an increase in size from an estimated 4.5kb
fragment to a 4.9kb fragment (arrow). (B: Panel 2). Southern-blot analysis of BAC36∆K8.1
DNA. The KpnI restriction fragment profile from panel 1 was hybridized with a probe derived
from a kanamycin PCR product that was labeled with biotin. A biotinylated kanamycin probe
hybridized to an estimated 4.9kb KpnI DNA fragment in BAC36∆K8.1 KpnI restricted DNA,
which is absent in the wild-type BAC36 DNA (arrow).
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of the kanamycin gene cassette within the K8.1 gene and deletion of most of the K8.1
ORFs.
Transient Expression of K8.1A
The K8.1 gene was cloned into the transient expression plasmid pCDNA3.1 and
expressed in 293 cells by transfection. Detection of the transiently expressed K8.1A
glycoprotein was achieved via indirect immunofluorescence utilizing anti-K8.1 mAb
19B4 (Figure 2.3A: panel A) (Wu et al., 2000). Approximately, 50% of the transfected
cells reacted strongly with the anti-K8.1 19B4 mAb, while mock-transfected cells failed
to react in immunofluorescence assays (Figure 2.3A: panels B, D). Similar results were
produced via immunohistochemical staining of 293 cells transfected with plasmid
pCDNA3.1-K8.1A (Figure 2.3A: panel C). To further characterize expression of K8.1A
under transient expression conditions, lysates of 293 transfected cells were
electrophoretically separated in SDS-PAGE and tested via immunoblotting using mAb
19B4 and compared to K8.1 expressed in BCBL-1 cells after TPA induction (Figure
2.3B). Transiently expressed K8.1A migrated with an apparent molecular mass of 37
kDa, while BCBL-1 cells expressed K8.1 migrating with molecular masses ranging from
34-37 kDa (Figure 2.3B: lanes 2, 3). The 37 kDa glycoprotein species has been shown to
represent fully glycosylated K8.1 glycoprotein (Raab et al., 1998). The 19B4 mAb
reacted with proteins of higher apparent molecular masses presumably corresponding to
higher order multimers of K8.1 (Wu et al., 2000).
Characterization of Latent and Lytic Gene Expression
Log-phase 293 cells were transfected with BAC36 or BAC36∆K8.1 DNA and
expression profiles of the latent gene LANA and the lytic genes ORF59 and K8.1 were
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Figure 2.3: Detection of K8.1A gene expression in transiently transfected cells.
(A) Immunofluorescence (panel A) and immunohistochemical staining (panel C) of
K8.1A transiently transfected 293 cells. Immunofluorescence (panel B) and
immunohistochemical reactivities (panel D) of mock-transfected 293 cells. (B)
Immunoblot of cell lysates from mock-transfected cells (lane 1), cells transiently
transfected with K8.1A (lane 2), and induced BCBL-1 cells (lane 3).
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assessed via immunohistochemical staining using mAbs specific for each protein (Figure
2.4). Typically, the BAC36∆K8.1 DNA transfected more cells (20-30%) versus the
BAC36 DNA (10-15%). In the absence of TPA induction, the anti-LANA antibody
reacted with cells transfected with either BAC36 or BAC36∆K8.1 DNA (Figure 2. 4,
panels F, L). Similar results were obtained after the transfected 293 cells were induced
with TPA (Figure 2.4, panels I, O). Immunostaining of 293 transfected cells with the antiORF59 antibody detected expression of ORF59 (lytic gene) in either the absence (Figure
2.4: panels E, K) or presence (Figure 2.4: panels H, N) of TPA induction, although after
TPA induction, approximately 2-fold more cells stained positive for ORF59. Similar
results were obtained with the anti-K8.1 mAb immunostaining with the exception that
K8.1A was not expressed in 293 cells transfected with the BAC36∆K8.1 DNA (Figure
2.4: panels J, M). No reactivity was observed by the anti-K8.1, anti-ORF59 or the antiLANA antibodies against the 293 mock-transfected negative control cells (Figure 2.4:
panels A, B, C).
Production of Infectious KSHV by BAC36 and BAC36∆K8.1 Transfected 293 Cells
To assess the role of K8.1 in viral infectivity, purified BAC36 and BAC36∆K8.1 DNAs
were co-transfected with an RTA plasmid transiently expressing the RTA (ORF50) gene
and either pCDNA3.1 (control) or pCDNAK8.1 (complementing plasmid). The number
of transfected cells expressing GFP remained constant in the presence or absence of the
RTA expressing plasmid (not shown). RTA is the major KSHV transactivator protein
capable of inducing lytic replication of KSHV (Sun et al., 1998). KSHV lytic replication
was further enhanced through the addition of TPA and interferon-α for five days, at
which point supernatants of transfected cells were clarified of cellular debris and tested
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Figure 2.4: Latent and lytic gene expression profiles of uninduced and induced
293 cells transfected with either BAC36 DNA or BAC36∆K8.1 DNA. Transfections
with BAC36∆K8.1 DNA did not result any expression of a K8.1A gene product after
RTA and TPA induction (panels J and M). As a positive control, transiently transfected
293 cells with BAC36 DNA reacted with the K8.1A antibody (panels D and G). The antiORF59 mAb reacted with uninduced or induced (TPA plus RTA) 293 cells transfected
with either BAC36∆K8.1(panels K and N) or BAC36 DNA (panels E and H). Similarly,
the anti-LANA mAb reacted with both uninduced and induced BAC36 DNA (panels F
and I, respectively) or BAC36∆K8.1 DNA(panels L and O, respectively) transfected 293
cells. Mock-transfected 293 cells failed to show any reactivity with either anti-K8.1, antiORF59 and anti-LANA mAbs (panels, A, B and C, respectively). Arrows indicate K8.1,
ORF59, or LANA expression in 293 cells.
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for the presence of infectious KSHV. The relative infectivity of supernatant viruses was
determined by monitoring the number of GFP-expressing cells (see Materials and
Methods) after infection of 293 cells (Gao, Deng, and Zhou, 2003) (Figure 2.5: panels A,
B, C). Control experiments were also performed in parallel to determine whether cellular
debris from transfected cells carried over the GFP during the infection process. 293 cells
were transfected with plasmids pRTA and pCDNA3.1 and the pEGFP-C1 constitutively
expressing GFP, and extracellular fluids were treated similarly to those containing
infectious virus and tested for their ability to produce GFP-expressing cells under similar
infection conditions. These control experiments revealed no GFP carry over from
ruptured cells (Figure 2.5A: panel D). Transfection experiments performed in triplicate
revealed that BAC36 and BAC36∆K8.1 DNAs consistently produced on the average 260
and 460 GFP-expressing cells/ml, respectively. Co-transfection of BAC36∆K8.1 DNA
with the complementing pCDNA-K8.1A plasmid seemed to enhance infectious virus
production by approximately two-fold (Figure 2.5B). Co-transfection of BAC36 DNA
with pCDNA-K8.1 or other control plasmids did not have an effect on infectious virus
production. Furthermore, different isolates of BAC36 or BAC36∆K8.1 exhibited similar
infectivities (data not shown).
Quantitation of KSHV via TaqMan PCR
To better quantify the amount of virus produced by transfection of 293 cells, a realtime PCR assay targeting the ORF37 gene was employed essentially as described
previously (Stamey et al., 2001). The relative amounts of BAC36 DNA and
BAC36∆K8.1 DNA found in supernatants of 293 transfected cells were obtained from a
standard curve based on known amounts of BAC36 DNA (see Materials and Methods).
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Figure 2.5: Relative infectivity of KSHV mutants. 293 cells were infected with
virus obtained from supernatants of 293 cells transfected with BAC36 and BAC36∆K8.1
DNA. (A) Approximately 104 293 cells per well in a 96 well plate were incubated with
50µl of supernatant containing virus obtained from transfections of 293 cells with
BAC36, pRTA and pCDNA3.1 (panel A2), BAC36∆K8.1, pRTA and pCDNA3.1 (panel
B2), BAC36∆K8.1, pRTA and pCDNAK8.1 plasmid (panel C2), or pEGFP-C1, pRTA
and pCDNA3.1 (panel D2). Matching phase contrast images are shown (panels: A1, B1,
C1, D1). (B) Virus infectivity was determined by the number of GFP-expressing cells.
Error bars indicate standard deviations. All experiments were performed in triplicates.
Infectious virions were obtained from 293 cells transfected with DNA mixtures as shown.
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All BAC-transfected 293 cells produced relatively high number of genome equivalents in
supernatants (Figure 2.6). The number of BAC36∆K8.1 genomes found in supernatants
of transfected cells was consistently higher than that of BAC36, in part due to the higher
transfection efficiency of the BAC36∆K8.1 DNA over the BAC36 DNA (data not
shown). Cotransfection of the pCDNA-K8.1A plasmid with BAC36∆K8.1 produced
approximately two-to-three fold more viral genomes in 293 cellular supernatants than did
transfection BAC36∆K8.1 alone (Figure 2.6). This effect was pCDNAK8.1-specific,
since co-transfection of BAC∆K8.1 DNA with vector plasmid pCDNA3.1 did not
increase the number of viral genomes found in supernatants (Figure 2.5B).
Viral genomes in supernatants were protected from TurboDNase treatment
indicating that most of the viral genomes in 293 supernatants were encapsidated (Figure
2.6). These results were most likely not due to differences in transfection efficiencies,
since the number of transfected cells expressing the viral GFP gene remained
approximately constant in the presence or absence of the complementing pCDNA-K8.1A
plasmid (data not shown). Therefore, the two-to-three fold increase of encapsidated
KSHV(∆K8.1) genomes in the supernatants from cells transfected with pCDNA-K8.1A,
when compared to transfections with BAC36∆K8.1 alone, is probably due to the
production of a greater number of encapsidated KSHV virions (Figure 2.6).
DISCUSSION
Viral glycoproteins encoded by herpesviruses are important determinants of viral
infectivity and spread. Although there are significant differences among herpesviruses
belonging to the three herpesvirus subfamilies: alpha, beta and gamma, there are
important similarities among all herpesviruses with regard to virus entry and egress out of
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Figure 2.6: Quantitative, real-time PCR assay determination of KSHV
genomes in supernatants of transfected 293 cells. Supernates were either treated (gray,
striped bars) or not treated (black, solid bars) with DNase I. Viral DNA extraction and
real-time PCR were performed in triplicate from supernatants obtained from cells
transfected with either BAC36, BAC36∆K8.1, or BAC36∆K8.1 DNAs and various
plasmid mixtures. Supernatants from 293 cells transfected with pEGFP-C1, pCDNA3.1,
and pRTA plasmids were included as a negative control. Error bars indicate standard
deviations.
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infected cells. Generally, all herpesviruses require initial attachment onto cell surfaces,
often mediated by binding to ubiquitous glycosaminoglycans such as heparan sulfate.
Virus penetration is achieved via either direct fusion of viral envelopes with cellular
membranes or after virion endocytosis and subsequent fusion of viral envelopes with
endosomal membranes releasing capsids into the cytoplasm of infected cells. For KSHV,
initial attachment onto cell surfaces is mediated by binding of glycoproteins gB and K8.1
onto heparan sulfate moieties(Akula et al., 2001a; Akula et al., 2001b; Birkmann et al.,
2001; Wang et al., 2001). In addition, gB binds to the α3β1 integrin receptor, which is
thought to facilitate virus penetration into certain cells via endocytosis (Akula et al.,
2002). The role of K8.1A in virus infectivity is not immediately apparent, since an initial
report indicated that soluble K8.1A substantially inhibited virion attachment onto cells
(Wang et al., 2001), while a later report suggested that a similar soluble form of K8.1A
did not inhibit virus infectivity (Birkmann et al., 2001). In this report, we directly
addressed the role of K8.1 in virus infectivity by generating a KSHV recombinant virus
with a deletion of both spliced variants of the K8.1 gene. Characterization of this mutant
virus in 293 cell culture assays revealed that the K8.1 gene were not essential for virus
entry.
The BAC36∆K8.1 virus was made using the GET homologous recombination
system to insert a gene cassette coding for kanamycin resistance within the BAC36 K8.1
genomic region. The K8.1 gene deletion spanned the K8.1 ORF immediately after the
initiation codon (ATG) and extended to approximately 90 bases upstream of the K8.1
termination codon. KSHV ORF50 specifying the major lytic transactivator RTA as well
as the K8 ORF specifying the K-bZIP gene, which is suggested to act either as a
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repressor of lytic replication (Izumiya et al., 2003; Liao et al., 2003) or as a replication
activator protein (rap) (Wu et al., 2001), lie immediately 5’ to the K8.1 gene. All three
genes code for mRNAs that utilize the same polyadenylation signal immediately
downstream of K8.1. The engineered deletion of K8.1 removes the last splice acceptor
site and consequently, splicing of the 3’ most exon. It is possible that the resultant 3’
modification of the RTA and K8 mRNAs adversely affected expression of these proteins.
To ensure that the transfected BAC36∆K8.1 DNA could enter into lytic replication, a
plasmid capable of transient expression of RTA was co-transfected with the
BAC36∆K8.1 DNA. Consistently, the BAC36∆K8.1 DNA produced 3-5-fold more
infectious virus than BAC36 DNA. A possible explanation for this result may be that
deletion of the terminal exon of K-bZIP (K8) reduced its expression allowing for
improved trans-activation by the exogenously provided RTA.
KSHV genomes remain latent in BCBL-1 cells and could be activated to lytic
replication as evidenced by the expression of lytic proteins such as ORF59 and K8.1 after
induction with TPA and/or exogenously provided RTA. Transfection experiments in 293
cells revealed that both BAC36 and BAC36∆K8.1 genomes expressed a low level of
ORF59 indicating that under transient transfection conditions some of the viral genomes
may be activated for lytic replication in the absence of exogenously provided TPA or
RTA, which is consistent with previous observation (Zhou et al., 2002). These results are
also in agreement with recent observations that infection of primary human umbilical
vein endothelial cell (HUVEC) cultures occurred in two phases: 1) a permissive phase, in
which the cultures undergo active viral lytic replication and infectious virus production;
2) a latent phase, in which the surviving cells from the lytic phase switch into latent
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infection, with a small number of cells undergoing spontaneous viral lytic replication
(Gao, Deng, and Zhou, 2003). However, in most experiments, trans-activation by RTA
produced at least 2-3 fold more cells in which KSHV replicated in a lytic phase as
evidenced by the expression of the ORF59 and K8.1 genes. As expected, the
BAC36∆K8.1 failed to express any K8.1 under either induced or uninduced conditions.
Transfection of either BAC36 or BAC36∆K8.1 DNA into 293 cells produced
infectious virions in the supernatants of the transfected cells. The number of infectious
virions produced by the BAC36∆K8.1 DNA transfection in triplicate shown in Figure 5B
was higher than that of BAC36 DNA. This difference was largely due to lower
transfection efficiencies obtained with BAC36 DNA (approximately 15% of 293 cells
expressed GFP) in comparison to BAC36∆K8.1 DNA (approximately 30% of 293 cells
expressed GFP) as determined by the number of GFP-expressing cells (not shown).
Cotransfection of the BAC36∆K8.1 DNA with plasmid pCDNA-K8.1A, transiently
expressing the K8.1 glycoprotein, consistently produced approximately two-fold higher
numbers of infectious virions in extracellular fluids in comparison to transfections with
BAC36∆K8.1 DNA with pCDNA3.1 (control). This result was not due to differences in
transfection efficiencies between BAC36∆K8.1 with pCDNA3.1 DNAs and
BAC36∆K8.1 with pCDNAK8.1 DNAs because both transfections produced equivalent
numbers of GFP expressing 293 cells. In addition, supernatants from 293 cells transfected
with a plasmid expressing GFP (pEGFP-C1) with pCDNA3.1 did not produce any GFP
positive cells indicating that there was no GFP carry over by potentially ruptured cells.
These results indicate that K8.1 is not needed for virus entry, since BAC36∆K8.1 virions
remain infectious in the absence of K8.1.
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To differentiate the complementation effect of transiently expressed K8.1 on
BAC36∆K8.1 infectious virus production, the number of KSHV genomes contained in
extracellular fluids of transfected 293 cells was determined via real-time PCR. Cotransfection of BAC36∆K8.1 with the complementing plasmid pCDNA-K8.1 consistently
produced higher number of viral genome equivalents in supernatants in comparison to
BAC36∆K8.1 with pCDNA3.1. These genomes represented encapsidated DNA since
treatment with DNase I did not appreciably reduce the number of KSHV genomes
suggesting that K8.1 enhanced infectious virus production.
Previous studies addressing the role of K8.1A in virus attachment showed that a
soluble version of K8.1A reduced KSHV attachment by as much as 70% (Wang et al.,
2001). In a latter study, a similar soluble form of K8.1A did not affect virus infectivity
(Birkmann et al., 2001). In this report, we conclusively show that K8.1 is not necessary
for virus infectivity, in agreement with the latter study mentioned above. The relative
increase of encapsidated KSHV virions after transient expression of K8.1 suggest that
K8.1 may facilitate virion morphogenesis. A similar scenario may be occurring for the
EBV gp350/220, since deletion of this gene caused a decrease in infectivity, which was
complemented in-trans by exogenously supplied gp350/220 (Janz et al., 2000).
Characteristically, KSHV produces a high number of non-infectious virions in
supernatants of BCBL-1 cells after induction to lytic replication. In one study, it was
calculated that approximately 1 x 107 genome equivalents were produced per 1 ml of
BCBL-1 suspension culture at 48 hours post TPA induction (Renne et al., 1996).
However, typically, a very small portion of these viruses enters into susceptible cells and
initiate a viral infection as evidence by the expression of either latent or lytic genes
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(Baghian, Luna and Kousoulas, unpublished). Similarly, BAC36 or BAC36∆K8.1
transfections produced a relatively high number of encapsidated genomes in the
supernatants of transfected cells; however, a very small percentage of these virions were
infectious as evidenced by the expression of the virally encoded GFP gene after infection
of 293 cells. It is unclear at this time why KSHV produces such a high number of
noninfectious viruses, which are presumably defective in one or more functions. One
possibility is that 293 cells do not support efficient cytoplasmic morphogenesis and
egress resulting in a high percentage of partially defective virions in supernatants fluids.
Production of high titer infectious KSHV should enable the ultrastructural visualization
of egressing KSHV and enable visualization of the intracellular sites utilized by the virus
as well as dissection of the role of individual glycoproteins in efficient morphogenesis
and egress.
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CHAPTER III
CONSTRUCTION AND CHARACTERIZATION OF RECOMBINANT STRAINS
USING THE BAC36 VIRAL GENOME SUGGEST THAT THE
GLYCOPROTEIN B (gB) CARBOXYL-TERMINUS IS INVOLVED IN VIRUSINDUCED CELL-TO-CELL FUSION

INTRODUCTION
The Human Herpesvirus 8 (HHV-8) or Kaposi’s Sarcoma-Associated Herpesvirus
(KSHV) was first identified in 1994 by Patrick Moore and Yuan Chang (Chang et al.,
1994). KSHV is considered to be the etiologic agent of Kaposi’s Sarcoma, an angiogenic
vascular cancer of endothelial cells, which is more prevalent in HIV patients (Ablashi et
al., 2002; Dourmishev et al., 2003; Martin and Osmond, 1999). The KSHV genome
derived from the BC-1 cell line was fully sequenced in 1996 by the Moore/Chang
Laboratory (Moore et al., 1996). KSHV is a member of the herpesviridae family, which
include herpes simplex 1 & 2 (HSV-1 & 2), VZV (HHV-3), human cytomegalovirus
(HHV-5), and the Epstein-Barr virus (HHV-4) (Knipe et al., 2001).
KSHV expresses numerous glycoproteins during its virus lifecycle. Many of these
KSHV glycoproteins play important roles in virus entry and cell-to-cell spread(Knipe et
al., 2001). KSHV glycoprotein B (gB) is conserved among all herpesviruses and is
thought to be directly involved in fusion of the viral envelope with cellular membranes
during virus entry, as well as in virus-induced cell fusion mediated by expression of gB
and other viral glycoproteins on infected cell membranes. Virus-induced cell fusion
allows herpesviruses to spread to adjacent cells avoiding the immune system(Baghian et
al., 1993; Foster, Melancon, and Kousoulas, 2001). gB is a structural component of the
KSHV virion particle (Akula et al., 2001; Baghian et al., 2000), and it is thought to
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mediate similar membrane fusion functions to the other herpesviral gB homologues. One
unusual property of both herpes simplex virus type 1 (HSV-1) and KSHV gB is that
carboxyl terminal mutations cause enhanced virus-induced cell fusion (Baghian et al.,
1993; Foster, Melancon, and Kousoulas, 2001; Pertel, 2002). Specifically, a carboxyl
terminal deletion of KSHV gB was reported to cause increased amount of cell fusion in a
transient expression system where KSHV gB was co-expressed with gH and gL (Pertel,
2002). This gB truncation was not congruent to other HSV-1 gB truncations that were
previously shown to produce extensive virus-induced cell fusion, as well as cell-to-cell
fusion after transient co-expression of HSV-1 gB, gD, gH and gL. Based on the
conserved homology of the gB tail throughout the entire herpesvirus family, we
hypothesize that the carboxy-tail of KSHV gB plays a crucial role in gB’s ability to cause
membrane fusion.
Previously, classical methods for producing KSHV mutant viruses prevented the
rapid isolation of recombinant viruses containing specific mutations. In an effort to
delineate and map the functional domains of the gB carboxyl terminus, which are
involved in KSHV-induced cell fusion, a two-step BAC SacB mutagenesis method was
employed using the KSHV genome cloned into BAC36 (Gong et al., 2002; O'Connor,
Peifer, and Bender, 1989; Posfai et al., 1997; Smith and Enquist, 1999). In addition, a
SacB negative-selection process was applied to facilitate the rapid isolation of KSHV
mutant genomes. The two-step SacB mutagenesis system was used to insert two different
opal stop codons in the carboxy-tail of KSHV-gB resulting in carboxyl terminal
truncations: 1)gB-Pert; Ala 730 switched to opal stop codon 730, thus truncating the gB
carboxyl tail by 58 amino acids. 2) gB-Gus; Gly 749 switched to opal stop codon 749;
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thus truncating the gB carboxyl tail by 25 amino acids. The ability of these recombinant
viruses to induce different amounts of virus-induced cell fusion is currently under
investigation.
MATERIAL AND METHODS
Construction of Recombinant Plasmids Encoding Mutant gBs
Mutagenesis of BAC36 DNA was accomplished in E. coli via the SacB/RecA
two-step mutagenesis system. PCR using primers IX and X amplified the KSHV-gB
region (4.6kb), which included the entire gB-gene, 1 kb upstream viral sequence (arm A)
tagged with SacII and 1 kb downstream viral sequence (arm B) tagged with NotI. The
PCR product was digested with SacII and NotI and cloned into the similarly restricted
plasmid, pSacB/RecA. The newly constructed plasmid, named pSacB/RecA-gB, served
as the gB homologous recombination vector and was used as the template to insert the
gB-carboxyl tail mutations: gB-Pert and gB-Gus. The pSacB/RecA-gB vector, in addition
to containing the 4.6kb gB-region, contained the R6Kγ origin, the E. coli RecA gene, a
SacB gene, and an ampicillin-resistance gene.
The insertion of the gB-Pert mutation within the pSacB/RecA-gB plasmid was
performed by PCR overlap extensions of two individual PCR products which inserted a
stop codon and a BamHI site within the gB-carboxyl-tail. Two PCR products which
constituted a 5’-end product (Primers IX & IV; Table 3.1) and a 3’-End product (Primers
III & X; Table 3.1) were cut with BamHI and subsequently ligated to each other. A final
round of PCR (Primers IX and X; Table 3.1) was performed to amplify the mutated gBPert region including the entire gB-gene, 1 kb upstream arm A and 1 kb downstream arm
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B sequences; the final PCR product was subsequently cloned into pSacB/RecA via the
SacII and NotI restriction sites, thus producing the pSacB/RecA-gB-Pert vector.
A similar strategy was employed for the insertion of the gB-Gus carboxyl tail
mutation within the pSacB/RecA-gB plasmid. The insertion of the gB-Gus mutation was
performed by PCR overlap extensions of a 5’-End-product (Primers IX & II; Table 3.1)
and a 3’-End-product (Primers I & X; Table 3.1). The two PCR products which
constituted a 5’-End product (Primers IX & II; Table 3.1) and a 3’-End product (Primers I
& X; Table 3.1) were cut with BamHI and subsequently ligated to each other. A final
round of PCR (Primers IX and X; Table 3.1) was performed which produced a PCR
product which possessed an inserted stop codon and a BamHI site within the gBcarboxyl-tail. The final PCR product was subsequently cloned into pSacB/RecA via the
SacII and NotI restriction sites, thus producing the pSacB/RecA-gB-Gus vector.
Preparation of KSHV-BAC36 Competent Cells
Overnight culture of E.coli DH10B cells harboring the KSHV-BAC36 genome
was diluted 1000-fold in 100 mL of LB medium containing the antibiotic
chloramphenicol (Chlor) (12.5µg/mL). The optical density was monitored at 600nm
(OD600) to stop the growth of the bacteria at 0.7-0.8. The bacteria was chilled
afterwards on ice for 15 min. The cells were then harvested and made electrocompetent
by centrifuging and repeated resuspensions in 10% glycerol; the competent cells were
aliquoted and stored at -80°C. The pSacB/RecA-gB-Pert (100ng) or pSacB/RecA-gBGus (100ng) was added to 40µl of chilled KSHV-BAC36 competent cells.
Electroporation was performed with the BioRad Gene Pulser II with the following
conditions: 1.8kV/cm, 200Ω and 25µF.
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Identification of KSHV-BAC36-SacB/RecA-gB-Mutant Co-Integrates
(Recombination Step 1)
Following electroporation, cells were grown in 1ml of SOC for 60 min at 37°C
and subsequently diluted and grown in LB plates containing chloramphenicol (12.5
µg/ml) as well as ampicillin (100µg/ml) overnight at 37°C. The next day, colonies were
picked and grown overnight in LB broth (chlor and amp) and the culture was further
diluted 1:5,000 in LB broth (chlor and amp) and incubated for 10 hours at 37°C and the
culture was diluted 1:5,000 once again for 8 hours at 37°C. Subsequently the selected
bacteria were struck onto LB plates containing chloramphenicol (12.5 µg/ml) and
ampicillin (100µg/ml) overnight at 37°C. Colonies were picked and grown overnight in
LB broth (chlor and amp); the colonies were assayed by PCR for the integration of the
gB-mutation recombination shuttle vector (pSacB/RecA-gB-Pert or pSacB/RecA-gBGus) into to the KSHV-BAC36, thus forming a co-integrate (KSHV-BAC36-SacB/RecAgB-Pert or KSHV-BAC36-SacB/RecA-gB-Gus).
Resolution of KSHV-BAC36-SacB/RecA-gB-Mutant Co-Integrates (Recombination
Step 2)
The colonies, which were appropriately identified as a KSHV-BAC36SacB/RecA-gB-Mutant co-integrates (KSHV-BAC36-SacB/RecA-gB-Pert or KSHVBAC36-SacB/RecA-gB-Gus), were picked from LB-plates, containing chloramphenicol
(12.5 µg/ml) and ampicillin (100µg/ml), and subsequently grown at 37°C for 4 hours in
LB broth containing chloramphenicol (12.5 µg/ml) and 5% sucrose. The bacteria was
diluted and grown overnight at 37°C onto LB plates containing 10% sucrose and
chloramphenicol (12.5 µg/ml). Replica plating was employed for further screening;
colonies were picked and plated onto two agar plates: 1.) LB-plates with chloramphenicol
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(12.5 µg/ml) and ampicillin (100µg/ml) and 2.) LB-plates with only chloramphenicol
(12.5 µg/ml). The colonies that grew only on plates with chloramphenicol (not the plates
with double selection) were mini-prepped and screened by both restriction digest and
PCR analysis. This resolution procedure produced both wild-type and mutant KSHVBAC clones.
Transient Transfection of the KSHV BAC DNAs
Transient transfection of 293 cells with KSHV-BAC36 DNAs was performed by
using Superfect (Qiagen). 293 cells were grown to 80% confluence in six-well plates.
Cells were transfected with BAC DNA mixed with Superfect in DMEM as recommended
by the manufacturer. After 4 hours of incubation at 37°C, the medium was removed from
the transfected cells, and the cells were washed with PBS. Next, fresh DMEM with 10%
fetal calf serum was added. In order to induce KSHV late gene expression within the
KSHV-BAC transfected cells, TPA [12-O-Tetradecanoylphorbol-13-acetate] at (25
ng/ml) was added 24 h post-transfection.
RESULTS
Construction of the pSacB/RecA-gB Homologous Recombination Plasmid
More than a decade ago, our laboratory investigated the effect of several HSV-1
gB truncations on virus-induced cell fusion; the findings were clear, an HSV-1
recombinant virus expressing a 28 amino acid truncated gB resulted in extensive virusinduced cell fusion (Baghian et al 1993). In this study, we investigated KSHV virusinduced cell fusion by engineering an analogous truncation in the carboxyl tail of KSHVgB, wherein we truncated the KSHV-gB molecule by 25 amino acids (gB-Gus) (Figure
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TABLE 3.1. Synthetic Oligonucleotide Primers. The opal termination codon
‘TGA’ and its complementary sequence ‘TCA’ are in bold. Restriction sites are
underlined.
Primer

Primer Sequence

I: 5’-Bam-Gus
II: 3’-Bam-Gus

5’—AGTATATGAGGATCCAACGGCCTTCGTCAGCGTCTG—3’
5’—TTGTATGGATCCTCATGCGGTACGCTGAAACACCGA—3’

III: 5’-Bam-Pert
IV: 3’-Bam-Pert

5’--CGTCTCTGAGGATCCAAAAACATCCTGCTGGGAATG--3’
5’—ATAGAAGGATCCTCAGATTTCCTCCCGTGTTGGGGC--3’

V: 5’-F-Gus-Test 5’--CAGCGTACCGCATGAGGATCC--3’
VI: 3’-R-Gus-Test 5--ACGAAGGCCGTTGGATCCTCA--3’
VII: 5’-F-Pert-Test 5’--CGGGAGGAAATCTGAGGATCC --3’
VIII: 3’-R-Pert-Test5’--CAGGATGTTTTTGGATCCTCA --3’
IX: F-SacII-gBup 5’--ATATGACCGCGGAACTACACTACTGCACTGC --3’
X: R-NotI-gBdown 5’--AGTATAGCGGCCGCAGTTCCGTCCAAGAGTCTC--3’
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3.1). A virus-free cell fusion assay has been developed for herpesviruses (Foster,
Melancon, and Kousoulas, 2001; Muggeridge, 2000; Pertel, 2002; Pertel et al., 2001;
Turner et al., 1998), particularly a KSHV virus-free cell fusion assay has been developed,
in which transient transfection of KSHV-gB, gH and gL with gB having a 59 amino acid
carboxyl terminal gene truncation induced cell-to-cell fusion (Pertel, 2002). In this study
the ability of a KSHV-gB carboxyl tail truncation by 59 amino acids (gB-Pert), to induce
cell-to-cell fusion was compared to other gB truncations (Figure 3.1).
To facilitate the insertion of the gB-carboxyl tail mutations (gB-Pert and gB-Gus)
within the gB gene of the KSHV-BAC36 genome by homologous recombination in
bacteria, a recombination vector (pSacB/RecA-gB) was engineered, in which the gB gene
along with a 1 kb upstream homology arm ‘A’ and 1 kb downstream homology arm ‘B’,
amplified using primers IX & X (Table 3.1), was cloned into the pSacB/RecA shuttle
vector (Figure 3.2). The pSacB/RecA vector contains the versatile genetic elements
which can complement the deficiency of DH10B E.coli for homologous recombination
(see Materials and Methods) [1.) RecA gene, which mediates homologous recombination;
2.) SacB gene; a negative selection marker which allows for removal of any sequence
remnants left from the homologous recombination system; 3.) R6kγ replication origin;
can not replicate in DH10B E. coli (can only replicate in the presence of the π protein
encoded by the pir gene for replication; 4.) Ampicillin resistance cassette; allows for
positive selection of co-integrates, indicating the insertion of the shuttle vector into the
KSHV-BAC36 genome].

125

Figure 3.1. A schematic representation of the predicted secondary structure
of the cytoplasmic portion of KSHV glycoprotein B. This model depicts the gB
carboxyl tail mutations named gB-Pert and gB-Gus. In this study, these gB-tail
mutations were inserted within the wild-type KSHV-BAC36 producing the following
mutant viruses: KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus. The relevant
predicted α-helices are denoted as Tail Helix 1 and Tail Helix 2, which were marked by
dashed lines. The schematic was based on the secondary structure prediction produced
by using the PSIPRED Protein Structure Prediction Server.
http://bioinf.cs.ucl.ac.uk/psipred/
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Figure 3.2 Construction of pSacB/RecA-gB, a homologous recombination
vector encoding KSHV-gB along with 1kb upstream (arm A) and downstream (arm
B) overhang sequence. The overall strategy leading to the construction of the
recombination plasmid, pSac-RecA-gB KSHV-BAC36-gB. (1), PCR amplification of
the KSHV-gB region which includes 1 kb upstream viral sequence (arm A) tagged with
SacII and 1 kb downstream viral sequence (arm B) tagged with NotI. (2) Restriction
digestion of the PCR product and pSacB/RecA with SacII and NotI enzymes, which were
subsequently ligated. (3) The gB homologous recombination cassette within the
pSacB/RecA-gB was used as the basis for the subsequent insertion of gB-carboxyl tail
mutations.

128

129

The pSacB/RecA-gB vector, which contained the genomic region encompassing
the gB gene along with the 1kb upstream (arm A) and downstream sequences (arm B),
was used to insert the gB-Pert and gB-Gus mutations within the gB gene of the KSHVBAC36 genome. The overall strategy leading to the construction of the gB-mutated
recombination plasmids (pSacB/RecA-gB-Pert and pSacB/RecA-gB-Gus) was performed
by inserting within the gB carboxyl tail an Opal stop codon with a subsequent BamHI
site: 1)gB-Pert; Ala 730 switched to opal stop codon 730, thus truncating the gB carboxyl
tail by 58 amino acids. 2) gB-Gus; Gly 749 switched to opal stop codon 749; thus
truncating the gB carboxyl tail by 25 amino acids. The primer binding sites used for the
construction of the mutated gB-recombination shuttle vectors are shown in Figure 3.3
(see also Table 3.1). The insertion of either gB-Pert or gB-Gus mutations within the
pSacB/RecA-gB plasmid was performed by PCR overlap restriction with subsequent
extensions of two individual PCR products by the tagging of the gB-tail mutated
sequences with a stop codon and a BamHI site (see Materials and Methods).
Construction of the KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus
The complete KSHV genome was recently cloned into a BAC, yielding BAC36
and enabling the genetic manipulation of the KSHV genome in E. coli. KSHV-BAC36
constitutively expresses the GFP gene, allowing the detection of infected or transfected
eukaryotic cells containing KSHV-BAC36 genome. A targeted two-step mutagenesis
replacement procedure was employed to construct gB-mutant-KSHV-BAC36 genome,
with engineered gB carboxyl tail truncations, in E.coli. The details of the two-step
mutagenesis procedure are described in the Materials and Methods. Briefly, gB-mutant
homologous recombination shuttle vectors (gB-Pert and gB-Gus) containing the gB
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Figure 3.3 Schematic illustration of the insertion of gB-Pert and gB-Gus
mutations within the pSacB/RecA-gB plasmid. This model shows the primer binding
sites used for the construction of the mutated gB-recombination shuttle vectors:
pSacB/RecA-gB-Pert and pSacB/RecA-gB-Gus. The insertion of gB-Pert and gB-Gus
mutations within the pSacB/RecA-gB plasmid were performed by PCR overlap
extensions of two individual PCR product by the tagging of the gB-tail mutated
sequences with a stop codon and a BamHI site. The gB-Pert mutation within the carboxyl
tail was created by producing two PCR products which constituted a 5’-end (Primers IX
& IV; Table 3.1) and a 3’-End (Primers III & X; Table 3.1). The 5’-End and 3’-End were
cut with BamHI and subsequently ligated to each other. A final round of PCR (Primers
IX and X; Table 3.1) was performed to amplify the mutated gB-Pert region including the
1 kb upstream arm A and 1 kb downstream arm B sequences. A similar strategy was
employed for the insertion of the gB-Gus carboxyl tail mutation: 5’-End (Primers IX &
II; Table 3.1) and 3’-End (Primers I & X; Table 3.1).
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mutant gene, specifying mutations in the carboxyl tail, along with 1 kb homologous
upstream (arm A) and downstream (arm B) flanking sequences were utilized in the first
homologous recombination step (Figure 3.4). The first step includes the incorporation of
the shuttle vector into the KSHV-BAC36 genome, thus forming a co-integrate. The
homologous recombination mechanism is mediated by the RecA gene, which is provided
by the recombination shuttle vector. The second recombination step, which is also
mediated by the RecA enzyme, allows for the resolution of the co-integrate and
restoration of the wild-type KSHV-BAC36 genome or intended KSHV-BAC36-gBmutant. This resolution step results in complete excision of the shuttle vector from the
KSHV-BAC36-SacB/RecA-gB-mut co-integrate, which leaves the targeted mutagenic
sequences within the KSHV-BAC36 genome. Since the resolution of the co-integrate
does not occur with high frequency, negative selection pressure against the bacteria
harboring the cointegrate occurs due to SacB gene expression of levansucrase which
converts the supplemented sucrose within the LB-broth and/or plates into levan, a
bacterial toxin. In this study, we utilized the two-step SacB/RecA mutagenesis procedure
to insert gB-carboxyl tail truncations within the KSHV-BAC36 genome (KSHV-BAC36gB-Pert and KSHV-BAC36-gB-Gus).
Genetic Characterization of the KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus
The KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus constructs were tested for the
presence of engineered insertion of the Opal-stop codon and a BamHI site within the
carboxyl tail of the gB gene. Restriction enzyme analysis of the wild-type KSHVBAC36 and mutant KSHV-BAC36-gB-Pert & KSHV-BAC36-gB-Gus with BamHI
revealed similar DNA fragmentation patterns, with the exception that a new BamHI
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Figure 3.4. A schematic illustration of the two-step SacB/RecA shuttle
mutagenesis system for the insertion of point mutations within the KSHV-BAC36
genome. A schematic model of the two-step SacB/RecA mutagenesis system with
pPERT and pGUS as shuttle vectors. This vector contains a R6kγ origin, an Ampresistant gene, RecA for the restoration of homologous recombination competence, and
the SacB gene intended to act as a negative selection step. The two BAC modification
phases are illustrated: (1.) Shuttle vector pPERT and pGUS are co-integrated into BAC
via homologous recombination through ‘A’. (2.) There is a second homologous
recombination event in the resolution step of the co-integrant to eliminate the previous
vectors and any other unnecessary sequences from the co-integrate. Due to the loss of the
SacB gene, the resolved BACs (KSHV/BAC36-gB-Pert and KSHV/BAC36-gB-Gus)
were grown on sucrose and chloramphenicol plates.
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restricted fragment, which appeared in the vicinity of the 9,4 kb lambda molecular
marker. The new BamHI DNA fragment present within the KSHV-BAC36-gB-Pert and
KSHV-BAC36-gB-Gus (Figure 3.5; Lanes 3 and 4) is noticeably absent in the restricted
DNA fragmentation pattern of the wild-type KSHV-BAC36 genome (Figure 3.5; Lane
2). The new BamHI DNA fragment is caused by the insertion of the BamHI site at the
carboxyl terminal domain of the gB gene within the KSHV-BAC36 genome. The
remaining restriction pattern of the mutant KSHV-BAC36-gB-Pert and KSHV-BAC36gB-Gus is identical to the KSHV-BAC36 fragment pattern, thus the engineered insertion
of the BamHI site with the preceding contiguous opal stop codon was precisely inserted
within the KSHV-BAC36 genome without any obvious deletions of large regions of the
KSHV-BAC genome.
In order to confirm the precise location of the inserted mutation within the
KSHV-BAC, we used a diagnostic PCR assay to ensure the proper orientation of the
inserted opal stop codon and BamHI site within the carboxyl tail of the gB gene within
the KSHV-BAC36 genome. Primers IX & VI specific for the gB-Gus mutation were
used to amplify a diagnostic PCR product ~3kb (Table 3.1 and Figure 3.6; Lane 2).
Primer IX, the 5’primer, binds to the 5’-end of homology arm A and primer VI binds to
the gB-Gus inserted mutation: opal stop codon and the engineered BamHI site, thus a
PCR product would only arise if the inserted mutation is within the precise intended
location. Amplification using primers IX and VI on the wild-type KSHV-BAC36 DNA
does not produce a PCR product (Figure 3.6; Lane 3). Primers IX & VIII specific for the
gB-Pert mutation were used to amplify a diagnostic PCR product ~3kb (Table 3.1 and
Figure 3.6; Lane 1). Primer IX binds to the 5’-end of homology arm A and primer VIII
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Figure 3.5. Restriction Fragment Analysis with BamHI digestion of wild-type
KSHV-BAC36 and mutants KSHV-BAC36-gB-Pert & KSHV-BAC36-gB-Gus.
BamHI digestion of the wild-type KSHV-BAC36 episome (Lane 2) along with BamHI
digestion of mutant KSHV-BAC36 episomes: KSHV-BAC36-gB-Pert (Lane 3) and
KSHV-BAC36-gB-Gus (Lane 4). Lambda-HindIII DNA digested molecular size markers
are shown in Lane 1. BamHI restriction fragment analysis of the gB-carboxyl tail
mutants of KSHV-BAC36 in comparison with the wild-type KSHV-BAC36 episome
clearly shows size differences within the fragmentation pattern. An approximate 9,4 kb
BamHI restricted DNA fragment is clearly present in the lane containing mutant KSHVBAC36-gB-Pert episome (Lane 3) and slightly larger BamHI restricted DNA fragment is
present in the lane containing mutant KSHV-BAC36-gB-Gus episome (Lane 4), yet these
bands around the 9,4 kb lambda molecular marker fragment was absent within the lane
containing the wild-type KSHV-BAC36 episome (Lane 2). The BamHI enzyme
recognized an additional DNA sequence, GGATCC (BamHI) inserted directly after the
artificial Opal-stop codon introduced into both gB-mutant KSHV-BAC36 episomes:
KSHV-BAC36-gB-Pert (Lane 3) and KSHV-BAC36-gB-Gus (Lane 4). The missing
DNA fragment (9,416bp) within the wild-type KSHV-BAC36 genome is demarcated by
a yellow star in Lane 2.
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binds to the gB-Pert inserted mutation: opal stop codon and the engineered BamHI site,
thus a PCR product would only arise if the inserted mutation is within the precise
intended location. Amplification using primers IX and VIII on the wild-type KSHVBAC36 DNA did not lead to the production of a PCR product (not shown). The
confirmatory results of the restriction analysis and diagnostic PCRs are consistent with
the proper insertion of the gB-Pert and gB-Gus mutations within the gB gene of the
KSHV-BAC genome. The KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus
constructs were sequenced from the 3’-end of the gB gene (gB’s original stop codon); the
sequence results show the precise insertion of the both the Opal stop codon and BamHI
site within the carboxyl tail of gB (Figure 3.7).
Transient Transfection Assay to Determine Virus-Induced Cell Fusion Caused by
either KSHV-BAC36-gB-Pert or KSHV-BAC36-gB-Gus
To assess the fusogenic potential of the mutations within the carboxyl tail domain
of KSHV-gB, we developed a transient transfection assay, in which KSHV-BAC
eukaryotic transfected cells are induced with TPA for 48 hours and viewed under
fluorescence microscopy for cell fusion. Column-purified BAC DNA (wt-KSHVBAC36, KSHV-BAC36-gB-Pert, and KSHV-BAC36-gB-Gus) were used to transfect 293
cells (Figure 3.8; A1, B1 and C1, respectively). Transfected cells harboring the KSHVBAC genome constitutively expresses the GFP gene, thus allowing for facile detection of
cells containing the KSHV-BAC genomes via fluorescence microscopy. Also, BACtransfected cells were exposed to TPA (20ng/ml) for 48 hours in order to induce late gene
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Figure 3.6. Diagnostic PCR analysis of the viral mutants: KSHV-BAC36-gBPert and KSHV-BAC36-gB-Gus. Diagnostic PCR assay was used to confirm the
respective gB-carboxyl-tail mutations within the KSHV-BAC36 genome: KSHVBAC36-gB-Pert (Lane 1) and KSHV-BAC36-gB-Gus (Lane 2). The KSHV-BAC36-gB
mutant clones were produced via the modification of KSHV-BAC36 by pGUS and
pPERT recombination shuttle vector using a built-in resolution strategy at homology arm
‘A’. The PCR product of the region encompassing the mutated gB-carboxyl-tail region
(1kb upstream of the gB start codon to the mutated gB-tail region) using diagnostic
primers that only allowed for amplification of a 3kb product from the mutated gBKSHV-BAC36s (Lanes 1 & 2) and not from wild-type KSHV-BAC36 genome (Lane 3).
The 2-log DNA ladder was used as the molecular size marker (Lane 4).
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Figure 3.7. Nucleotide sequence analysis of KSHV-BAC36-gB-Pert and
KSHV-BAC36-gB-Gus. DNA sequencing was performed of the 3’-ends of the two
KSHV-gB-carboxyl-tail recombinant BAC clones after the modification of the gBcarboxyl tail by the insertion of both the Opal-stop codon and BamHI site to produce
KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus. The KSHV-BAC36-gB-Pert and
KSHV-BAC36-gB-Gus were sequenced using the ABI Prism 310 Genetic Analyzer. The
DNA sequence ‘GGATCCTCA’ are highlighted, which includes the BamHI site as well
as the Opal-stop codon of gB-Gus and gB-Pert.
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expression and enhance virus-induced cell fusion. Wild type-KSHV-BAC36 (Figure 3.8;
A1) and mutant KSHV-BAC36-gB-Pert (Figure 3.8; B1) did not produce significant cell
fusion, yet KSHV-BAC36-gB-Gus (Figure 3.8; C1) seemed to produce limited amounts
of virus-induced cell fusion. The KSHV-BAC36-gB-Gus (Figure 3.9; A1, B1 and C1)
was further examined by the transient transfection cell fusion assay and also showed
small levels of virus-induced cell fusion.
DISCUSSION
Kaposi’s Sarcoma Herpes Virus (KSHV) is considered to be the etiologic agent of
Kaposi’s Sarcoma. KSHV relies on different viral membrane proteins for virion
attachment to cell surfaces and penetration into cells. Glycoprotein B (gB) is conserved
among all human and animal herpesviruses, and it is thought to mediate membrane fusion
phenomena during virus entry and virus-induced cell fusion. The role of the gB carboxyl
terminus in virus-induced cell fusion was investigated by constructing recombinant
KSHV strains using the KSHV genome cloned into a bacterial artificial chromosome
(BAC36). Two recombinant BAC36-derived genomes were constructed specifying
truncations that fully or partially truncated a predicted α-helical structure of the gB
carboxyl terminus known to be involved in virus-induced cell fusion from studies with
the herpes simplex virus type 1 (HSV-1) gB. The first specific gB mutation site, gB-Pert,
within the carboxyl tail was selected to be identical to a previous KSHV study describing
an in vitro cell fusion assay by Pertel (Pertel, 2002). This gB mutation caused enhanced
cell fusion in the context of an in vitro virus-free cell fusion assay, presumably, in part,
because deletion of the 58 carboxyl terminal aa of gB containing putative endocytotic
motifs resulted in increased accumulation of gB on cell surfaces. The second specific gB
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Figure 3.8. Observation of virus-induced cell fusion via transient
transfections of KSHVgB Mutant BACs. Transient transfection of 293 cells with wild
KSHV-BAC36 DNA (A1), KSHV-BAC36 gB-Pert DNA (B1) and KSHV-BAC36-gBGus DNA (C1). The BAC-transfected 293 cells were induced with TPA induction for 48
hours. Wild-type KSHV-BAC36 and KSHV-BAC36-gB-Pert transfected cells produced
no significant cell fusion. The KSHV-BAC36-gB-Gus seemed to produced limited
amounts of virus-induced cell fusion. The panels show the corresponding cells via
fluorescence and phase-contrast microscopy (magnification, X200). Matching phasecontrast images are shown in panels A2, B2 and C2.
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Figure 3.9. Observation of cell-to-cell membrane fusion via transient
transfections of KSHV-BAC36-gB-Gus DNA. Transient transfection of 293 cells with
KSHV-BAC36-gB-Gus DNA (panels A1, B1 and C1). The KSHV-BAC36-gB-Gus
transfected 293 cells were induced with TPA for 48 hours. The KSHV-BAC36-gB-Gus
seemed to produce limited amounts of cell-to-cell fusion. The panels show the
corresponding cells via fluorescence and phase-contrast microscopy (magnification,
X400). Matching phase-contrast of KSHV-BAC36-gB-Gus images are shown in panels
A2, B2 and C2.
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mutation site (gB-Gus) was chosen based on studies with the HSV-1 gB homologue
which have suggested that the smaller of the two major α-helical domains in the gB
carboxyl terminus, which are conserved between KSHV and HSV-1 gB, is important in
virus-induced cell fusion and virus-free cell fusion assays.
Consistent with previous findings with the KSHV-gB virus-free cell fusion assay
and HSV-1-gB regulated virus-free cell fusion and virus-induced cell fusion assays, the
KSHV-gB mutant genes (expressing carboxyl terminal truncations gB-Pert and gB-Gus),
produced higher amounts of fusion than KSHV-BAC36 containing the wild-type-gB.
Moreover, the gB-Gus truncation (analogous to the HSV-1 gB truncation), which
interrupts the smaller of the two carboxyl-terminal α-helical domains of KSHV-gB,
seemed to produce higher amounts of virus-induced cell fusion than the gB-Pert
truncation or the wild-type gB. These preliminary results suggest that despite the
evolutionary divergence of KSHV gB and HSV-1 gB, functional domains involved in
virus-induced cell fusion are conserved suggesting a similar modus operandi. KSHV
recombinant viruses carrying gB carboxyl terminal truncations and other single amino
acid mutations would be instrumental in assessing the role of the gB carboxyl terminus in
virus-induced cell fusion.
One of the main difficulties in quantitatively assessing the extent of virus-induced
cell fusion by the different KSHV mutants is that under BAC transfection conditions only
a small percentage of the cells are capable of expressing the mutant genes. This limited
expression is due to the low levels of BAC-KSHV transfection rates (less than 10% of the
cells) and the low reactivation rates of the transfected cells upon induction with phorbol
esters (less than 20% of the transfected cells). To better assess the role of KSHV-gB
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carboxyl terminal truncations in virus-induced cell fusion, permanent TIME cell lines are
being constructed and characterized. These permanently transformed TIME cells
(telemorase immortalized microvascular endothelial cells) would serve as useful
reservoirs for efficient virus production and infection of cell cultures to adequately
quantitate the varying amounts of virus-induced cell fusion. The KSHV-BAC36-gBmutant-TIME cells could also potentially allow for sufficient mutant virus production for
structural and biochemical experiments.
We have demonstrated here for the first time that the KSHV BAC36 genome can
be manipulated in E. coli to generate site-directed mutations within a viral gene. The
RecA/SacB two-step mutagenesis system implemented in this study has allowed for the
rapid generation of mutant KSHV-BAC36 genomes, specifically the potential to deliver
point mutations. The KSHV-BAC36-gB-Pert and KSHV-BAC36-gB-Gus viral genomes
produced by the two-step bacterial mutagenesis system would serve crucial roles in the
delineation of KSHV-gB functional domains involved in membrane fusion in the future.
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CHAPTER IV
MUTAGENESIS OF THE KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS
GENOME BY USING A GET RECOMBINATION STRATEGY

INTRODUCTION
Herpesviruses are important pathogens associated with a wide range of diseases in
both humans and animals. Members of the Herpesviridae family possess large DNA
genomes (Knipe et al., 2001). Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8, belongs in the gammaherpesvirinae subfamily and is
believed to be the etiologic agent of the following diseases: 1.) Kaposi’s sarcoma, 2.)
primary effusion lymphoma, and 3.) a subset of multicentric Castleman’s disease(Moore
and Chang, 2001). The KSHV lifecycle is similar to other gammaherpesviruses, which
consist of both latent and lytic phases; however, the fundamental aspects of KSHV
infection regarding virology and cell-biology in KSHV-related malignancies remain
elusive and poorly understood (Ablashi et al., 2002). KSHV possesses approximately
ninety ORFs within its genome (Russo et al., 1996). Many of the individual KSHV genes
have been cloned and characterized in cell culture, yet the true function of a herpesviral
gene could only be assessed in the context of the viral genome (Moore and Chang, 2001).
Revolutionary experiments involving the propagation of infectious herpesviral
clones as bacterial artificial chromosomes (BACs) have lead to the unparalleled
experimental manipulation of herpesviral genomes, which exhibit cell-associated
properties and slow replication kinetics. The BAC technology has allowed the application
of tools of prokaryotic molecular biology to the study of viral genetics, whereby
permitting the genetic analysis of many herpesviruses (Borst et al., 1999; Britt, 2000;
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Brune et al., 1999; Delecluse et al., 2001; Janz et al., 2000; Messerle et al., 1997; Smith
and Enquist, 1999; Smith and Enquist, 2000; Yu et al., 2000; Zhou et al., 2002).
Recently, a recombinant KSHV, BAC36, has been produced by cloning the full-length
KSHV genome into a bacterial artificial chromosome (BAC) and recovering it in 293
cells (Zhou et al., 2002). Recombinant virions generated from BAC36 have been
recovered in 293 cells and are highly infectious to target cells, with primary-infection
efficiency close to 90-95% (Gao, Deng, and Zhou, 2003). BAC36-KSHV replication in
susceptible cells resembles an in vivo infection, in which KSHV quickly establishes latent
infection following primary infection without active productive lytic replication (Zhou et
al., 2002). KSHV, similar to the other viruses in the Herpesvirus Family, specifies
numerous glycoproteins which are expressed during the virus lifecycle. Many of these
KSHV glycoproteins have been shown to be important in virus entry.
The bacterial GET recombination strategy (Narayanan et al., 1999; Orford et al.,
2000) was employed to precisely engineer deletions of glycoproteins within the KSHVBAC36 genome. This system utilizes the pGET-Rec plasmid for bacterial recombination
thus allowing for insertional/deletional mutagenesis of the KSHV-BAC36 genome in E.
coli. The GET-Rec recombination system involves the coordinate induction with Larabinose of the plasmid encoding the RecE and RecT genes obtained originally from the
Rac bacteriophage, which mediates homologous recombination between linear DNA
fragments (homologous chimeric PCR products) and circular episomal DNA (KSHVBAC36). Linear PCR products are degraded quickly in DH10B cells by the RecBCD
exonuclease but this nuclease degradation is inhibited by the gam gene of the lambda
bacteriophage provided by the pGET-REC plasmid, which is expressed along with RecE
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and RecT genes on the same L-arabinose inducible polycistronic mRNA. The capability
of inducing site-specific recombination in RecA-negative DH10B cells allows for the
precise engineering of site-specific deletions of the KSHV-glycoproteins within the
KSHV-BAC36 genome. The simultaneous facilitation of the GET- Recombination
system to target site-specific mutagenesis of the KSHV-BAC36 and generate a panel of
KSHV-BAC36 glycoprotein deletions is extremely useful given the fact that Herpesvirus
genes are directionally expressed and the regulatory regions of its genes normally overlap
the contiguous upstream or downstream gene sequences. These mutant KSHV-BACs
harboring glycoprotein deletions would serve as critical tools to address the molecular
dynamics of viral entry mediated by KSHV glycoproteins.
MATERIALS AND METHODS
Cells and Viruses
293 cells were grown in Dulbecco’s modified Eagle medium
(DMEM; GIBCO-BRL, Grand Island, N.Y.) supplemented with 2 mM glutamine,
10% fetal calf serum, and antibiotics. KSHV BAC36 contains the green
fluorescent protein (GFP) gene cassette under the control of the human cytomegalovirus
immediate-early promoter, constitutively expressing the GFP gene, and inserted between
KSHV ORF18 and KSHV ORF19 (Zhou et al., 2002).
Construction of a Panel of KSHV-BAC36 mutants with deletions of gB, gH, K8.1,
gL and gM
Insertion-deletion mutagenesis of KSHV-BAC36 DNA was accomplished in
Escherichia coli using the λgam, recE recT (GET) recombination system (Narayanan et
al., 1999; Orford et al., 2000), as described previously for mutagenesis of the KSHV
genome (Luna et al., 2004). Electrocompetent KSHV-BAC36 DH10B E. coli cells were
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transformed with the plasmid pGETrec, which contains the genes encoding recE, recT
and bacteriophage λ gam, grown on plates containing chloramphenicol (12.5µg/ml) and
ampicillin (100µg/ml). Individual colonies were picked and grown overnight in LuriaBertani (LB) medium containing chloramphenicol and ampicillin. The next day, the
culture was inoculated into 250ml of LB containing chloramphenicol and ampicillin until
a 0.4 optical density was reached at 600nm. Addition of L-arabinose to a final
concentration of 0.2% (w/v) and further incubation of 40 minutes induced the expression
of the recE, recT and λ gam genes from the plasmid pGETrec. The bacteria cells were
then harvested and made electrocompetent. For the gB deletion-kanamycinR insertion
mutation within the KSHV-BAC36, a PCR fragment containing the kanamycinR gene
cassette flanked by approximately 60bp of gB homologous viral sequences on both sides
was used for recombination to construct BAC36∆gB, containing the kanamycinR gene
cassette within the targeted deletion of the majority of the KSHV genomic region. For the
gH-KanR mutation, a PCR fragment containing a kanamycinR gene cassette flanked by
approximately 60bp of gH homologous viral sequences on both sides was used for
recombination to construct BAC36∆gB, which contained the kanamycinR gene cassette
within the targeted deletion of the majority of gH gene within the KSHV genomic region.
For the K8.1-KanR mutation, a PCR fragment containing a kanamycinR gene cassette
flanked by approximately 60bp of K8.1 homologous viral sequences on both sides was
used for recombination to construct BAC36∆K8.1, which contained the kanamycinR gene
cassette within the targeted deletion of the majority of the K8.1 gene within the KSHV
genomic region. For the gL-KanR mutation, a PCR fragment containing a kanamycinR
gene cassette flanked by approximately 60bp of gL homologous viral sequences on both
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sides was used for recombination to construct BAC36∆gL, which contained the
kanamycinR gene cassette within the targeted deletion of the majority of the gL gene
within the KSHV genomic region. For the gM-KanR mutation, a PCR fragment
containing a kanamycinR gene cassette flanked by approximately 60bp of gM
homologous viral sequences on both sides was used for recombination to construct
BAC36∆gM, which contained the kanamycinR gene cassette within the targeted deletion
of the majority of the gM gene within the KSHV genomic region. Briefly, 40µl of
electrocompetent DH10B cells, harboring both KSHV-BAC36 and pGETrec, were
electroporated with 200ng of each chimeric PCR product, which encoded the kanamycinR
gene cassette with respective flanking KSHV homologous sequences, to delete the target
gene (gB, gH, gpK8.1, gL or gM) using standard electroporation parameters (1.8kV/cm,
200Ω and 25µF). Following electroporation, cells were grown in 1ml of LB for 60 min
and subsequently streaked onto LB agar plates containing both chloramphenicol (12.5
µg/ml) and kanamycin (50µg/ml). Mutant KSHV-BAC36 DNAs, containing a
glycoprotein deletion in either the gB, gH, gL, gpK8.1, gL or gM gene, was isolated from
bacterial colonies and a second round of electroporation was performed to remove the
plasmid pGETrec. Following electroporation, cells were grown on agar plates containing
both chloramphenicol and kanamycin.
Confirmation of the Glycoprotein Deletion within the KSHV-BAC36 Genome
KSHV BAC DNAs (BAC36, BAC36∆gB, BAC36∆gH, BAC36∆K8.1,
BAC36∆gL and BAC36∆gM) were purified from 1 liter of BAC cultures by using a
large-construct kit (Qiagen, Valencia, Calif.). BAC DNA was digested with KpnI and run
on 0.8% agarose gels, and the restricted DNA was transferred to charged nylon
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membranes (Bio-Rad, Richmond, Calif.). Southern blot hybridization was performed
with a biotin-labeled kanamycin resistance gene probe by labeling a 1.1-kb kanamycin
PCR fragment with biotin (New England Biolabs, Boston, Mass.). Chemiluminescence
detection of the DNA was performed by using a North2South chemiluminescence
hybridization and detection kit as described by the manufacturer (Pierce Inc., Rockford,
Ill.).
Stable Transfection of Mutant KSHV-BAC DNAs
Transient transfection of 293 cells with the respective members of the panel of
KSHV-BAC36 mutant DNAs was performed by using Superfect (Qiagen). 293 cells were
grown to 80% confluence in six-well plates. Cells were transfected with KSHV-BAC36
mutant DNA mixed with Superfect in DMEM as recommended by the manufacturer.
After 4 h of incubation at 37°C, the medium was removed from the transfected 293 cells,
and the cells were washed with PBS. One day after transfection, fresh DMEM with 10%
fetal calf serum and hygromycin B (100µg/ml) was added. Cells were fed weekly with
fresh DMEM with the same concentration of hygromycin B. After 6 weeks, hygromycin
B resistant colonies were picked, expanded and subsequently frozen in liquid nitrogen for
later use.
RESULTS
Construction of a Panel of Mutant KSHV-BAC36
The KSHV genome encodes several glycoproteins, gB, gH, gL and gM, which
possess conserved sequence homology among all herpesvirus subfamilies; in addition,
the K8.1 glycoprotein, which does not possess conserved sequence homology with any
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TABLE 4.1. Synthetic oligonucleotide primers
Primer
Name
5’-gB-KanF
3’-gB-KanR
5’-gH-KanF
3’-gH-KanR
5’K8.1KanF
3’ K8.1-KanR
5’-gL-KanF
3’-gL-KanR
5’-gM-KanF
3’-gM-KanR
5’-gB-Zt
3’-gB-nostop
5’-gHup
3’-gHdown
5’K8.1up
3K8.1nostop
5’-gLup
3’gL
5’gM-Z
3’gM-stop
5’KanFwd
3’KanRev

Primer Sequence
ACCAAACCTGGTGAGGAAGCATCTGGTCCTAAGAGTGTGGACTTT
TACCAGTTCAGATAGCCACGTTGTGTCTCAAAATCTCTGATGTTA
CTAGATTTCCTCCCGTGTTGGGGCTCCGCCGCTAGGAGGTGCCCT
GCGATCTACGTCCGGTTGATGAGAGCTTTGTTGTAGGTGGAC
CAGCTCATCAATGGGAGAACCAACCTCTCCATAGAACTGGAATTC
AACGGCACTAGTTAGCCACGTTGTGTCTCAAAATCTCTGATGTTA
CTACATGAGAGACTGCAGGCCATCGCTCTCATCGTAGCTCATGAT
TACAGAGTCACAAAGCGGTTGATGAGAGCTTTGTTGTAGGTGGAC
CAATATTAAAGGGACCCAAGTTAATCCCTTAATCCTCTGGGATTA
ATAACCATGAGTTAGCCACGTTGTGTCTCAAAATCTCTGATGTTA
CTAGCACAGGTAAAGTATAAGGACAAGTCCCAGCAATAAACCCA
CAGCCCATAGTATGTACGGTTGATGAGAGCTTTGTTGTAGGTGGAC
CATTAGTCGGGACTCGCGCATGCGTGAACCCTCACTATATAAAAC
AGATATTACGGAAGGCCACGTTGTGTCTCAAAATCTCTGATGTTA
CTAGTTCATGGCCTTTCCCACGCTTATTATAATTATGTTTACGTT
GTGAATAGAGCTATCCGGTTGATGAGAGCTTTGTTGTAGGTGGAC
GAGAAACCAGAGATGCTGGTGTACATATTTTGGACTTTTATCGTG
GACGGCATTGCCTAACCACGTTGTGTCTCAAAATCTCTGATGTTA
TTACATTTGCGTTTCGTCGATTTCACTGTCACTTTCATGGTCGGA
CTGGTATTGGGTCCTCGGTTGATGAGAGCTTTGTTGTAGGTGGAC
TGCAACTGAGCAACCACAATG
TAACCTCGAATCCACTGTCAC
GCAGTTAATCACCTAGAGGA
CGAACTGATATGTGACGGCAATC
CATGCTGATGCGAATGTGCCA
CACTATGTAGGGTTTCTTACG
ATGGGGATCTTTGCGCTATTT
TTTTCCCTTTTGACCTGCGTG
AACATGCGCGCTTCAAAGAGCGAC
CTAAATGAATATCATTTGCGTTTC
ATGAGCCATATTCAACGG
CTCATCGAGCATCAAATG
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other herpesvirus glycoproteins, exhibits positional homology with two EBV
glycoproteins: gp350/220 and gp42/38. The KSHV genome has been successfully cloned
into a bacterial artificial chromosome, named KSHV-BAC36, thus enhancing the
feasibility of KSHV mutagenesis, particularly via the implementation of bacterial
recombination mechanisms. The bacteria based GET homologous recombination system
was employed to construct a KSHV-BAC36 panel of mutants in E. coli depicted in
Figure 4.1 The panel of KSHV mutants is listed as follows: KSHV-BAC36∆gB, KSHVBAC36∆gH, KSHV-BAC36∆K8.1, KSHV-BAC36∆gL and KSHV-BAC36∆gM
(Sequence of Primers used for recombination and diagnostic assays are shown in Table
4.1).
Genetic Characterization of Glycoprotein-Deleted Mutant KSHV-BAC36 DNAs
Qiagen purified glycoprotein-deleted mutant KSHV-BAC36 DNA was isolated from
bacteria and used in a diagnostic PCR to determine the presence of the kanamycinRinsertion/glycoprotein-deletion mutation within the targeted region within the KSHV
genome. 5’gB-Zt and 3’gB-nostop was designed to amplify the entire gB gene which
approximates to 2.5kb within the wild-type genomes of KSHV-BAC36 episomes or
KSHV obtained from induced BCBL-1 cells (Figure 4.2; lanes 1 & 2). The insertion of
the kanamycinR gene cassette along with the concomitant deletion of a major region of
the gB gene is predicted to lead to a PCR product ~1.7kb (Figure 4.2; lane 3). 5’gHup
and 3’gHdown was designed to amplify the entire gH gene which approximates to 2.3kb
within the wild-type genomes of KSHV-BAC36 episomes or KSHV obtained from
induced BCBL-1 cells (Figure 4.2; lanes 5 & 6). The insertion of the kanamycinR gene
cassette along with the concomitant deletion of a major region of the gH gene is predicted
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Figure 4.1. Schematic illustration of the GET homologous recombination
system used on KSHV-BAC36. This model depicts the deletion of the gB gene via the
GET recombination system, the same approach was used to construct the following
glycoprotein deletion, which were not illustrated: KSHV-BAC36∆gH, KSHVBAC36∆K8.1, KSHV-BAC36∆gL, KSHV-BAC36∆gM . In this illustration detailing
the overall recombination strategy used to produce KSHV-BAC36∆gB, a chimeric PCR
fragment containing the kanamycin resistance gene flanked by 60 base pairs of gB
homologous sequences was used to construct BAC36∆gB genome recombinants
containing the kanamycin resistance gene cassette within the targeted gB ORF within the
KSHV genome.
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to lead to a PCR product ~1.8kb (Figure 4.2; lane 7). 5’K8.1up and F:3’K8.1nostop were
designed to amplify the entire K8.1 gene along with the 5’-upstream region which
approximates to 1kb within the wild-type genome of KSHV-BAC36 episomes (Figure
4.2; lane 9). The insertion of the kanamycinR gene cassette along with the concomitant
deletion of a major region of the K8.1 gene is predicted to lead to a PCR product ~1.4kb
(Figure 4.2; lane 10). 5’gL and H: 3’gL were designed to amplify the entire gL gene
which approximates to 0.6 kb within the wild-type genomes of KSHV-BAC36 episomes
or KSHV obtained from induced BCBL-1 cells (Figure 4.2; lane 11). The insertion of the
kanamycinR gene cassette along with the concomitant deletion of a major region of the gL
gene is predicted to lead to a PCR product ~1.4kb (Figure 4.2; lane 12). 5’gM-Z and
3’gM-stop was designed to amplify the entire gM gene which approximates to 1.3 kb
within the wild-type genomes of KSHV-BAC36 episomes (Figure 4.2; lane 14). The
insertion of the kanamycinR gene cassette along with the concomitant deletion of a major
region of the gM gene is predicted to lead to a PCR product ~1.6kb (Figure 4.2; lane 15).
Further confirmation of the genetic content of the panel of KSHV-BAC36
mutants was obtained by restriction endonuclease fragment analysis and Southern
blotting (Figures 4.3 and 4.4) Restriction ezyme analysis of the panel of KSHV-BAC36
mutants (KSHV-BAC36∆gB, KSHV-BAC36∆gH, KSHV-BAC36∆K8.1, KSHVBAC36∆gL and KSHV-BAC36∆gM) with KpnI revealed similar but noticeably different
DNA fragmentation patterns. Restriction enzyme analysis is an important assay when
using BACs, maintenance of a restriction pattern ensures that the BAC is still intact and
that major deletions of the BAC genome have not occurred, particularly after a
mutagenesis procedure. Upon comparison to KSHV-BAC36 (Figure 4.3; Lane 2),
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Figure 4.2. Diagnostic PCR analysis of the panel of KSHV-BAC36 mutants.
PCR assay to confirm respective deletions of the glycoprotein genes within the panel of
KSHV-BAC36 mutants: KSHV-BAC36∆gB, KSHV-BAC36∆gH, KSHV-BAC36∆K8.1,
KSHV-BAC36∆gL, KSHV-BAC36∆gM. Amplification of the various glycoprotein
regions from wild-type genomes of KSHV-BAC36 and BCBL-1 cells compared to the
KSHV-BAC36 mutants clearly showed appropriate size differences between each
respective insertional/deletional mutagenesis performed to obtain individual KSHVBAC36 glycoprotein-deleted mutants. The lambda molecular size markers are shown on
Lanes 4, 8, 13. PCR amplification of the wild-type genomes were performed and run in
the following lanes: BCBL-1(Lanes 1 & 5) and BAC36 (Lanes 2, 6, 9, 11 & 14). Primers
used for amplification of each glycoprotein region are listed in table 4.1.
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restricted DNA fragments were absent from KSHV-BAC36∆gH (~3.0kb), KSHVBAC36∆K8.1 (4.6kb), KSHV-BAC36∆gL (2.3kb) (Figure 4.3; Lanes 4, 5 and 6,
respectively). KSHV-BAC36∆gB and KSHV-BAC36∆gM (Figure 4.3; Lanes 3 and 7,
respectively) show remarkably similar patterns of restriction when compared to BAC36,
which is due to the location of the kanamycin insertion, which are located on the larger
restricted DNA fragments thus the size differential is beneath the sensitivity of the KpnI
fragment analysis. These results show that the panel of KSHV-BAC mutants (KSHVBAC36∆gB, KSHV-BAC36∆gH, KSHV-BAC36∆K8.1, KSHV-BAC36∆gL and KSHVBAC36∆gM) maintained their genome after the GET-REC mutagenesis procedure.
To confirm the presence of only one insertion of the kanamycin resistance
cassette within the KSHV-BAC genome due to the GET-REC mutagenesis system,
Southern blotting with a biotinylated kanamycin resistance gene probe for the KpnI
digested panel of KSHV-BAC36 mutants revealed the presence of a unique kanamycin
resistance cassette insertion within each KSHV-BAC mutant’s KpnI-restricted DNA
fragment pattern (Figure 4.4; Lanes 3-7). The varying sizes of hybridized fragments
indicate the different locations of the kanamycin insertion of the KSHV genome
consistent with the differing positions of the glycoproteins on the viral genome. The
KSHV-BAC36 genome was used as a negative control; the biotinylated kanamycin probe
did not hybridize with the KSHV-BAC36 genome (Figure 4.4; Lanes 2). A
prebiotinylated molecular weight ladder was used for DNA fragment size determination
(Figure 4.4; Lane 1). These results are consistent with the insertion of the kanamycin
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Figure 4.3. Restriction Fragment Analysis with KpnI digestion of KSHVBAC36 and the panel of KSHV-BAC36 mutants. KpnI digestion of the wild-type
KSHV-BAC36 episome (Lane 2) along with KpnI digestion of the panel of KSHVBAC36 mutant episomes: KSHV-BAC36∆gB (Lane 3), KSHV-BAC36∆gH (Lane 4),
KSHV-BAC36∆K8.1 (Lane 5), KSHV-BAC36∆gL (Lane 6), KSHV-BAC36∆gM (Lane
7). Molecular size markers are shown in Lane 1. Restriction fragment analysis of the
panel of KSHV-BAC36 mutants in comparison with wild-type genomes of KSHVBAC36 clearly shows size differences within the KSHV-BAC36∆gH (Lane 4), KSHVBAC36∆K8.1 (Lane 5) and KSHV-BAC36∆gL (Lane 6) when compared to the wildtype KSHV-BAC36 episome (Lane 2). Bands that were present within the wild-type
KSHV-BAC36 episome (Lane 2) but are missing due to alterations caused by the
insertion of the kanamycin resistance cassette within the KSHV-BAC36 genome are
demarcated by yellow arrows in Lanes 3, 4 and 5.
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resistance gene cassette within the targeted glycoprotein-deletions within the panel of
KSHV-BAC36 mutants.
Since the confirmation of the panel of mutant KSHV-BAC episomes was
established, stable 293 cell lines of the panel of mutant KSHV-BAC36 episomes (293KSHV-BAC36∆gB, 293-KSHV-BAC36∆gH, 293-KSHV-BAC36∆K8.1, 293-KSHVBAC36∆gL and 293-KSHV-BAC36∆gM) were produced via hygromycin selection over
a period of six weeks (Figure 4.5; Panels A-E). These established cell lines harbor
mutant KSHV-BAC episomes, and the GFP gene under the eukaryotic CMV promoter
allow for detection of the stable cells maintaining the mutant KSHV-BACs via
fluorescence microscopy. This study has utilized the GET-Rec recombination system in
E.coli to effectively target the KSHV glycoproteins within the KSHV genome for
deletional/insertional mutagenesis procedures (Figure 4.6).
DISCUSSION
Characterization of KSHV has relied on the growth of the virus in cell culture systems
(Moore and Chang, 2001). The isolation and characterization of cell lines of pleural
effusion lymphomas (PELs) has allowed the culturing of KSHV, wherein KSHV is
primarily maintained in latent replication but can be reactivated into lytic replication
through induction with various chemicals, such as phorbol ester, 12-O-tetradecanoyl
phorbol-13-acetate (TPA) (Arvanitakis et al., 1996; Cannon et al., 2000; Carbone et al.,
2000; Carbone et al., 1998; Cesarman et al., 1995; Drexler et al., 1998; Gao et al., 1996b;
Gao et al., 1999; Katano et al., 1999; Lacoste et al., 2000; Renne et al., 1996; Uphoff et
al., 1998).
The ability to grow KSHV in PEL cell lines has been vital in the development of
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Figure 4.4. Southern Blot Analysis with a kanamycin probe of the panel of
KSHV-BAC36 mutants. The KpnI restriction pattern from Figure 2.3 was hybirdized
with a probe derived from a kanamycin PCR product that was labeled with biotin.
Biotinylated molecular size markers are shown in Lane 1. The biotinylated kanamycin
probe the probe did not hybridize with KSHV-BAC36 (Lane 2), which does not possess a
kanamycin cassette; however, the probe hybridized precisely at one location within the
KSHV-BAC36 mutant episomes (Lanes 3-7), which indicates that there is only one copy
of the kanamycin cassette per KSHV-BAC36 mutant episome: KSHV-BAC36∆gB (Lane
3), KSHV-BAC36∆gH (Lane 4), KSHV-BAC36∆K8.1 (Lane 5), KSHV-BAC36∆gL
(Lane 6), KSHV-BAC36∆gM (Lane 7).. The biotinylated kanamycin probe hybridized
to differing KpnI restriction fragments within the respective KSHV-BAC36 mutants,
which is in accordance with the differing locations of the glycoprotein genes along the
KSHV genome.
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Figure 4.5. Stable 293 cell lines harboring Mutant-KSHV-BAC36 episomes.
293 cells were transfected with the respective mutant KSHV-BAC36 DNAs and
subsequently selected with hygromycin over a period of six weeks. The 293-KSHV cell
lines were produced and labeled in the following panels: A.) 293-KSHV-BAC36∆gB,
B.) 293-KSHV-BAC36∆gH, C.) 293-KSHV-BAC36∆K8.1, D.) 293-KSHV-BAC36∆gL,
E.) 293-KSHV-BAC36∆gM. The panels show the corresponding cells via
fluorescencmicroscopy (magnification, X200).
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Figure 4.6. Overall strategy leading to the generation of recombinant KSHVBAC36∆gB with the subsequent production of hygromycin resistant 293 cells
harboring the KSHV-BAC36∆gB. This model depicts five steps required for the
production of hygromycin resistant 293 cells harboring the KSHV-BAC36∆gB genome,
the same approach was used to produce hygromycin resistant 293 cells harboring the
following glycoprotein deletions within the KSHV-BAC36: KSHV-BAC36∆gH, KSHVBAC36∆K8.1, KSHV-BAC36∆gL, KSHV-BAC36∆gM (not shown). Step 1,
Electrocompetent E. coli DH10B cells harboring the KSHV-BAC36 genome were
transformed with plasmid pGETrec. Step 2, Transformation of E. coli DH10B-KSHVBAC36 with a linearized chimeric PCR product containing the entire Kanamycin
resistance cassette with flanking gB homologous sequences (60 base pairs) thus allowing
for most of the gB gene to be deleted and replaced with the kanamycin resistance cassette
upon homologous recombination, Step 3. After allowing for homologous recombination
in E. coli, clones harboring the KSHV-BAC36 genome were selected for
chloramphenicol and kanamycin resistance. Step 4, A second round of electroporation
was performed in order to remove the plasmid pGETrec, the recombinant clones
harboring the mutant KSHV-BAC36 underwent alkaline lysis and the prepped episomes,
containing KSHV-BAC36 ∆gB DNA and pGETrec, were then transformed into E. coli
DH10B cells and grown on agar plates containing both chloramphenicol and kanamycin.
Step 5, Eucaryotic 293 cells were transfected with KSHV-BAC36∆gB DNA and selected
with hygromycin B.
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serologic assays (Gao et al., 1996a; Gao et al., 1996b; Kedes et al., 1996; Simpson et al.,
1996) and studies investigating the molecular properties of the virus or individual viral
genes in the absence of the context of the virus (Moore and Chang, 2001). In order to
fully understand the dynamic interplay of viral and cellular mechanisms, especially
during viral entry into susceptible cells, requires the establishment of a reliable primary
infection system whereby KSHV mutants can be generated and efficiently produced.
Characterization of viral gene function via the generation of herpesvirus mutants
and observation of the resultant phenotypic changes has been critical for understanding
the molecular aspects of herpesvirus replication and pathogenesis. In classical herpesviral
genetics, recombinant herpesviruses can be generated by homologous recombination in
infected eukaryotic cells with large DNA fragments (~1-3kb) specifying homologous
viral sequences, which can recombine with shuttle vectors to deliver the engineered
mutation into the herpesviral genome (Knipe et al., 2001). Mutagenic approaches based
on homologous recombination in eukaryotic cells have been limited to genetic
manipulation of only the most rapidly replicating and promiscuous herpesviruses, such as
herpes simplex virus (HSV) (Knipe et al., 2001) and pseudorabies virus (PRV)(Post and
Roizman, 1981), largely, due to the need of isolating single plaque-forming virions. In
contrast, the generation of a homogenous population of KSHV mutants has been
untenable due to the difficulties associated with viral propagation and plaque formation,
thus severely impeding the systematic delineation of viral gene functions in the context of
the viral genome.
Recently, the KSHV genome was cloned into a bacterial artificial chromosome
(BAC) and shown to produce infectious virus; recombinant KSHV genome was named
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KSHV-BAC36 (Zhou et al., 2002). The KSHV-BAC36 genome allows the genetic
manipulation, particularly gene deletions or site-directed mutagenesis, of the KSHV
genome using the prokaryotic recombination machinery. Since KSHV is maintained in
bacteria, essential genes required for virion morphogenesis can be genetically altered and
the mutant viral genome can be recovered as homogeneous population by propagation in
bacteria.
This study reported the generation of a panel of mutant-KSHV-BAC36-based
genomes, which contain different glycoprotein-deletions. These gene deletions were
produced through the use of the pGET-Rec bacterial recombination system for
insertional/deletional mutagenesis of the KSHV-BAC36 genome. Targeted deletion of
the complete ORFs of herpesviruses for functional analysis of individual genes is
complicated by the presence of overlapping ORFs and regulatory sequence elements
controlling the gene expression of neighboring genes. The approximate 60bp homology
arms used for recombination in this study allowed the deletion of the majority of the
targeted gene sequences the glycoprotein intended for deletion with minimal affect on the
neighboring genes.
The panel of KSHV-BAC36 mutants (KSHV-BAC36∆gB, KSHV-BAC36∆gH,
KSHV-BAC36∆K8.1, KSHV-BAC36∆gL and KSHV-BAC36∆gM) as well as other
KSHV mutant viruses constructed in this laboratory will be instrumental in determining
the role of KSHV-glycoproteins in virus attachment, entry, virion maturation and egress.
Furthermore, the panel of stable 293 cell lines harboring the mutant KSHV genomes
(293-KSHV-BAC36∆gB, 293-KSHV-BAC36∆gH, 293-KSHV-BAC36∆K8.1, 293KSHV-BAC36∆gL and 293-KSHV-BAC36∆gM) would be useful in the characterization
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of these mutant viruses. Unlike transient transfections, these cell lines can produce large
amounts of virions for virion structural analysis as well as high MOI- infection of
permissive cells.
REFERENCES
Ablashi, D. V., Chatlynne, L. G., Whitman, J. E., Jr., and Cesarman, E. (2002). Spectrum
of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.
Clin Microbiol Rev 15(3), 439-64.
Arvanitakis, L., Mesri, E. A., Nador, R. G., Said, J. W., Asch, A. S., Knowles, D. M., and
Cesarman, E. (1996). Establishment and characterization of a primary effusion
(body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcomaassociated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood 88(7), 2648-54.
Borst, E. M., Hahn, G., Koszinowski, U. H., and Messerle, M. (1999). Cloning of the
human cytomegalovirus (HCMV) genome as an infectious bacterial artificial
chromosome in Escherichia coli: a new approach for construction of HCMV
mutants. J Virol 73(10), 8320-9.
Britt, W. J. (2000). Infectious clones of herpesviruses: a new approach for understanding
viral gene function. Trends Microbiol 8(6), 262-5.
Brune, W., Menard, C., Hobom, U., Odenbreit, S., Messerle, M., and Koszinowski, U. H.
(1999). Rapid identification of essential and nonessential herpesvirus genes by
direct transposon mutagenesis. Nat Biotechnol 17(4), 360-4.
Cannon, J. S., Ciufo, D., Hawkins, A. L., Griffin, C. A., Borowitz, M. J., Hayward, G. S.,
and Ambinder, R. F. (2000). A new primary effusion lymphoma-derived cell line
yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J
Virol 74(21), 10187-93.
Carbone, A., Cilia, A. M., Gloghini, A., Capello, D., Perin, T., Bontempo, D.,
Canzonieri, V., Tirelli, U., Volpe, R., and Gaidano, G. (2000). Primary effusion
lymphoma cell lines harbouring human herpesvirus type-8. Leuk Lymphoma 36(56), 447-56.
Carbone, A., Cilia, A. M., Gloghini, A., Capello, D., Todesco, M., Quattrone, S., Volpe,
R., and Gaidano, G. (1998). Establishment and characterization of EBV-positive
and EBV-negative primary effusion lymphoma cell lines harbouring human
herpesvirus type-8. Br J Haematol 102(4), 1081-9.

178

Cesarman, E., Chang, Y., Moore, P. S., Said, J. W., and Knowles, D. M. (1995). Kaposi's
sarcoma-associated herpesvirus-like DNA sequences in AIDS-related bodycavity-based lymphomas. N Engl J Med 332(18), 1186-91.
Delecluse, H. J., Kost, M., Feederle, R., Wilson, L., and Hammerschmidt, W. (2001).
Spontaneous activation of the lytic cycle in cells infected with a recombinant
Kaposi's sarcoma-associated virus. J Virol 75(6), 2921-8.
Drexler, H. G., Uphoff, C. C., Gaidano, G., and Carbone, A. (1998). Lymphoma cell
lines: in vitro models for the study of HHV-8+ primary effusion lymphomas
(body cavity-based lymphomas). Leukemia 12(10), 1507-17.
Gao, S. J., Deng, J. H., and Zhou, F. C. (2003). Productive lytic replication of a
recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary
infection of primary human endothelial cells. J Virol 77(18), 9738-49.
Gao, S. J., Kingsley, L., Hoover, D. R., Spira, T. J., Rinaldo, C. R., Saah, A., Phair, J.,
Detels, R., Parry, P., Chang, Y., and Moore, P. S. (1996a). Seroconversion to
antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear
antigens before the development of Kaposi's sarcoma. N Engl J Med 335(4), 23341.
Gao, S. J., Kingsley, L., Li, M., Zheng, W., Parravicini, C., Ziegler, J., Newton, R.,
Rinaldo, C. R., Saah, A., Phair, J., Detels, R., Chang, Y., and Moore, P. S.
(1996b). KSHV antibodies among Americans, Italians and Ugandans with and
without Kaposi's sarcoma. Nat Med 2(8), 925-8.
Gao, S. J., Zhang, Y. J., Deng, J. H., Rabkin, C. S., Flore, O., and Jenson, H. B. (1999).
Molecular polymorphism of Kaposi's sarcoma-associated herpesvirus (Human
herpesvirus 8) latent nuclear antigen: evidence for a large repertoire of viral
genotypes and dual infection with different viral genotypes. J Infect Dis 180(5),
1466-76.
Janz, A., Oezel, M., Kurzeder, C., Mautner, J., Pich, D., Kost, M., Hammerschmidt, W.,
and Delecluse, H. J. (2000). Infectious Epstein-Barr virus lacking major
glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral
ligands. J Virol 74(21), 10142-52.
Katano, H., Sato, Y., Kurata, T., Mori, S., and Sata, T. (1999). High expression of HHV8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J
Pathol 155(1), 47-52.
Kedes, D. H., Operskalski, E., Busch, M., Kohn, R., Flood, J., and Ganem, D. (1996).
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated
herpesvirus): distribution of infection in KS risk groups and evidence for sexual
transmission. Nat Med 2(8), 918-24.

179

Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B.,
and Straus, S. E. (2001). "Fields Virology." Fourth ed. Fields Virology (D. M.
Knipe, and P. M. Howley, Eds.), 2. 2 vols. Lippincott Williams & Wilkins,
Philadelphia, PA.
Lacoste, V., Judde, J. G., Bestett, G., Cadranel, J., Antoine, M., Valensi, F., Delabesse,
E., Macintyre, E., and Gessain, A. (2000). Virological and molecular
characterisation of a new B lymphoid cell line, established from an AIDS patient
with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV
viruses. Leuk Lymphoma 38(3-4), 401-9.
Luna, R. E., Zhou, F., Baghian, A., Chouljenko, V., Forghani, B., Gao, S. J., and
Kousoulas, K. G. (2004). Kaposi's sarcoma-associated herpesvirus glycoprotein
K8.1 is dispensable for virus entry. J Virol 78(12), 6389-98.
Messerle, M., Crnkovic, I., Hammerschmidt, W., Ziegler, H., and Koszinowski, U. H.
(1997). Cloning and mutagenesis of a herpesvirus genome as an infectious
bacterial artificial chromosome. Proc Natl Acad Sci U S A 94(26), 14759-63.
Moore, P. S., and Chang, Y. (2001). Molecular virology of Kaposi's sarcoma-associated
herpesvirus. Philos Trans R Soc Lond B Biol Sci 356(1408), 499-516.
Narayanan, K., Williamson, R., Zhang, Y., Stewart, A. F., and Ioannou, P. A. (1999).
Efficient and precise engineering of a 200 kb beta-globin human/bacterial
artificial chromosome in E. coli DH10B using an inducible homologous
recombination system. Gene Ther 6(3), 442-7.
Orford, M., Nefedov, M., Vadolas, J., Zaibak, F., Williamson, R., and Ioannou, P. A.
(2000). Engineering EGFP reporter constructs into a 200 kb human beta-globin
BAC clone using GET Recombination. Nucleic Acids Res 28(18), E84.
Post, L. E., and Roizman, B. (1981). A generalized technique for deletion of specific
genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential
for growth. Cell 25(1), 227-32.
Renne, R., Zhong, W., Herndier, B., McGrath, M., Abbey, N., Kedes, D., and Ganem, D.
(1996). Lytic growth of Kaposi's sarcoma-associated herpesvirus (human
herpesvirus 8) in culture. Nat Med 2(3), 342-6.
Russo, J. J., Bohenzky, R. A., Chien, M. C., Chen, J., Yan, M., Maddalena, D., Parry, J.
P., Peruzzi, D., Edelman, I. S., Chang, Y., and Moore, P. S. (1996). Nucleotide
sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad
Sci U S A 93(25), 14862-7.

180

Simpson, G. R., Schulz, T. F., Whitby, D., Cook, P. M., Boshoff, C., Rainbow, L.,
Howard, M. R., Gao, S. J., Bohenzky, R. A., Simmonds, P., Lee, C., de Ruiter, A.,
Hatzakis, A., Tedder, R. S., Weller, I. V., Weiss, R. A., and Moore, P. S. (1996).
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by
antibodies to recombinant capsid protein and latent immunofluorescence antigen.
Lancet 348(9035), 1133-8.
Smith, G. A., and Enquist, L. W. (1999). Construction and transposon mutagenesis in
Escherichia coli of a full-length infectious clone of pseudorabies virus, an
alphaherpesvirus. J Virol 73(8), 6405-14.
Smith, G. A., and Enquist, L. W. (2000). A self-recombining bacterial artificial
chromosome and its application for analysis of herpesvirus pathogenesis. Proc
Natl Acad Sci U S A 97(9), 4873-8.
Uphoff, C. C., Carbone, A., Gaidano, G., and Drexler, H. G. (1998). HHV-8 infection is
specific for cell lines derived from primary effusion (body cavity-based)
lymphomas. Leukemia 12(11), 1806-9.
Yu, D., Ellis, H. M., Lee, E. C., Jenkins, N. A., Copeland, N. G., and Court, D. L. (2000).
An efficient recombination system for chromosome engineering in Escherichia
coli. Proc Natl Acad Sci U S A 97(11), 5978-83.
Zhou, F. C., Zhang, Y. J., Deng, J. H., Wang, X. P., Pan, H. Y., Hettler, E., and Gao, S. J.
(2002). Efficient infection by a recombinant Kaposi's sarcoma-associated
herpesvirus cloned in a bacterial artificial chromosome: application for genetic
analysis. J Virol 76(12), 6185-96.

181

CHAPTER V
CONCLUDING REMARKS

SUMMARY
Infectious KSHV inoculum obtained from pleural effusion lymphoma cell lines
(PEL) and occasionally from KS tumors have been shown to infect several cell types,
including the following cell lines: monocytes, fibroblasts, lymphocytes, and keratinocytes
(Cerimele et al., 2001; Foreman et al., 1997; Kliche et al., 2001; Mesri et al., 1996;
Moore et al., 1996; Panyutich, Said, and Miles, 1998; Renne et al., 1998; Vieira et al.,
2001). Unfortunately, KSHV primary-infection efficiencies in these cells are typically
low, and the cultures are unable to efficiently passage the virus or produce large amounts
of virus-stock production upon the induction of the infected cell with the phorbol ester,
TPA.
The KSHV viral system remains a difficult experimental system due to multiple
difficulties associated with virus replication including: the inability to sufficiently
passage KSHV; the low primary infection efficiencies; the production and
characterization of viral mutants in order to assess the structure and function of individual
viral gene products; the low percentage of latent cells that can be reactivated to express
lytic genes: the low percentage of cell expressing lytic genes that can actually. (Ciufo et
al., 2001; Moses et al., 1999).
Recently, the full-length KSHV genome has been cloned into a bacterial artificial
chromosome (BAC) and successfully recovered in 293 cells. Wild-type KSHV generated
from the BAC clone was named BAC36 and has been shown to be highly infectious to
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293 cells and endothelial cells, with primary-infection efficiency close to 90-95% (Gao,
Deng, and Zhou, 2003). The work included in this dissertation has focused on the genetic
manipulation of the KSHV-BAC36 in order to address the role of K8.1 in viral entry and
the role of the gB-carboxyl tail α-helices in virus-induced cell fusion. In addition, a
panel of KSHV-glycoprotein mutants was constructed in order to address the specific role
of each glycoprotein in viral entry, egress and virus-induced cell fusion.
These investigations have shown that the K8.1 glycoprotein is dispensable for
viral entry. The K8.1 glycoprotein is a structural component of the KSHV particle and is
thought to facilitate virus entry by binding to heparan sulfate moieties on cell surfaces.
To further address the role of the K8.1 glycoprotein in virus infectivity, a K8.1-null
recombinant virus (BAC36∆K8.1) was constructed by deletion of most of the K8.1 open
reading frame and insertion of a kanamycin resistance gene cassette within the K8.1
gene. Southern blotting and diagnostic PCR confirmed the presence of the engineered
K8.1 gene deletion. Transfection of the wild-type genome (BAC36) and mutant genome
(BAC36∆K8.1) DNAs into 293 cells in the presence or absence of the complementing
plasmid (pCDNAK8.1A), transiently expressing the K8.1A gene, produced infectious
virions in the supernatants of transfected cells. Hence, these results clearly demonstrated
that the K8.1 glycoprotein is not required for KSHV entry into 293 cells.
The role of the gB carboxyl terminus in virus-induced cell fusion was investigated
by constructing recombinant KSHV strains using the KSHV genome cloned into a
bacterial artificial chromosome (BAC36). KSHV glycoprotein B (gB) is conserved
among all human and animal herpesviruses, and it is thought to mediate membrane fusion
phenomena during virus entry and virus-induced cell fusion. Two recombinant BAC36-
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derived genomes were constructed specifying truncations that fully or partially truncated
a predicted alpha helical structure of the gB carboxyl terminus known to be involved in
virus-induced cell fusion from studies with the herpes simplex virus type 1 (HSV-1) gB.
Mutated gB genes specifying the two gB truncations were introduced via homologous
recombination into the KSHV BAC36 viral genome using a shuttle vector containing the
mutated gB and several other genes to aid in the selection of the mutant KSHV BACs in
E. coli. Co-integrates were resolved using SacB as a negative selection marker. gBcarboxyl-tail KSHV-Mutant BACs were transfected into 293 cells and viral lytic
replication was induced by TPA. Initial experiments suggested that disruption of the
predicted α-helical structure gBtH2 enhanced virus-induced cell fusion. The SacB/RecA
two-step mutagenesis system allows for the rapid generation of mutant KSHVs, and this
mutagenesis procedure will be useful in the delineation of gB functional domains
involved in membrane fusion. Currently, permanently transformed TIME cells are being
constructed to better assess the role of the gB carboxyl terminus on virus-induced cell
fusion.
The culmination of this dissertation has led to the generation of a panel of mutantKSHV-BAC36 viral genomes, which specify glycoprotein-deletions within the KSHV
genome. Utilization of the pGET-Rec bacterial recombination system for
insertional/deletional mutagenesis of the KSHV-BAC36 genome was successfully
performed to produce the following KSHV-BAC36 mutants: KSHV-BAC36∆gB,
KSHV-BAC36∆gH, KSHV-BAC36∆K8.1, KSHV-BAC36∆gL and KSHV-BAC36∆gM.
Subsequently, a panel of stable 293 cell lines, harboring the mutant KSHV-BAC
genomes, were established: 293-KSHV-BAC36∆gB, 293-KSHV-BAC36∆gH, 293-
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KSHV-BAC36∆K8.1, 293-KSHV-BAC36∆gL and 293-KSHV-BAC36∆gM. These
stable cell lines would serve critical roles in the characterization of these mutant viruses
via the production of large amounts of mutant virus stocks and the assessment of the
individual glycoprotein role in virus-induced cell fusion.
In conclusion, this dissertation work has capitalized on the recent development of
the KSHV-BAC36 genome in order to deliver targeted mutations to the KSHV genome.
The results in this dissertation include the first characterization of a KSHV mutant. The
results of these investigations have also produced the first targeted point mutations within
the KSHV genome. Currently, the work produced herein this dissertation has contributed
to the advancement of the genetics and functional characterization of KSHV mutants, and
has investigated the function of genes in the context of the viral genome. This work has
contributed to the field of KSHV via the elucidation of the structure and function of
KSHV-glycoprotein K8.1 and the preparations of a panel of KSHV glycoprotein mutants
which would aid in granting insight into the multi-functional roles of glycoproteins
throughout the viral lifecycle.
FUTURE RESEARCH CHALLENGES
The dynamic interplay between KSHV and the infected cell which ultimately
leads to cellular transformation and the subsequent manifestation of malignant tumors
and pleural effusion lymphomas, termed as Kaposi’s Sarcoma and Body Cavity Based
Lymphomas respectively, is of tremendous importance to the field of viral pathogenesis
and oncogenesis, thus research in this area could possibly lead to the elucidation of
fundamental mechanisms involved in viral transformation and cancer development.
KSHV or human herpesvirus 8 is the most recently identified human herpesvirus, and the

185

potential cellular pathways and usurp of cellular pathways by the virus has led to intense
research effort in this field. The holy grail of this virus would be the elucidation of the
viral mechanisms leading to the transformation of the infected cell. The role of
glycoproteins in cellular transformation is an interesting supposition; however, the
immediate concern regarding glycoproteins is to define the functional characteristics of
KSHV glycoproteins in viral entry, egress and virus-induced cell fusion.
These investigations clearly showed the dispensable role of the K8.1-glycoprotein
in viral entry. This research supports the model that the K8.1-glycoprotein possesses a
functional role in viral egress, since the complementation of the mutant KSHVBAC36∆K8.1 with a K8.1-plasmid has led to enhanced viral production from transfected
cells when compared to cells transfected with only the BAC36∆K8.1. This observation is
an interesting one in light of recent results presented at the 2004 Kaposi’s Sarcomaassociated herpesvirus workshop, in which a group showed that the complementation of a
KSHV-BAC36∆gB with a gB plasmid corrected an egress defect of cells that were only
transfected with the KSHV-BAC36∆gB genome. gB and K8.1glycoproteins both bind to
heparan-sulfate receptors during the viral entry process, thus gB and K8.1 may also both
possess functional roles in viral egress. Herpesviruses glycoproteins have been known to
possesss redundant functional roles, yet the functional redundancy of glycoproteins varies
depending on the individual herpesvirus and these mechanisms merits further
investigation.
These studies have also led to construction of gB-mutant KSHVs, specifically
with insertion of the opal stop codons within the carboxyl tail of the gB molecule, thus
truncating the protein in order to assess the role of the KSHV-gB tail in virus-induced
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fusion. Recently another research group has shown that the telomerase-immortalized
microvascular endothelial (TIME) permanent cell line is susceptible to high levels of
primary infection with KSHV and sustains several passages of the virus, thus stable
transfection of TIME cells with mutant KSHV-BACs could theoretically serve as
reservoirs for viral production and assist characterization studies of the KSHV-mutantBACs(Lagunoff et al., 2002). Current experiments are focused on the establishment of
permanent TIME cells allowing for an infectious model in which passage of the KSHVmutant virus would be possible along with the ability to efficiently quantitate virusinduced cell fusion. In addition, permanent TIME cells, harboring members of the panel
of KSHV-glycoprotein deletion mutants, are currently being prepared in order to produce
an infectious system in which passage of the KSHV mutant virions would be made
possible. Once the KSHV-glycoprotein deletion mutant-TIME cells are produced,
complementation studies involving transient delivery of the complementing gene could
be used to assess the dispensable roles of these glycoproteins in viral entry, egress and
virus-induced cell fusion. The complementation system would allow the molecular
dissection of functional domains of each glycoprotein and their respective roles in the
virus lifecycle. The most appealing experiments would be investigation of the role of
glycoproteins in viral transformation of the infected cell. In this regard, the KSHVglycoprotein deletion mutant-TIME cells would allow us to glean significant findings.
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